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“It was the best of times, it was the worst of times, 
it was the age of wisdom, it was the age of 
foolishness, it was the epoch of belief, it was the 
epoch of incredulity, it was the season of Light, it 
was the season of Darkness, it was the spring of 
hope, it was the winter of despair, we had 
everything before us, we had nothing before us, 
we were all going direct to heaven, we were all 
going direct the other way - in short, the period 
was so far like the present period, for good or for 
evil, in the superlative degree of comparison 
only.” 
 
Charles Dickens (A Tale of two cities; 1859) 
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Thyroid carcinoma is the most common endocrine malignancy accounting for >90% of 
malignancies of endocrine glands (1), but the overall incidence is low. Differentiated thyroid 
carcinoma (DTC), which is the most prevalent thyroid carcinoma, has an excellent 10-year 
prognosis of around 85%, which is due to the biological behavior of DTC (2, 3) and the 
available treatment options (4). Effective treatment in most DTC patients consists of total 
thyroidectomy followed by therapy with radioactive iodide (RAI), which is based on the 
unique ability of follicular thyroid cells to take up iodine via the Sodium Iodide Symporter 
(NIS) (5). 
Despite the excellent prognosis of DTC, clinical challenges remain. First, the diagnosis of 
DTC is hampered by the fact that although the incidence is low, thyroid nodules are prevalent. 
Effective diagnostic strategies are warranted to identify patients with clinically relevant DTC 
without subjecting the many patients with thyroid nodules to unnecessary and invasive 
procedures. In this thesis, the diagnostic value of a potential marker for DTC is being 
evaluated. Although prognosis of DTC is favorable, unfortunately, in a high proportion of 
patients with metastases the capacity for RAI accumulation is diminished or lost. In this 
thesis, fundamental aspects of the regulation of NIS are being studied, that may have 
implications for improving RAI therapy. Furthermore, the long-term efficacy of a new 
treatment with the multikinase inhibitor sorafenib is evaluated. As this treatment is associated 
with various adverse events, including hypothyroidism, a potential mechanism of sorafenib 
associated hypothyroidism is evaluated. Finally, DTC patients have traditionally been treated 
with high dosages of levothyroxine substitution, in order to suppress serum thyroid 
stimulating hormone (TSH) levels. However, high thyroid hormone concentrations may have 
adverse effects on various organ systems, including the heart. In this thesis, we evaluate the 
effects of various thyroid hormone concentrations on cardiac function in DTC, using 
dedicated cardiac ultrasound.   
THYROID PHYSIOLOGY 
The cornerstone of the non-surgical therapy of DTC is the ability of the thyroid gland to 
accumulate iodide through NIS. NIS is a glycoprotein located at the basolateral plasma 
membrane of thyrocytes. It actively accumulates iodide by a factor of 20 to 40 relative to its 
concentration in the blood. Although other tissues such as breast, stomach and salivary gland 







ability to oxidize iodide by thyroid peroxidase (TPO) and its subsequent organification into 
thyroglobulin (Tg) (6). NIS has a long half-life of about 7 days with a complex transcriptional, 
post-transcriptional, and post-translational regulation in order to target NIS to the plasma 
membrane; the only location where NIS is functional. TSH stimulates NIS transcription and 
de novo synthesis, and plays a role in the targeting of NIS to the plasma membrane (6).  
After uptake of iodide into the thyroid epithelial cells, it is subsequently transported to the 
follicular lumen by pendrin (6). At the apical plasma membrane, iodide is oxidized by TPO 
and coupled to tyrosine residues in Tg, forming monoiodotyrosines (MIT) and diiodotyrosines 
(DIT). The next step in thyroid hormone synthesis is the coupling of two iodotyrosyl residues 
(6). Iodinated Tg is subsequently endocytosed and hydrolyzed in the lysosomes thus releasing 
thyroxine (T4) and triiodothyronine (T3). The synthesis of thyroid hormones is regulated by 
the hypothalamus-pituitary-thyroid axis. Thyrotropin releasing hormone (TRH), which is 
produced by the hypothalamus, stimulates the secretion of TSH by the anterior pituitary.  
T3 is the active form of thyroid hormone. Circulating T3 produced by the thyroid gland 
accounts for only 20% of T3 (7). The majority of T3 is formed after conversion of T4 into T3 
in peripheral tissues like liver, kidney and muscle. T4 and T3 exert a negative feedback on 
TRH and TSH secretion.  
Peripheral thyroid metabolism is mainly regulated by the iodothyronine deiodinases D1, 
D2, and D3 (8). D1 is present in the thyroid, liver and kidneys and converts T4 to T3. In 
addition, it plays a role in the breakdown of reverse T3 (9). D2 enhances local T3 production 
in various tissues. It is expressed in brain, skeletal muscle, thyroid, pituitary, brown adipose 
tissue, aortic smooth muscle cells, osteoblasts and the heart  (8, 10). In the brain, D2 is 
expressed mainly in astrocytes in the cerebral cortex, hippocampus and amygdala (8). D3 
inactivates T3 and T4 and thus regulates the clearance of T3 and T4. It is present in the brain, 
skin, placenta and fetal tissues. 
Thyroid hormone has numerous effects on growth, differentiation and metabolism (11). 
 
receptors that bind to specific DNA binding sites, called thyroid hormone responsive elements 
(TRE). Binding of T3 to TR can either lead to transcription or repression of T3 dependent 
genes. Activation or repression of TRE is a complex process in which co-activators and 




non-genomic actions of thyroid hormones through non-nuclear TR have been postulated (14-
19).  
DIFFERENTIATED THYROID CARCINOMA 
Epidemiology 
Although thyroid nodules are common, more than 95% of these nodules are benign (20) 
thyroid cancers represent 1.7% of  newly discovered cancer cases in the world according to 
GLOBOCAN (2002-2008) with a female to male ratio 2.3:1 (21). In Europe, thyroid cancer 
has the highest incidence and prevalence of endocrine carcinomas (1). Worldwide, the 
incidence of thyroid carcinoma is increasing. In the Netherlands the annual overall incidence 
of thyroid cancers has risen from 2.0 in 1989 to 3.25 per 100.000 person/years in 2011 with a 
female to male ratio of 2.4:1 (22) accompanied with an increase in the 5-years survival rate 
from ~76%  in 1993 to 82% in 2011. The increase in incidence can be explained by the more 
intensive use of imaging modalities that increased the detection of small, non-symptomatic 
tumors (23). 
Thyroid cancer pathology 
Thyroid carcinomas are categorized into 3 main groups. DTC (97%) and anaplastic thyroid 
carcinoma (ATC) (1%) originate from follicular epithelial cells, whereas medullary thyroid 
carcinoma (2%) originates from neuroendocrine parafollicular cells. DTC can be 
distinguished in many histological subtypes, major groups being papillary thyroid carcinoma 
(PTC), which is the most common type of thyroid cancers (87% of thyroid carcinomas), and 
follicular thyroid carcinoma (6%). Hürthle cell carcinomas (3-4%) form a distinct subgroup of 
DTC that are mostly FTC but can also be PTC. Mixed FTC and PTC also occur. The 
follicular variant of PTC (FVPTC) is a subtype of PTC that is hard to differentiate from 
benign follicular adenoma and is indeed considered by some as a benign tumor.  
Molecular pathogenesis 
The genetic events involved in DTC include gene rearrangements and mutations. As a 
consequence of these genetic mutations and/or rearrangements, signaling pathways are 
activated in favor of cell growth, survival and angiogenesis. PTC frequently harbor point 
mutations of BRAF (30-69%) and rearrangements of the RET oncogene (40-70%) leading to 
MAP-kinase pathway activation (24-27). To a lesser extent, RAS gene mutations also occur in 







rearrangements (25-56%) (28). Mutations of PTEN may also be present in FTC. RAS 
mutations may activate both MAPK and PI3K/AKT signaling pathways. Genetic alterations 
involving the PI3K/AKT signaling pathway are rare in DTC.  
In ATC, genetic alterations in the PI3K/AKT signaling pathway may be present (29-31). Also, 
mutations of the p53 tumor suppressor gene (32) -
catenin gene have been described in ATC (33-35).  
Dedifferentiation 
DTC initially retains the biological properties (iodide uptake, Tg synthesis and response to 
TSH) of normal thyroid cells (36-38). However, NIS, TPO, Tg and TSH receptor (TSHR) 
expression gradually decrease in DTC with NIS and TPO disappearing at an earlier stage than 
other proteins (39-41). NIS expression has been studied extensively. Most studies showed 
reduction or even absence of NIS mRNA in thyroid carcinomas (42-44), while 
immunohistochemistry studies have demonstrated that NIS protein is over-expressed in many 
thyroid tumors and is predominantly located in the cytoplasm (36, 40). TSHR expression is 
persistent in nearly all DTC (40, 45, 46). Tg production remains preserved even in the absence 
of iodide uptake. In ATC, Tg secretion may decrease and is eventually lost (40, 45, 46). A 
causal relationship between genetic alterations and loss of functional NIS expression is 
present: tumor cells harboring BRAFV600E mutation have decreased NIS, TPO and TSHR 
gene expression compared to other tumor cells without this mutation (47-51). In addition, a 
relationship between activation of PI3K and mTOR and loss of NIS expression has also been 
described (52). 
Diagnosis 
Ultrasonography (US) guided fine needle aspiration cytology (FNAC) is the cornerstone of 
the evaluation of thyroid nodules for malignancy (53). Diagnostic accuracy of FNAC for DTC 
is influenced by decision rules for subsequent thyroid surgery. Sensitivity of FNA for DTC is 
generally regarded as 90-95%. The specificity is lower (60-80%) when all patients with a non-
benign FNA are referred for surgery (54). FNAC results are currently described according to 
the Bethesda classification  (see table 1) (53). The problem is that with the increased 
application of US, more small asymptomatic nodules are being discovered, that even if they 
harbor DTC, may not have clinical consequences at all. Yet, when DTC is diagnosed by FNA, 
most patients will undergo surgery, which explains the impressive rise in DTC incidence. A 




mainly directed by clinical suspicion and/or US selection by experienced radiologists as 
recommended in the updated Dutch thyroid carcinoma guidelines (www.oncoline.nl). 
Indeterminate FNAC results (Bethesda class III and IV) constitute 17-30% of cases with 
an overall risk of malignancy of up to 30% (55). Bethesda class III and IV may correspond 
with FVPTC, FTC or FA (56). Most of these indeterminate cases are referred for diagnostic 
hemithyroidectomy, but the majority of patients will have benign disease. Yet they are 
exposed to a 2-10% risk of surgical complications, and most patients will require 
levothyroxine replacement therapy for life (57). Therefore improved preoperative diagnostic 
evaluation for patients with indeterminate cytologic findings on FNA is warranted. In order to 
improve the preoperative diagnostic evaluation for patients with indeterminate cytologic 
findings on FNA, additional approaches have emerged to improve the accuracy of the 
diagnosis, most importantly immunohistochemical and molecular genetic markers.  
 
















2- 20 4 Repeat FNAC 
II Benign  60- 70 3 Clinical follow-up 
III 
Atypia of Undetermined 
Significance/ Follicular 
Lesions of Undetermined 
significance 
 
3- 15 5- 15 (Estimated) Repeat FNA 
IV 
Follicular Neoplasm/ 









2- 3 60- 75 Surgical intervention  
VI Malignancy 3- 7 97- 99 Surgical intervention  
Data adapted from (Cibas and Ali, AmJClinPathol, 2009(58)  and Baloch et al, Diagnostic cytopathology, 2008 (59). PPV 
(malignancy): positive predictive value for malignancy 
 
Immunohistochemical markers  
Microarray technology enabled molecular characterization of thyroid pathologies and 







CK19 have been identified as the most promising makers so far (60). HBME-1 is considered 
the most sensitive marker for PTC and was even found to be useful in the differentiation 
between FA and FVPTC (61, 62). The problem with these markers is that their sensitivity 
progressively declines for the diagnosis and differentiation of FVPTC, FTC, and less common 
malignant variants (63).  
Bone morphogeneic protein 7 (BMP7) is an interesting protein to study in the context of 
DTC as BMP7 among other bone morphogenic proteins may be involved in thyroid 
proliferation (64, 65). Unlike the oncogenic actions of TGF-
superfamily) in tumorigenesis, BMP7 appears to be involved in the preservation of the 
epithelial phenotype (66); and showed anti-tumor effect in breast, prostate cancers and 
anaplastic thyroid carcinoma cell lines (67). Using tissue microarray (TMA), which facilitates 
a comprehensive expression analysis of proteins in multiple tissues (68, 69) we studied the 
differential expression of the proteins in the BMP7 signaling pathway as a possible diagnostic 
biomarker for thyroid lesions (Chapter 2).  
Molecular diagnostics 
Since 60 to 70% of thyroid cancers harbor at least one known genetic mutation, molecular 
analysis of thyroid tissue is a promising strategy to improve diagnosis in the indeterminate 
group of FNAC. The presence of established genetic alterations in FNA indicates malignancy 
with high specificity (70), which can lead to a recommendation for total thyroidectomy rather 
than for hemithyroidectomy. This approach is in particular useful when the pretest likelihood 
for malignancy is high (71).  
Another clinical application of molecular genetics in thyroid cancer is represented by the 
Gene Expression Classifier (GEC) (Veracyte, Inc.; South San Francisco, CA). GEC is a 167-
gene expression assay used to further re-diagnose cytological indeterminate samples into 
either benign or suspicious for malignancy. The ability of GEC to reclassify Bethesda III and 
IV nodules as benign or non-benign has a negative predictive value of > 94% implying that 
thyroid nodules with indeterminate cytologic abnormalities and benign gene-expression 
classifier results have a post-test probability of malignancy that is similar to the probability for 
nodules with cytologically benign features on FNAC (72). 
Initial therapy 
According to the consensus of the European Thyroid Association (ETA) and the guidelines of 




subjected to initial therapy consisting of near-total thyroidectomy followed by RAI remnant 
ablation therapy. Very-low-risk patients (small unifocal intrathyroidal lesions) may be treated 
with hemithyroidectomy alone. When lymph node metastases are present, modified neck 
dissection of the affected side is recommended, rather than picking-out. 
In recent years, the benefits of RAI ablation therapy are debated and a strategy based on 
risk of recurrence is recommended (73). RAI ablation is considered beneficial in high-risk 
patients (incomplete resection, distant metastases, lymph node metastases, aggressive 
histologies). For other patients, the effects of RAI on recurrence are controversial. As RAI is 
associated with side effects and a small but significant risk for other malignancies (75), the 
current position is to limit the indications for RAI and to use lower dosages. Recent landmark 
studies from France (ESTAMIBL) and the UK (HiLo) have indicated that 37 mCi is as 
efficacious as 100 mCi for thyroid remnant ablation (76, 77). Studies in the UK and France 
are now underway to evaluate abstention from RAI in intermediate risk patient groups.     
Successful RAI therapy is dependent on the stimulation of iodide uptake by TSH. In 
terms of preparation for RAI, high TSH levels can be realized either by discontinuation of 
levothyroxine therapy or by the application of rhTSH during levothyroxine therapy. In the 
ESTAMIBL and HiLo studies, ablation success was comparable between levothyroxine 
withdrawal and rhTSH.  Withdrawal however is poorly tolerated by patients and negatively 
affects quality of their life (78). The ultimate conclusion on comparability between thyroid 
hormone withdrawal and rhTSH can be drawn when long-term results on clinical outcome 
between the 2 approaches become available. 
The assumption of rhTSH aided RAI therapy is that the continuation of levothyroxine 
substitution has no effect on iodide uptake, or, in other words, that T3 does not have a direct 
effect on NIS expression. To investigate this important question, in Chapter 3, we performed 
in vitro studies in thyroid cell lines, to verify a direct effect of T3 on NIS expression and 
iodide uptake. 
Evaluation of initial therapy and follow-up 
The aim of the evaluation of initial therapy is to restratify patients in groups who are likely to 
be cured and groups with persistent disease or high risk for recurrent disease. As most patients 
will be cured after initial therapy, this restratification will allow a limited follow-up protocol 









An essential element in the evaluation of initial therapy is ultrasound of the neck, which is 
performed 6-9 months after surgery. Ultrasound combined with FNA has the highest 
sensitivity (94%) for local recurrence and lymph node metastases (79, 80) and thus, 
ultrasound has an important role in the follow-up of DTC. When suspicious lesions are 
present, FNA will be performed and when tumor is present, the patient will undergo re-
surgery, when cure is possible.   
Thyroglobulin 
The cornerstone in the biochemical evaluation of primary therapy are measurements of serum 
Tg. Serum Tg should be below an institutionally defined cut off level after total 
thyroidectomy and postoperative RAI ablation therapy. Until recently, it was recommended to 
measure Tg during TSH stimulation (73, 74). As in RAI ablation, traditionally, this approach 
was achieved by levothyroxine withdrawal. Currently, exogenous elevation of TSH levels is 
achieved via rhTSH injections without subjecting the patients to the disadvantages of 
iatrogenic hypothyroidism. The diagnostic sensitivity and negative predictive value of 
combining rhTSH stimulated Tg measurements with neck ultrasound is 96.3% and 99.5% 
respectively (81, 82). The advent of high sensitive Tg measurements has revealed that 
unstimulated Tg measurements have comparable diagnostic accuracy as rhTSH stimulated Tg 
measurements in subgroups of DTC patients with either very low or high Tg levels (83). 
When antibodies against Tg (TgAb) are present, Tg measurements are considered less 
reliable, and other imaging techniques (ultrasound and others) are needed to establish cure. 
Although TgAb titers may be related to disease state in epidemiological studies, they have 
insufficient diagnostic accuracy for use as tumor marker in individual patients (84). 
Diagnostic whole body scan (WBS) 
Diagnostic whole body scan (WBS) with RAI is no longer recommended for routine 
evaluation of the success of initial therapy in all patients and is now only recommended when 
TgAb are present or in selected subgroups of high risk patients (74).  
Restratification 
According to retrospective studies of Castagna and Tuttle, DTC patients with undetectable Tg 
levels, absent TgAb and negative ultrasound after initial therapy have a very low risk of 




Patients with elevated Tg levels may be followed by repeat Tg measurements, as Tg levels 
may decrease in a substantial proportion of patients during the first year after initial therapy 
(85, 86). When Tg levels increase, imaging (CT and/or FDG-PET) may be performed and 
RAI therapy may be performed. Presence of FDG-PET positive lesions is related with a worse 
prognosis (87, 88). 
Patients with high-risk of recurrence and metastasis are followed up with regular Tg 
measurements and/or imaging procedures.  
TSH suppression 
Until recently, it was recommended in all DTC patients, irrespective of their disease state, to 
maintain low TSH levels, as TSH is considered as a tumor promoting hormone (37). As recent 
studies have demonstrated a negative effect of TSH on prognosis only in high-risk patients 
(88, 89), it is now recommended to maintain low TSH levels  (<0.1 mU/L) in high-risk 
patients or patients with active disease while in others, levothyroxine therapy can be titrated to 
normal TSH levels  (20, 37).  
Recurrent or persistent disease 
Conventional therapy 
When a malignant lesion is accessible surgery can be performed. In the majority of patients, 
this will be loco-regional recurrences with no distant metastases. In solitary pulmonary, bone 
or brain metastases, surgery can also be attempted. If a malignant lesion is present which 
cannot be cured by surgery, RAI therapy may be performed. The remission rate in pulmonary 
metastases treated with RAI varies from 90% in patients with microscopic metastases to 10% 
in macroscopic metastatic disease and from 20-7% in bone metastases (90, 91). High 
cumulative dosages of RAI are associated with increased risk of secondary malignancies in 
addition to other complications (92-94).  
Palliative therapies include external irradiation, radiofrequency ablation, 
chemoembolization and for pulmonary metastases, endobronchial laser therapy (95-98).  
Resistance to radioactive iodide  
Five to 15% of DTC patients will develop or present with local recurrent disease or 
metastasis. In 25-66% of these patients, the susceptibility to RAI is diminished or lost (4). The 
clinical definition of RAI refractoriness that also was used in the DECISION trial (see below) 







after RAI therapy and/or the absence of a beneficial effect of RAI, despite uptake of RAI. It 
has been established by a French group that no additional beneficial effect of RAI is observed 
after a cumulative dose of 600 mCi (3). Absence of a beneficial effect of RAI can be defined 
as disease progression, according to RECIST, within 1 year after the last RAI therapy (99).  
The mechanism of RAI refractoriness not only involves the loss of NIS expression, which 
is related with genetic changes in DTC (see earlier), but also defective transport of NIS to the 
cell membrane. Furthermore, changes in RAI kinetics, related to the loss of follicular 
architecture and/or defects in the apoptotic machinery in DTC may be involved. 
Treatment options for patients with RAI resistance were until recently limited to 
palliative treatment, as conventional chemotherapy is not effective in DTC. Recently, novel 
treatment options have become available in terms of kinase inhibitors. 
KINASE INHIBITORS 
Kinase inhibitors selectively bind to the substrate binding domain of intracellular signaling 
peptides with kinase activity. In many types of cancer, genetic alterations directly or indirectly 
lead to the activation of kinase pathways. Therefore, the identification of activated kinase 
pathways as well as the development of compounds that selectively interfere with these 
pathways has offered important new perspectives for cancer therapy. The identification of the 
molecular pathogenesis of DTC (see earlier) has led to the selection of kinase inhibitors that 
specifically interfere with these pathways and therefore open new roads in the treatment of 
RAI refractory DTC. Kinase inhibitors target either one specific kinase (selective KI) or 
multiple kinases (MKI) (100, 101).   
Motesanib was the first MKI to be tested in a multicenter, open-label phase II trial in 93 
patients with radiographically progressive DTC resulting in a partial response (PR) of 14% 
according to RECIST criteria (102, 103). Other MKIs have been studied for their efficacy and 
safety in phase II trials, such as axitinib (104), sunitinib (105), imatinib (106), cabozantinib 
(107), lenvatinib (108) and sorafenib (109-121) (table 2).  
Some MKI have been investigated in phase III studies. The DECISION trial, with 
sorafenib, was the first phase III study with a MKI in DTC (121). A phase III study with 
lenvatinib (SELECT study) was recently completed (126). Data of DECISION and SELECT 





In addition to MKI, compounds have been developed that selectively target mutated 
kinases. Vemurafenib, which specifically targets mutated BRAFV600E, has been studied in 
patients with BRAFV600E positive PTC. Median progression free survival (PFS)  after 
treatment with vemurafenib in treatment naive patients was 15.6 months, in patients who 
failed on sorafenib 6.8 months (128). Another recent study involved 15 BRAFV600E positive 
PTC patients, where 47% showed PR (129).    
 
Table 2: Clinical trials of  Tyrosine Kinase inhibitors in advanced thyroid cancer with focus on differentiated 
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1,2, 3&  
cKit 
II DTC 37   49  (124) 
Selumetinib 
(SKI) 
MEK-1/2 II PTC 32 7.4  3 54 (100) 
II PTC 20 New/ increase RAI uptake in 60% of 
patients (100% with NRAS 
mutations). PR 5/8; SD 3/8 
(125) 
MKI: multikinase inhibitor; SKI: single kinase inhibitor; PFS: mean Progression Free Survival; CR: complete 




Sorafenib (BAY 43-9006) is an oral MKI targeting the serine/threonine kinase wild-type 
and mutant BRAF V600E, along with several other tyrosine-kinases including RET and the 
angiogenic tyrosine kinase growth receptors (VEGFR 2,VEGFR 3 and PDGFR beta). It also 
targets c-KIT and Flt-3 (109, 114). The drug actions in thyroid cancer are thus 
antiproliferative and anti-angiogenic.   
Sorafenib has been approved by the the FDA and the EMA for the treatment of metastatic 
RAI resistant DTC (130, 131). Between 2008 and 2013 sorafenib was studied in a number of 
phase II clinical trials, one retrospective longitudinal study and 1 phase III, randomized, 
placebo-controlled, multicenter trial study (DECISION trial) (109, 110, 114, 116, 117, 119-
121, 132). The phase II studies included either DTC patients only or DTC with ATC and 
MTC. The median PFS in phase II studies ranged from 13-19.5 months. PR rates observed in 
these studies ranged from 15%-25%. In Chapter 4, we report the long-term outcomes of one 




The DECISION trial is a multicentre, randomised, double-blind, placebo-controlled, 
phase 3 trial in which 417 patients with radioactive iodide-refractory locally advanced or 
metastatic DTC that had progressed within the past 14 months were treated with sorafenib 
(400 mg orally twice daily) or placebo. Median PFS was significantly longer in the sorafenib 
group (10.8 months) than in the placebo group (5.8 months). PFS improved in all prespecified 
clinical and genetic biomarker subgroups, irrespective of mutation status (121). 
The SELECT study is randomized, double-blind, placebo -controlled phase III study in 
which 392 DTC patients with the same characteristics as DECISION were randomized 2:1 to 
lenvatinib or placebo. Median PFS was 18.3 months in lenvatinib vs. 3.6 months in placebo.  
Benefit was observed in all predefined subgroups (126)  
Both studies have for the first time shown that MKI have a benefit on PFS in patients 
with advanced DTC and are therefore landmark studies. Questions to be answered remain the 
selection of subgroups of patients who benefit most from these drugs, the optimal time point 
of initiation of therapy and the optimal dosing strategy. It is now recommended to initiate 
therapy with MKI when RAI resistance is present, when progression has been established 
according to RECIST and when considerable tumor load is present (99) . 
Toxicity is common in all kinase inhibitors. Most of the side effects include muco-
cutaneous problems (hand foot syndrome, skin rash, stomatitis, dysphonia, photosensitivity, 
keratoacanthomas and malignant squamous cell lesion), fatigue, weight loss, cardiovascular 
manifestations (hypertension, QT interval prolongation and thromboembolism) and 
gastrointestinal manifestations (diarrhea and nausea). In the DECISION trial, adverse events 
occurred in 99% patients receiving sorafenib during the double-blind period and in 88% 
patients receiving placebo. Most adverse events were grade 1 or 2. The most frequent 
treatment-emergent adverse events in the sorafenib group were hand-foot skin reaction (76%), 
diarrhoea (68·6%), alopecia (67%), and rash or desquamation (50%) (121). In the SELECT 
study, the 5 most common adverse events of lenvatinib were hypertension (68%), diarrhea 
(59%), weight loss (46%), nausea (41%) and proteinuria (126).  
Metabolic side effects are reported in MKI therapy, including hypocalcaemia and 
hypothyroidism (133, 134). Hypothyroidism has been reported in motesanib (102), sorafenib  
(135), imatinib (136, 137), sunitinib (135) and vandetanib requiring adjustments in the dosage 
of thyroid hormone replacement therapy (138). As DTC patients are athyreotic after surgery, 







degradation. In chapter 5, we studied the hypothesis that sorafenib enhances peripheral 
inactivation of thyroid hormone via increased activity of type 3 deiodinase. 
REDIFFERENTIATION 
Despite the fact that the above mentioned studies with MKI offer important new perspectives 
for DTC patients with RAI refractory tumors, the proportion of complete remissions is very 
low. Consequently, additional approaches are warranted, which include both combination 
therapies as well as strategies aimed at redifferentiation.  
In recent years, a number of studies have been performed to investigate the potential to 
induce redifferentiation of thyroid carcinoma cells, with retinoic acid, lithium and histone 
modification agents (139-141). These treatments however had only a modest clinical benefit. 
Preclinical studies showed that switching off the BRAF activation, either genetically or 
through inhibition of its downstream signalling molecules (MAPK), restores the iodide uptake 
in TC cells and that selective MAPK pathway antagonists increase the iodide uptake in these 
cells (142-144). Based on these observations Ho et al carried out a trial in 20 patients with 
advanced, RAI refractory DTC who underwent treatment with selumetinib for 4 weeks after 
which RAI uptake was evaluated. Patients showing sufficient iodide uptake (8/20) were 
subsequently treated with RAI. Of these, 5 had confirmed PR and 3 had stable disease. 
Moreover enhanced iodide uptake was also found in bone and nodal metastases (125). 
In Chapter 6, we performed in depth studies on the regulation of functional NIS 
expression, in order to identify new approaches to enhance RAI uptake in DTC. These studies 
are based on the observation that 5`Adenosine monophosphate-activated protein kinase 
(AMPK) plays an important role in NIS expression.  
Both AMPK and thyroid hormone play a crucial role in energy metabolism (11, 145). 
Recently, AMPK has been associated with direct regulatory effects on thyroid function (146, 
147). AMPK is an energy sensing heterotrimeric complex that plays an important role in the 
energy balance on both the cellular level and the whole body by balancing nutrient supply and 
demand (145).  
Metformin is the first-line drug of choice for the treatment of type 2 diabetes (148). The 
AMPK-dependent signalling pathway is considered the key effector of the action of 
metformin (148, 149). Two recent studies have shown that AMPK activation in thyrocytes 
decreases iodide uptake and NIS expression and increases glucose uptake (146, 147). In 




thyrocyte function both in-vivo and in-vitro and the transcriptional regulatory role of the 
AMPK- dependent signalling pathway on NIS protein expression. 
 
ADVERSE EFFECTS OF ABNORMAL THYROID HORMONE SERUM 
CONCENTRATIONS IN DTC PATIENTS 
Patients with DTC experience abnormal thyroid hormone levels in two ways: in many 
patients, levothyroxine substitution is withdrawn in preparation for RAI therapy in order to 
realize high TSH levels. As a consequence, patients will experience episodes of 
hypothyroidism, which may have disadvantageous effects.   
As mentioned above (Evaluation of primary therapy and Follow up), patients are being 
treated with TSH-suppressive therapy to inhibit TSH-dependent growth of residual cancer 
cells (37). Unless recurrence or metastases develop patients are then switched to euthyroidal 
doses of levothyroxine (20). Although long-term TSH suppression may be associated with an 
overall better prognosis in high-risk patients (37), harmful effects on the cardiovascular 
system, carbohydrate metabolism, psychological well-being and bone mineral density may be 
present (37). Studies about the adverse effects on bone mineral density have been inconsistent, 
possibly because of the different lengths of treatment, administered dosages, methodologies or 
sample sizes. Most studies did not find adverse effects in premenopausal women or men (150-
155), whereas the effects on postmenopausal women are inconsistent (150-152, 156).  
Cardiovascular system 
A recent published retrospective cohort study showed that the risk of cardiovascular mortality 
is increased 3.3-fold in patients with DTC compared with controls, independent of age, sex, 
and cardiovascular risk factors (157). Each 10-fold decrease in the geometric mean TSH level 
is independently associated with a 3.1-fold increased risk of cardiovascular mortality. Another 
recent study in mortality in DTC showed that cardiac and cerebrovascular diseases are the 
most frequent causes of non-cancer mortality (158). Long- term subclinical hyperthyroidism 
in middle aged individuals results in increased heart rate, increased left ventricular mass 
(LVM), increased mean arterial pressure, and diastolic dysfunction while in elderly patients 
(>60 years old) supraventricular arrhythmias, including atrial fibrillation are prevalent (37, 







Increased LVM with left ventricular concentric remodelling in long-standing subclinical 
hyperthyroidism leads to systolic dysfunction (161, 162), and is associated with increased 
mortality (163). 
In Chapter 7, we analysed the effects of prolonged TSH suppressive levothyroxine 
therapy on cardiac dimensions and function using 2-dimensional (2D) speckle tracking 
echocardiography, which permits the study of multidirectional active deformation of the 
myocardium (radial, circumferential and longitudinal strain and strain rate), providing 
comprehensive information on myocardial function (contractility) (164-166).  
During levothyroxine withdrawal, patients are repeatedly exposed to short-term 
hypothyroidism. Young- and middle-aged patients with short-term hypothyroidism show 
reduced exercise capacity and an increased prevalence of hypertension. In patients with pre-
existing cardiovascular diseases, their condition worsens (78). Short-term hypothyroidism 
mostly results in impaired diastolic and/or systolic function (78, 167-174). Most of these 
cardiovascular alterations are reversible after reinduction of levothyroxine therapy (78, 175).  
In Chapter 8, using 2D speckle tracking echocardiography, we analysed changes in left 
ventricular function in DTC patients in transition from exogenous subclinical hyperthyroidism 
via euthyroidism to overt hypothyroidism. 
 
Health-related quality of life (HRQOL) 
It is obvious that a diagnosis of cancer has a major impact on psychological well-being. This 
is evident in patients with active and progressive disease. As DTC is considered a malignancy 
with an overall limited aggressiveness, until recently, it was not suspected that cured DTC 
patients may suffer from impaired quality of life, even as these patients were sometimes 
subjected to lifelong follow-up.  
In a systematic review it was found that thyroid cancer survivors generally have a similar 
or worse HRQoL compared with controls (176). 
In a subsequent large controlled study, the same authors found that long-term thyroid cancer 
survivors experienced more symptoms and deteriorated HRQoL compared to the normative 
population (177). Interestingly, it was found that thyroid cancer survivors experienced several 
areas of information provision as insufficient, which could contribute to their diminished 





OUTLINE OF THE THESIS 
In this thesis several basic and clinical questions regarding diagnosis, therapy and adverse 
effects of therapy in DTC are addressed in clinical and preclinical studies.  
In Chapter 2, we describe an immmunohistochemical study in patients with benign and 
malignant thyroid disorders to explore the diagnostic value of BMP-7 and its signalling 
pathway. 
In Chapter 3 we study the hypothesis of a short negative feedback effect of thyroid 
hormone on the regulation and expression of the sodium iodide symporter (NIS). 
In Chapter 4 we describe the long-term efficacy and safety of the multikinase inhibitor 
sorafenib in patients with advanced DTC that are no longer RAI responsive. 
In Chapter 5, we study the hypothesis that sorafenib induced hypothyroidism is related 
to alterations in enhanced metabolism of levothyroxine through induction of type 3 
deiodinase. 
 In Chapter 6 we describe mechanistic studies aimed at the improvement of functional 
NIS expression by interfering with AMPK  
In Chapters 7 and 8, the consequences of TSH suppressive levothyroxine dosages as 
well as short term hypothyroidism on the cardiovascular system are being described, using 
dedicated cardiac ultrasound.  
Finally, Chapter 9 provides a summary of the results and a discussion of their 














1. Vanderzwan J, van der Zwan S, Mallone B, van Dijk M, Bielska Lasota Rƒ-e, Otter R, et 
al. Carcinoma of endocrine organs: Results of the RARECARE project. Eur J Cancer. 
2012;48(13):1923-31. 
2. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A 
population-based study of 15,698 cases from the Surveillance, Epidemiology and End 
Results (SEER) program 1973-1991. Cancer. 1997;79(3):564-73. 
3. Durante C, Haddy NF, Baudin EFAUL, Leboulleux SFAUH, Hartl DF, Travagli Jp FAU, et 
al. Long-term outcome of 444 patients with distant metastases from papillary and 
follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin 
Endocrinol Metab. 2006;91(8):2892-9. 
4. Brose M, Brose J, Smit J, Capdevila R, Elisei C, Nutting F, et al. Regional approaches to 
the management of patients with advanced, radioactive iodine-refractory 
differentiated thyroid carcinoma. Expert Revi Anticancer Ther. 2012;12(9):1137-47. 
5. Dohan O, Carrasco N. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid 
and beyond. Mol Cell Endocrinol. 2003;213(1):59-70. 
6. Colin IM. Recent Insights into the Cell Biology of Thyroid Angiofollicular Units. Endocr 
Rev. 2013;34(2):209-38. 
7. Theodoropoulou A, Vagenakis AG, Makri M, Markou KB. Thyroid hormone synthesis 
and secretion in humans after 80 milligrams of iodine for 15 days and subsequent 
withdrawal. J Clin Endocrinol Metab. 2007;92(1):212-4. 
8. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and 
molecular biology, and physiological roles of the iodothyronine selenodeiodinases. 
Endocr Rev. 2002;23(1):38-89. 
9. Fekkes D, Hennemann G, Visser TJ. Evidence for a single enzyme in rat liver catalysing 
the deiodination of the tyrosyl and the phenolic ring of iodothyronines. Biochem J. 
1982;201(3):673-6. 
10. Hosoi Y, Murakami M, Mizuma H, Ogiwara T, Imamura M, Mori M. Expression and 
regulation of type II iodothyronine deiodinase in cultured human skeletal muscle 
cells. J Clin Endocrinol Metab. 1999;84(9):3293-300. 
11. Tata JR. Looking for the mechanism of action of thyroid hormone. J Thyroid Res. 
2011;2011:730630. 
12. Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, et al. The c-erb-A protein is 
a high-affinity receptor for thyroid hormone. Nature. 1986;324(6098):635-40. 
13. Yen PM, Ikeda M, Brubaker JH, Forgione M, Sugawara A, Chin WW. Roles of v-erbA 
homodimers and heterodimers in mediating dominant negative activity by v-erbA. J 




14. Gnocchi D, Leoni S, Incerpi S, Bruscalupi G. 3,5,3'-triiodothyronine (T3) stimulates cell 
proliferation through the activation of the PI3K/Akt pathway and reactive oxygen 
species (ROS) production in chick embryo hepatocytes. Steroids. 2012;77(6):589-95. 
15. Lei J, Mariash CN, Bhargava M, Wattenberg EV, Ingbar DH. T3 increases Na-K-ATPase 
activity via a MAPK/ERK1/2-dependent pathway in rat adult alveolar epithelial cells. 
Am J Physiol Lung Cell Mol Physiol. 2008;294(4):L749-L54. 
16. Lopez M, Varela L, Vazquez MJ, Rodriguez-Cuenca S, Gonzalez CR, Velagapudi VR, et 
al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of 
energy balance. Nat Med. 2010;16(9):1001-8. 
17. Irrcher I, Walkinshaw DR, Sheehan TE, Hood DA. Thyroid hormone (T3) rapidly 
activates p38 and AMPK in skeletal muscle in vivo. J Appl Physiol. 2008;104(1):178-85. 
18. Cohen K, Ellis M, Khoury S, Davis PJ, Hercbergs A, Ashur-Fabian O. Thyroid hormone is 
a MAPK-dependent growth factor for human myeloma cells acting via alphavbeta3 
integrin. Mol Cancer Res. 2011;9(10):1385-94. 
19. Lin HY, Tang HY, Davis FB, Mousa SA, Incerpi S, Luidens MK, et al. Nongenomic 
regulation by thyroid hormone of plasma membrane ion and small molecule pumps. 
Discov Med. 2012;14(76):199-206. 
20. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management 
guidelines for patients with thyroid nodules and differentiated thyroid cancer. 
Thyroid. 2006;16(2):109-42. 
21. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide 
burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer Journal international du 
cancer. 2010;127(12):2893-917. 
22. Husson O, Haak HR, van Steenbergen LN, Nieuwlaat WA, van Dijk BA, Nieuwenhuijzen 
GA, et al. Rising incidence, no change in survival and decreasing mortality from 
thyroid cancer in The Netherlands since 1989. Endocr Relat Cancer. 2013;20(2):263-
71. 
23. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-
2002. JAMA. 2006;295(18):2164-7. 
24. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation 
between genetic alterations and microscopic features, clinical manifestations, and 
prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 
2006;30(2):216-22. 
25. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of 
BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the 








26. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and 
RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. 
Oncogene. 2003;22(29):4578-80. 
27. Frattini M, Ferrario C, Bressan P, Balestra D, De CL, Mondellini P, et al. Alternative 
mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene 
expression patterns in papillary thyroid cancer. Oncogene. 2004;23(44):7436-40. 
28. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. RAS 
point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence 
for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol 
Metab. 2003;88(5):2318-26. 
29. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular 
pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16(1):17-44. 
30. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in 
thyroid cancer. Thyroid. 2010;20(7):697-706. 
31. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational 
profile of advanced primary and metastatic radioactive iodine-refractory thyroid 
cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 
2009;69(11):4885-93. 
32. Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler MP, Allou L, et al. BRAF, p53 
and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. 
Pathology. 2011;43(5):447-52. 
33. Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De PG, Pierotti MA, et al. RET/PTC1-
driven neoplastic transformation and proinvasive phenotype of human thyrocytes 
involve Met induction and beta-catenin nuclear translocation. Neoplasia. 
2009;11(1):10-21. 
34. Castellone MD, De FV, Rao DM, Bellelli R, Muthu M, Basolo F, et al. The beta-catenin 
axis integrates multiple signals downstream from RET/papillary thyroid carcinoma 
leading to cell proliferation. Cancer Res. 2009;69(5):1867-76. 
35. Tartari CJ, Donadoni C, Manieri E, Mologni L, Mina PD, Villa A, et al. Dissection of the 
RET/beta-catenin interaction in the TPC1 thyroid cancer cell line. Am J Cancer Res. 
2011;1(6):716-25. 
36. Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N. Rapid communication: 
predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large 
sampling of thyroid cancer cases. J Clin Endocrinol Metab. 2001;86(6):2697-700. 
37. Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse 
effects in differentiated thyroid cancer. Thyroid. 2010;20(2):135-46. 
38. Torrens JI, Burch HB. Serum thyroglobulin measurement. Utility in clinical practice. 




39. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M. The efficacy of the thyroid 
peroxidase marker for distinguishing follicular thyroid carcinoma from follicular 
adenoma. Exp Oncol. 2006;28(1):70-4. 
40. Gerard AC, Daumerie C, Mestdagh C, Gohy S, De BC, Costagliola S, et al. Correlation 
between the loss of thyroglobulin iodination and the expression of thyroid-specific 
proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol 
Metab. 2003;88(10):4977-83. 
41. Tanaka T, Umeki K, Yamamoto I, Sugiyama S, Noguchi S, Ohtaki S. 
Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: 
strong suppression of peroxidase gene expression. J Pathol. 1996;179(1):89-94. 
42. Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, et al. Expression of the Na+/I- 
symporter gene in human thyroid tumors: a comparison study with other thyroid-
specific genes. J Clin Endocrinol Metab. 1999;84(9):3228-34. 
43. Ward LS, Santarosa PL, Granja F, da Assumpcao LV, Savoldi M, Goldman GH. Low 
expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer 
Lett. 2003;200(1):85-91. 
44. Sodre AK, Rubio IG, Galrao AL, Knobel M, Tomimori EK, Alves VA, et al. Association of 
low sodium-iodide symporter messenger ribonucleic acid expression in malignant 
thyroid nodules with increased intracellular protein staining. J Clin Endocrinol Metab. 
2008;93(10):4141-5. 
45. Tanaka K, Sonoo H, Yamamoto Y, Udagawa K, Kunisue H, Arime I, et al. Changes of 
expression level of the differentiation markers in papillary thyroid carcinoma under 
thyrotropin suppression therapy in vivo immunohistochemical detection of 
thyroglobulin, thyroid peroxidase, and thyrotropin receptor. J Surg Oncol. 
2000;75(2):108-16. 
46. Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, Hoang-Vu C, et al. Human 
thyrotropin receptor gene: expression in thyroid tumors and correlation to markers 
of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol. 1991;82(1):R7-
12. 
47. Kleiman DA, Buitrago D, Crowley MJ, Beninato T, Veach AJ, Zanzonico PB, et al. 
Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during 
BRAF silencing. J Surg Res. 2013;182(1):85-93. 
48. Riesco-Eizaguirre G, Rodriguez I, De lV, Costamagna E, Carrasco N, Nistal M, et al. The 
BRAFV600E oncogene induces transforming growth factor beta secretion leading to 
sodium iodide symporter repression and increased malignancy in thyroid cancer. 
Cancer Res. 2009;69(21):8317-25. 
49. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al. BRAF mutations 
in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin 







50. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients 
with sporadic papillary thyroid carcinomas: correlation with more aggressive 
phenotype and decreased expression of iodide-metabolizing genes. Cancer. 
2009;115(5):972-80. 
51. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, et al. BRAFV600E 
mutation, but not RET/PTC rearrangements, is correlated with a lower expression of 
both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. 
Endocr Relat Cancer. 2008;15(2):511-20. 
52. Serrano-Nascimento C, da Silva Teixeira S, Nicola JP, Nachbar RT, Masini-Repiso AM, 
Nunes MT. The acute inhibitory effect of iodide excess on sodium/iodide symporter 
expression and activity involves the PI3K/Akt signaling pathway. Endocrinology. 
2014;155(3):1145-56. 
53. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular 
diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 
2011;96(7):2016-26. 
54. Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle aspiration in the 
diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer. 
2000;90(6):357-63. 
55. Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, et al. A large 
multicenter correlation study of thyroid nodule cytopathology and histopathology. 
Thyroid. 2011;21(3):243-51. 
56. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat 
Rev Endocrinol. 2011;7(10):569-80. 
57. Bergenfelz A, Jansson S, Kristoffersson A, Martensson H, Reihner E, Wallin G, et al. 
Complications to thyroid surgery: results as reported in a database from a 
multicenter audit comprising 3,660 patients. Langenbecks Arch surgery / Deutsche 
Gesellschaft fur Chirurgie. 2008;393(5):667-73. 
58. Cibas ES, Ali SZ. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin 
Pathol. 2009;132(5):658-65. 
59. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, et al. Diagnostic 
terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a 
synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the 
Science Conference. Diagn Cytopathol. 2008;36(6):425-37. 
60. de Matos PS, Ferreira AP, de Oliveira FF, Assumpcao LV, Metze K, Ward LS. Usefulness 
of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid 
malignancy. Histopathology. 2005;47(4):391-401. 
61. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW. Combined 
immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-




sodium/iodide symporter antibodies for the differential diagnosis of non-medullary 
thyroid carcinoma. Eur J Endocrinol. 2008;158(3):375-84. 
62. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, et al. Immunohistochemical 
separation of follicular variant of papillary thyroid carcinoma from follicular 
adenoma. Endocr Pathol. 2006;17(3):213-23. 
63. de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima FM, Del GA, da Silva Pinhal MA. 
Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: 
systematic review and diagnostic meta-analysis. Diagn Pathol. 2012;7:97. 
64. Franzen A, Piek E, Westermark B, ten DP, Heldin NE. Expression of transforming 
growth factor-beta1, activin A, and their receptors in thyroid follicle cells: negative 
regulation of thyrocyte growth and function. Endocrinology. 1999;140(9):4300-10. 
65. Suzuki J, Otsuka F, Takeda M, Inagaki K, Miyoshi T, Mimura Y, et al. Functional roles of 
the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid 
cells. Biochem Biophys Res Commun. 2005;327(4):1124-30. 
66. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, ten Dijke P, van der Pluijm 
G. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin 
Exp Metastasis. 2007;24(8):609-17. 
67. Franzen A, Heldin NE. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma 
cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun. 2001;285(3):773-
81. 
68. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue 
microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 
1998;4(7):844-7. 
69. Hewitt SM. Tissue microarrays as a tool in the discovery and validation of predictive 
biomarkers. Methods Mol Biol. 2012;823:201-14. 
70. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. 
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of 
thyroid nodules. J Clin Endocrinol Metab. 2009;94(6):2092-8. 
71. Eszlinger M, Eszlinger R, Paschke. Molecular fine-needle aspiration biopsy diagnosis 
of thyroid nodules by tumor specific mutations and gene expression patterns. Mol 
Cell Endocrinol. 2010;322(1):29-37. 
72. Alexander E, Alexander G, Kennedy Z, Baloch E, Cibas D, Chudova J, et al. 
Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. N 
Engl J Med. 2012;367(8):705-15. 
73. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised 
American Thyroid Association management guidelines for patients with thyroid 







74. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European 
consensus for the management of patients with differentiated thyroid carcinoma of 
the follicular epithelium. Eur J Endocrinol. 2006;154(6):787-803. 
75. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl 
Compr Canc Netw : JNCCN. 2010;8(11):1277-86; quiz 87. 
76. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies 
of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 
2012;366(18):1663-73. 
77. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose 
radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674-
85. 
78. Duntas LH, Biondi B. Short-term hypothyroidism after Levothyroxine-withdrawal in 
patients with differentiated thyroid cancer: clinical and quality of life consequences. 
Eur J Endocrinol. 2007;156(1):13-9. 
79. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, et al. Serum 
thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in 
the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol. 
2003;148(1):19-24. 
80. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck 
recurrences in patients with differentiated thyroid carcinoma. Cancer. 2003;97(1):90-
6. 
81. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. 
Radioiodine ablation of thyroid remnants after preparation with recombinant human 
thyrotropin in differentiated thyroid carcinoma: results of an international, 
randomized, controlled study. J Clin Endocrinol Metab. 2006;91(3):926-32. 
82. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, et al. Post-surgical 
use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and 
the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153(5):651-
9. 
83. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, et al. Long-
term follow-up of patients with papillary and follicular thyroid cancer: a prospective 
study on 715 patients. J Clin Endocrinol Metab. 2011;96(5):1352-9. 
84. Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, et al. Implications of 
thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a 
clinical position statement. Thyroid. 2013;23(10):1211-25. 
85. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, et al. 
Delayed risk stratification, to include the response to initial treatment (surgery and 
radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer 




86. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of 
recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive 
iodine remnant ablation: using response to therapy variables to modify the initial risk 
estimates predicted by the new American Thyroid Association staging system. 
Thyroid. 2010;20(12):1341-9. 
87. Mosci C, Iagaru A. PET/CT imaging of thyroid cancer. Clin Nucl Med. 
2011;36(12):e180-e5. 
88. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, et al. 
Associations of serum thyrotropin concentrations with recurrence and death in 
differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92(7):2610-5. 
89. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of 
patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 
2006;16(12):1229-42. 
90. Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, et al. 
Clinical outcomes and molecular profile of differentiated thyroid cancers with 
radioiodine-avid distant metastases. J Clin Endocrinol Metab. 2013;98(5):E829-36. 
91. Schlumberger M, Tubiana M, De VF, Hill C, Gardet P, Travagli JP, et al. Long-term 
results of treatment of 283 patients with lung and bone metastases from 
differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63(4):960-7. 
92. Mandel SJ. Radioactive iodine and the salivary glands. Thyroid. 2003;13:265-71. 
93. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA. Nasolacrimal drainage 
system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin 
Endocrinol Metab. 2002;87(12):5817-20. 
94. Rubino C. Second primary malignancies in thyroid cancer patients. Br J Cancer. 
2003;89:1638-44. 
95. Haugen BR. Management of the patient with progressive radioiodine non-responsive 
disease. Semin Surg Oncology. 1999;16(1):34-41. 
96. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. Radiofrequency ablation and 
percutaneous ethanol injection treatment for recurrent local and distant well-
differentiated thyroid carcinoma. Ann Surg. 2006;244(2):296-304. 
97. Vogl TJ, Lehnert T, Zangos S, Eichler K, Hammerstingl R, Korkusuz H, et al. 
Transpulmonary chemoembolization (TPCE) as a treatment for unresectable lung 
metastases. Eur Radiol. 2008;18(11):2449-55. 
98. Wood DE. Management of malignant tracheobronchial obstruction. Surg Clin North 
Am. 2002;82(3):621-42. 
99. Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition 
and management of radioactive iodine-refractory differentiated thyroid cancer. 







100. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, et al. 
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-
142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular 
elements. Clin Cancer Res. 2012;18(7):2056-65. 
101. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. Clinical 
responses to vemurafenib in patients with metastatic papillary thyroid cancer 
harboring BRAF(V600E) mutation. Thyroid. 2013;23(10):1277-83. 
102. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, et al. Motesanib 
diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 
2008;359(1):31-42. 
103. Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, et al. 
Biomarkers as predictors of response to treatment with motesanib in patients with 
progressive advanced thyroid cancer. J Clin Endocrinol Metab. 2010;95(11):5018-27. 
104. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an 
active treatment for all histologic subtypes of advanced thyroid cancer: results from a 
phase II study. J Clin Oncol. 2008;26(29):4708-13. 
105. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of 
daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer 
and metastatic medullary carcinoma of the thyroid with functional imaging 
correlation. Clin Cancer Res. 2010;16(21):5260-8. 
106. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, et al. A phase II study of 
imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 
2010;20(9):975-80. 
107. Cabanillas ME. Antitumor activity of cabozantinib (XL184) in a cohort of patients with 
differentiated thyroid cancer (DTC). Thyroid. 2012;2(1):7. 
108. Schlumberger M. A phase II trial of the multi-targeted kinase inhibitor lenvatinib 
(E7080) in advanced medullary thyroid cancer (MCT). Ann Oncol. 2012;23:35. 
109. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, et al. Analysis of 
the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based 
population. Eur J Endocrinol. 2011;165(2):315-22. 
110. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, et al. 
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, 
in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923-
31. 
111. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. 
Combination targeted therapy with sorafenib and bevacizumab results in enhanced 




112. Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, et al. Combination 
therapy: intermittent sorafenib with bevacizumab yields activity and decreased 
toxicity. Br J Cancer. 2010;102(3):495-9. 
113. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, et al. Inhibition of 
the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the 
multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in 
medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 
2011;96(4):997-1005. 
114. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-
term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine 
refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J 
Endocrinol. 2012;167(5):643-50. 
115. Sherman EJ. A phase II study of temsirolimus/sorafenib in patients with radioactive 
iodine (RAI)-refractory thyroid carcinoma. J Clin Oncol. 2012;30:5514. 
116. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et 
al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 
2008;26(29):4714-9. 
117. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of 
sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675-84. 
118. Keefe SM. Phase II trial of sorafenib in patients with advanced thyroid cancer. J Clin 
Oncol. 2011;29:5562. 
119. Chen L, Shen Y, Luo Q, Yu Y, Lu H, Zhu R. Response to sorafenib at a low dose in 
patients with radioiodine-refractory pulmonary metastases from papillary thyroid 
carcinoma. Thyroid. 2011;21(2):119-24. 
120. Capdevila J, Iglesias L, Halperin I, Segura A, Martinez-Trufero J, Vaz MA, et al. 
Sorafenib in metastatic thyroid cancer. Endocr Rrelat Cancer. 2012;19(2):209-16. 
121. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in 
radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid 
cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319-28. 
122. Cohen E, Needles B, Cullen K, Wong S, Wade J, Ivy S, et al. Phase 2 study of sunitinib 
in refractory thyroid cancer. J Clin Oncol. 2008;26(15 suppl):6025. 
123. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, et al. 
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a 
randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897-905. 
124. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, et al. Efficacy 
of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid 







125. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-
enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 
2013;368(7):623-32. 
126. Schlumberger M, Tahara M, Wirth L, Robinson B, Brose M, Elisei R. A phase 3, 
multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients 
with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol. 
2014;32(suppl):LBA6008. 
127. Clinical Trials.gov (2015). "Evaluation of Efficacy, Safety of Vandetanib in Patients 
With Differentiated Thyroid Cancer (VERIFY)." Retrieved 9 June, 2015, from 
https://clinicaltrials.gov/show/NCT01876784. 
128. Brose, M. Vemurafenib in Patients With RAI Refractory, Progressive, BRAFV600E-
mutated Papillary Thyroid Cancer. Late-breaking abstract  (Abstract E17-7119). ESMO 
@ ECC. 28th September, 2013. 
129. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, et al. Efficacy and 
Tolerability of Vemurafenib in Patients with BRAF -Positive Papillary Thyroid Cancer: 
M.D. Anderson Cancer Center Off Label Experience. J Clin Endocrinol Metab. 
2014:jc20142246. 
130. U.S. Food and Drug Administration (2013). "FDA approves Nexavar to treat type of 
thyroid cancer." Retrieved 9 June, 2015, from 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376443.htm 
131.     European Medicines Agency (2014). "European Medicines Agency recommends 
extending use of Nexavar to include treatment of differentiated thyroid cancer." 
Retrieved 9 June, 2015, from 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/201
4/04/news_detail_002081.jsp&mid=WC0b01ac058004d5c1. 
132. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, et al. Rationale and 
design of decision: a double-blind, randomized, placebo-controlled phase III trial 
evaluating the efficacy and safety of sorafenib in patients with locally advanced or 
metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC 
Cancer. 2011;11:349. 
133. Zygulska AL, Krzemieniecki K, Sowa-Staszczak A. Hypothyroidism during treatment 
with tyrosine kinase inhibitors. Endokrynol Pol. 2012;63(4):302-6. 
134. Brassard M, Neraud BF, Trabado S Fau - Salenave S, Salenave S Fau - Brailly-Tabard S, 
Brailly-Tabard S Fau - Borget I, Borget IF, et al. Endocrine effects of the tyrosine 
kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol 
Metab. 2011;96(9):2741-9. 
135. Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, et al. 
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients 




136. de Groot JW, Links TP, van der Graaf WT. Tyrosine kinase inhibitors causing 
hypothyroidism in a patient on levothyroxine. Ann Oncol. 2006;17(11):1719-20. 
137. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib 
induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 
2005;78(4):433-8. 
138. Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, et al. Thyroid dysfunction 
in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, 
for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012;42(8):742-7. 
139. Coelho SM, Vaisman MF, Carvalho DP. Tumour re-differentiation effect of retinoic 
acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des. 
2005;11(19):2525-31. 
140. Russo D, Durante C, Bulotta S, Puppin C, Puxeddu E, Filetti S, et al. Targeting histone 
deacetylase in thyroid cancer. Expert opin Ther Targets. 2013;17(2):179-93. 
141. Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, et al. 
Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated 
thyroid carcinoma. J Clin Endocrinol Metab. 1999;84(3):912-6. 
142. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, et al. Small-molecule 
MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with 
conditional BRAF activation. J Clin Invest. 2011;121(12):4700-11. 
143. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, et al. Selective growth 
inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase 
kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab. 2007;92(12):4712-8. 
144. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, et al. B-
Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl 
Acad Sci U S A. 2010;107(23):10649-54. 
145. Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiol Rev. 2009;89(3):1025-
78. 
146. Andrade BM, Araujo RL, Perry RL, Souza EC, Cazarin JM, Carvalho DP, et al. A novel 
role for AMP-kinase in the regulation of the Na+/I--symporter and iodide uptake in 
the rat thyroid gland. Am J Physiol Cell Physiol. 2011;300(6):C1291-C7. 
147. Andrade BM, Cazarin J, Zancan P, Carvalho DP. AMP-activated protein kinase 
upregulates glucose uptake in thyroid PCCL3 cells independent of thyrotropin. 
Thyroid. 2012;22(10):1063-8. 
148. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old 
or new insights? Diabetologia. 2013;56(9):1898-906. 
149. Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. 







150. Heemstra KA, Hamdy NA, Romijn JA, Smit JW. The effects of thyrotropin-suppressive 
therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. 
Thyroid. 2006;16(6):583-91. 
151. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass 
of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol 
Metab. 1996;81(12):4278-89. 
152. Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on 
bone mineral density in patients with papillary thyroid carcinoma: a prospective 
controlled study. Surgery. 2011;150(6):1250-7. 
153. Reverter JL, Colome E, Holgado S, Aguilera E, Soldevila B, Mateo L, et al. Bone mineral 
density and bone fracture in male patients receiving long-term suppressive 
levothyroxine treatment for differentiated thyroid carcinoma. Endocrine. 
2010;37(3):467-72. 
154. Schneider R, Schneider M, Reiners C, Schneider P. Effects of levothyroxine on bone 
mineral density, muscle force, and bone turnover markers: a cohort study. J Clin 
Endocrinol Metab. 2012;97(11):3926-34. 
155. Faber J, Galløe AM. Changes in bone mass during prolonged subclinical 
hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 
1994;130(4):350-6. 
156. Eftekhari M, Asadollahi A, Beiki D, Izadyar S, Gholamrezanezhad A, Assadi M, et al. 
The long term effect of levothyroxine on bone mineral density in patients with well 
differentiated thyroid carcinoma after treatment. Hell J Nucl Med. 2008;11(3):160-3. 
157. Klein Hesselink EN, Klein Hesselink MS, de Bock GH, Gansevoort RT, Bakker SJ, 
Vredeveld EJ, et al. Long-term cardiovascular mortality in patients with differentiated 
thyroid carcinoma: an observational study. J Clin Oncol. 2013;31(32):4046-53. 
158. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the 
probability of death resulting from thyroid cancer and other causes among patients 
with thyroid cancer. J Clin Oncol. 2013;31(4):468-74. 
159. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-
stimulating hormone concentration and morbidity from cardiovascular disease and 
fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 
2010;95(1):186-93. 
160. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. 
Endocr Rev. 2008;29(1):76-131. 
161. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of thyroid hormone on cardiac 
function: the relative importance of heart rate, loading conditions, and myocardial 
contractility in the regulation of cardiac performance in human hyperthyroidism. J 




162. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca L, et al. Endogenous 
subclinical hyperthyroidism affects quality of life and cardiac morphology and 
function in young and middle-aged patients. J Clin Endocrinol Metab. 
2000;85(12):4701-5. 
163. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and 
hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 
1998;32(5):1454-9. 
164. Leitman M, Lysyansky P, Sidenko S, Shir V, Peleg E, Binenbaum M, et al. Two-
dimensional strain-a novel software for real-time quantitative echocardiographic 
assessment of myocardial function. J Am Soc Echocardiogr. 2004;17(10):1021-9. 
165. Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E, et al. 
Noninvasive myocardial strain measurement by speckle tracking echocardiography: 
validation against sonomicrometry and tagged magnetic resonance imaging. J Am Coll 
Cardiol. 2006;47(4):789-93. 
166. Delgado V, Mollema SA, Ypenburg C, Tops LF, van der Wall EE, Schalij MJ, et al. 
Relation between global left ventricular longitudinal strain assessed with novel 
automated function imaging and biplane left ventricular ejection fraction in patients 
with coronary artery disease. J Am Soc Echocardiogr. 2008;21(11):1244-50. 
167. Aydin M, Reyhan M, Sukan A, Yapar AF, Aktas A. Gated SPECT findings revealing 
diastolic dysfunction in acute hypothyroidism. Clin Nucl Med. 2007;32(2):94-100. 
168. Botella-Carretero JI, Gomez-Bueno M, Barrios V, Caballero C, Garcia-Robles R, Sancho 
J, et al. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term 
overt hypothyroidism after thyroxine withdrawal are associated with undesirable 
cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr Relat 
Cancer. 2004;11(2):345-56. 
169. Di PR, Alagona C, Pezzino V, Mangiameli S, Regalbuto C. Left ventricular function in 
acute hypothyroidism: a Doppler echocardiography study. Ital Heart J. 
2004;5(11):857-63. 
170. Grossmann G, Keck FS, Wieshammer S, Goller V, Schmidt A, Hombach V. Systolic 
ventricular function in acute hypothyroidism: a study using Doppler 
echocardiography. Exp Clin Endocrinol. 1994;102(2):104-10. 
171. Grossmann G, Wieshammer S, Keck FS, Goller V, Giesler M, Hombach V. Doppler 
echocardiographic evaluation of left ventricular diastolic function in acute 
hypothyroidism. Clin Endocrinol (Oxf). 1994;40(2):227-33. 
172. Hoftijzer HC, Bax JJ, Heemstra KA, Bleeker GB, Delgado V, van der Klaauw AA, et al. 
Short-term overt hypothyroidism induces discrete diastolic dysfunction in patients 







173. Kahaly G, Mohr-Kahaly S, Beyer J, Meyer J. Left ventricular function analyzed by 
Doppler and echocardiographic methods in short-term hypothyroidism. Am J Cardiol. 
1995;75(8):645-8. 
174. Wieshammer S, Keck FS, Waitzinger J, Henze E, Loos U, Hombach V, et al. Acute 
hypothyroidism slows the rate of left ventricular diastolic relaxation. Can J Physiol 
Pharmacol. 1989;67(9):1007-10. 
175. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the 
cardiovascular system. Recent Prog Horm Res. 2004;59:31-50. 
176. Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll-Franse LV. Health-
related quality of life among thyroid cancer survivors: a systematic review. Clin 
Endocrinol (Oxf). 2011;75(4):544-54. 
177. Husson O, Haak Hr Fau - Buffart L, Buffart Lm Fau - Nieuwlaat W-A, Nieuwlaat Wa Fau 
- Oranje W, Oranje Wa Fau - Mols F, Mols FF, et al. Health-related quality of life and 
disease specific symptoms in long-term thyroid cancer survivors: a study from the 
population-based PROFILES registry. Acta Oncol. 2013;52(2):249-58. 
178. Husson O, Mols FF, Oranje Wa FAU, Haak Hr FAU, Nieuwlaat WAFAUN-M, Netea-
Maier RTFAUS, et al. Unmet information needs and impact of cancer in (long-term) 









Expression of the Bone 
Morphogenetic Protein 7 
Pathway in Differentiated 
Thyroid Disease,  






















Objective: bone morphogenetic proteins (BMPs) are important regulators of growth and 
apoptosis in numerous tissues. Until now, no systematic studies on tissue expression of BMP7 
and its downstream proteins (Smad4 and pSmad1) in normal and pathological human thyroid 
tissues have been performed. We conducted an immunohistochemical study aiming for 
exploring the differential expression of these 3 proteins in normal and diseased thyroid 
tissues. 
Methods: a tissue array was prepared containing 750 thyroid samples from 118 patients; 
benign thyroid tissues from 38 patients (multinodular goiter, graves disease and follicular 
adenoma (FA)) and non-medullary differentiated thyroid carcinoma tissues (DTC) from 80 
patients (papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), follicular 
variant of PTC (FVPTC) and tumors with mixed areas of both PTC and FTC (PTC/FTC 
mix)]. Expression of the above mentioned proteins was studied and analyzed semi 
quantitatively by 3 observers independently. The differential expression was analyzed by a 
multilevel regression model with Bonferroni correction for multiple testing. Normal thyroid 
tissue was considered as a reference. 
Results: In DTC, cytoplasmic BMP7, Smad4 and pSmad1 expression was increased with low 
nuclear pSmad1 expression. This pattern was present in all malignant subtypes except for 
PTC where the cytoplasmic Smad4 was over-expressed. In GD, BMP7 expression was low. In 
the analysis of follicular lesions, nuclear pSmad1 expression was lower in FvPTC compared 
with FA.  
Conclusion: In conclusion, we found differentially expressed proteins of BMP7 signaling 
pathway in a large array of thyroid tissues. The underlying functional mechanisms remain to 















Bone morphogenetic proteins (BMPs) are the largest subgroup of the transforming growth 
factor-  (TGF- ) superfamily (1). Although the first function identified was the induction of 
ectopic bone formation in vivo, it has become evident that BMPs have an important function 
in embryonic development, and the regulation of growth, differentiation and apoptosis of 
various adult cell types ) (2, 3). Binding of BMP7 to its receptor leads to the phosphorylation 
of R-Smads (Smad1/5/8), which then bind to co-Smad (Smad4) and translocate into the 
nucleus to regulate gene expression (3). Smad4 is the co-Smad of all the TGF-
members. Its absence or reduced expression has been found in various cancers including 
papillary thyroid carcinomas, which alters the TGF- - 6). Smad4 mutations are 
frequent in thyroid neoplasms (7) where one point mutation (C324Y) seems to play an 
important role in thyroid carcinogenesis, growth and invasiveness (8, 9). 
BMP7 is involved in growth and apoptosis and is expressed in many tissues (10) 
including the thyroid (1) and therefore, it is not surprising that aberrant expression of BMP7 
has been found in a variety of diseases. The performed studies on the BMPs system in the 
thyroid are few (11- 16).  Several BMPs including BMP7 seems to be inhibitory to thyroid 
function and growth (12, 13). In thyroid tumors, a missense mutation in BMP2& BMP3 
overexpression seems to correlate to tumor aggressiveness (15, 16) and BMP7 has shown 
growth inhibitory effects in anaplastic thyroid carcinoma cell lines (11). 
As neither BMP7 nor its R-Smads differential expression have been studied in thyroid; 
we set out to study the expression of BMP7, Smad4 and phospho-Smad1 (pSmad1), by 
immunohistochemistry in a large array of human thyroid tissues, including a spectrum of 
benign and malignant thyroid disorders, hypothesizing that a differential expression would be 
present, which could have potential value for the differential diagnosis of thyroid disorders. 
 
MATERIALS AND METHODS 
Thyroid tissues 
We analyzed the nuclear and cytoplasmic expression of BMP7, Smad4 and pSmad1 by 
immunohistochemistry in 750 histological samples of 118 patients from surgically removed 




thyroid normal tissue were obtained from the archive of the Department of Pathology of the 
Leiden University Medical Centre. Formalin-fixed, paraffin-embedded blocks from  benign 
thyroid tissues of 38 patients (multinodular goiter (MNG) n=15, Graves disease (GD): n=10 , 
follicular adenoma (FA) n=13), and differentiated  non-medullary thyroid carcinoma tissues 
(DTC) from 80 patients (papillary thyroid carcinoma (PTC) n=47, follicular thyroid 
carcinoma (FTC) n=15, and follicular variant of PTC (FVPTC) n=13 and  tumors having 
mixed areas of both PTC and FTC (PTC/ FTC mix) n= 5) were included plus adjacent normal 
thyroid tissue of the pathological tissues (NT) n=69. These diagnoses were based on original 
histological assessment and again were reassessed by two independent pathologists before 
inclusion in this study. Given the variability in phenotype of follicular lesions, only 
microfollicular FA and widely invasive FTC’s were included. Likewise, we only included 
encapsulated FVPTC tumors with a typical PTC nuclear pattern. 
Tissue microarrays (TMA) 
The selected blocks were routinely prepared from surgically removed thyroids. From each 
specimen 3 and up to 18 tissue cores with a diameter of 0.6 mm were taken reaching a total of 
750 samples (Beecher Instruments, Silver Springs, MD, USA). They were arrayed on a 
recipient paraffin block, using standard procedures (19). Renal tissue samples were used as 
positive control for the proteins expression. 
Antibodies 
-human BMP7 antibody (1: 200; 2854 Ab; 
rabbit polyclonal directed against pro-domain of BMP7, kindly provided by Prof.Dr. S. 
Vukicevic (Zagreb University, Croatia); Smad4 antibody  (1:200; clone B8; monoclonal Ab 
Santa Cruz, Santa Cruz, CA, USA) and antibody against pSmad1/5/8 (1: 100; #9511; rabbit 
polyclonal Antibody; Cell Signaling Technology, Danvers, MA, USA); Secondary antibodies 
were: biotinylated goat-anti-mouse Ig/HRP and rabbit-anti-goat Ig/HRP (1: 200; Dako 
Cytomation, Glostrup, Denmark). All antibodies were diluted in 1% PBS/BSA. 
Immunohistochemistry 
Four micrometer consecutive tissue sections were cut from each arrayed paraffin block and 
prepared on pathological slides. The sections were deparaffinized in xylene followed by 0.3% 









peroxidase. After rehydration, antigen retrieval was performed by microwave treatment in 
citrate buffer (0.01 M, pH 6.0). After 2 h of cooling, the sections were incubated overnight 
with the primary antibodies at room temperature. Afterwards, the sections were incubated for 
30 min with the secondary antibodies. Avidin: Biotinylated enzyme Complex was applied 
using VECTASTAIN ABC kit (VECTOR LABORATORIES, INC. U.S.A) for 30 minutes. 
The antibody complexes were visualized using 0.04% diaminobenzidine-tetrahydrochloride 
(DAB) in 0.05-M Tris/HCl (pH 7.6) for 10 minutes in room temperature. Lastly the sections 
were counterstained with Mayers Haematoxylin. Negative controls were stained with the 
primary antibody omitted.  
Immunohistochemical scoring 
A semi-quantitative scoring assessment of the immunostaining was performed for both the 
intensity and the percentage of staining for each protein both in cytoplasm and nucleus per 
tissue sample. Cells with negative staining were scored zero. The percentage of cells with 
positive staining was scored between 1 and 4 as follows: 1= >1–20%; 2= >20–50%; 3= >50–
70%; and 4= >70%. The staining intensity was scored between 1 and 3 as follows: 1= faint; 
2= intermediate; and 3= intense. For proportional representation of each protein expression, 
the percentage and intensity scores of its immunostaining were multiplied. The total score per 
sample therefore ranged from 0 to 12.  Nuclear (n) and cytoplasmic (c) expression patterns 
were scored separately and registered as nBMP7, cBMP7, nSmad4, cSmad4, npSmad1 and 
cpSmad1. The scoring was independently conducted by three investigators (RA, HV and HH). 
TMA slides were viewed by the panoramic viewer 1.14.50; RTM software obtained from 
3DHISTECH website (http://www.3dhistech.com/pannoramic_viewer).  
Statistical analyses 
The studied tissues represent a 3 levels hierarchy of: several samples per patient, patients per 
subcategory and lastly subcategories per main category and the differential expression of 
these proteins was analyzed by a multilevel linear regression analysis accounting for 
clustering of histological samples. Initially, quantitative score of each protein were expressed 
as mean ± standard error of mean (SEM) per histological category. Next, at the 1st stage for 
comparison of proteins expression in normal tissue versus GD, MNG, FA and malignant 
tissue, a total of 24 statistical tests were performed (3 proteins in 2 sites for 4 different 




DTC category (PTC, FTC, FVPTC and PTC/FTC mix) vs. normal tissue, again a total of 24 
tests. The 3rd stage of regression analysis compared expression in FTC and FvPTC vs. FA (12 
tests). Bonferroni correction was applied to adjust for multiple testing in each stage of the 
analysis (B-adjustment). Differences were considered significant at an overall of P < 0.05 for 
each stage, and after B-adjustment: p < 0.0021 (= 0.05/24) for stage 1 and 2; p < 0.0042 (= 
0.05/12) for stage 3.  The choice for an overall p-value of 0.05 at each stage was based on the 
consideration that every stage represents one single hypothesis. 
 
RESULTS  
BMP-7 axis differential expression in differentiated thyroid lesions and normal tissue 
(Figure 1& 2): 
Figure 1 shows the pattern of expression of BMP7, Smad4 and pSmad1. Semi-quantitative 
BMP7, Smad4 and pSmad1 expression (mean± SEM) are shown in (Figure 2).  
First, in all DTC tissues combined, as well as GD, FA and MNG cytoplasmic and nuclear 
expression were compared with normal tissue (Figure2 A& C respectively). In GD, cBMP7 
expression was lower than in normal tissue, whereas downstream proteins cSmad4 and 
cpSmad1 were higher than in normal tissue. With B-adjustment, only the lower cBMP7 
expression in GD versus normal tissue remained statistically significant. MNG revealed only 
higher cSmad4 expression versus normal tissue, which was no longer significant after B-
adjustment. FA had higher cBMP7 and cSmad4 expression as compared with normal tissue, 
which was no longer significant with B-adjustment. All malignant tissues combined revealed 
higher cBMP7, cSmad4, cpSmad1 expression as compared with normal tissues, whereas 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Next, the regression model was used to compare these proteins in individual thyroid 
cancer categories vs. normal tissue in cytoplasm and nucleus (Figure 2 B& D respectively). 
With the previously detected pattern of expression seen in all malignant tissues combined vs. 
normal tissue (see above) as a reference in describing the expression in malignant categories: 
PTC showed the same differential expression pattern both with and without B-Adjustment; In 
FTC, cSmad4 was not differentially expressed in comparison to normal tissue and with B-
adjustment also npSmad1 expression was also no longer different; PTC/FTC mix also had the 
same differential expression pattern as in all malignant tissues combined and with B-
adjustment cBMP7 and npSmad1 remained significant.  In FVPTC, BMP7 and cpSmad1 were 
Figure 2: Expression of BMP-7 axis (BMP7, Smad4 and pSmad1) in normal (NT) and pathological thyroid tissues 
(mean± SEM). (A) and (C) represent Differential of cytoplasmic and nuclear expression respectively of BMP7 axis in: 
Graves disease (GD (n=10)), multinodular goiter (MNG (n=15)) and differentiated thyroid carcinoma tissues (DTC 
(n=80)) vs. NT (n=69)). (B) and (D): Differential cytoplasmic and nuclear expression (respectively) of BMP7 axis in 
DTC subcategories vs. NT. DTC subcategories: Papillary thyroid carcinoma (PTC (n=47)), follicular thyroid carcinoma 
(FTC (n=15)), follicular variant of PTC (FVPTC (n=13)) and tumors having mixed areas of both PTC and FTC 










higher, whereas nuclear expression of BMP7, Smad4 and pSmad1 were lower than in normal 
tissue and with B-adjustment, only nBMP7 and npSmad1 remained significant.  
BMP-7 axis differential expression in follicular thyroid lesions: 
The 3rd level of regression analysis included the follicular lesions (FTC and FVPTC vs. FA).  
Morphologically, FTC and FVPTC can be difficult to distinguish from FA. In FTC, nBMP7 
and cBMP7 were higher than in FA whereas cSmad4 was lower (Table 1).  
However, with B-adjustment, these differences were no longer significant. In FVPTC, 
cSmad4, nSmad4 and npSmad1 expression were lower than in FA (Table 1) and with B-
adjustment, differences in nSmad4 and npSmad1 expression remained significant. 
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c: cytoplasmic;    n: nuclear; FA: follicular adenoma;  FTC: follicular thyroid carcinoma; FVPTC: follicular variant papillary 
thyroid carcinoma; p: p value . 




The present study was conducted to analyze the protein expression of BMP7 and 2 
downstream proteins, Smad4 and pSmad1 in a large array of normal and pathological human 
thyroid tissues, which has not been documented before. We hypothesized that a differential 
expression would be present, which could have potential value for differential diagnosis of 
thyroid disorders. In general, we found cytoplasmic BMP7 overexpression in thyroid 
carcinoma, which is in line with observations in breast cancer, bone metastasis of prostate 




prostate carcinoma, BMP7 expression was associated with increased aggressiveness. This 
finding seems paradoxical, as experimental studies revealed that BMP7 is an important 
inhibitor of TGF-
formation of distant metastases (19, 20). However, BMP7 protein expression may not be 
necessarily associated with increased activity. As in our study, nuclear expression of pSmad1, 
an important downstream protein in the BMP7 signaling cascade was consistently decreased 
in all tumor types (together with increased cytoplasmic pSmad1 expression) which may point 
to decreased activity of the BMP7 pathway in thyroid carcinoma. Smad4 is a key mediator 
downstream protein of the transforming growth factor- - members (21).  
In line with Matsu etal, 2010 (22), we found mild/moderate cytoplasmic over expression of 
Smad4 in PTC and FTC. Yet the fact, Smad4 gene carry a wide range of mutations in both 
benign and malignant thyroid tumors that yields different phenotypes ranging from no- to 
over-expression (7) render the IHC staining per se non reflective to the mutational Smad4 
status.   
The association between decreased BMP7 pathway activity and progression of cancer 
may implicate that the BMP7 pathway may be an attractive target for future interventions in 
thyroid cancers. Indeed, experimental studies in several tumor types have revealed beneficial 
effects of BMP7 treatment (23- 26) including the anaplastic thyroid carcinoma cell lines 
where BMP7 treatment showed growth inhibition (11). Unfortunately, our study did not 
include any anaplastic or medullary thyroid cancer tissue, which might have shed light on the 
expressional pattern of this pathway in such aggressive cancers.   
In addition to potential therapeutic implications of BMP7 expression in thyroid 
carcinoma, protein expression of the BMP7 pathway may also be helpful in the differential 
diagnosis of follicular neoplasm. Unfortunately, we found no differences in BMP7 or 
downstream proteins between FTC and FA with diagnostic potential. However, the decreased 
npSmad1 expression in FVPTC vs. increased expression in FA may be worthwhile to explore 
in further large and multi-center studies 
Interestingly, decreased nuclear and cytoplasmic BMP7 expression was found in GD. As 
in GD, TSH receptors (TSHR) activation by stimulating autoantibodies is the underlying 
pathogenetic mechanism; the observed effects on the BMP7 pathway in our study are likely 









been suggested in experimental studies: BMP7 was shown to inhibit TSH receptor expression, 
whereas TSH selectively inhibits BMP signaling (12, 13). In GD, decreased, rather than 
increased nuclear expression of pSmad1 would have been expected, which was however not 
observed in our study. At this point no definite conclusions on the relationship between TSHR 
activation and BMP signaling in GD can be reached from our observations and further 
functional studies are needed to affirm this relation.  
In conclusion, we found differentially expressed proteins of the BMP7 signaling pathway 
in a large array of normal, benign and malignant thyroid tissues. The underlying functional 
mechanisms remain to be established, whereas the diagnostic potential of our observations 
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Background: Thyroid hormone production by the thyroid is regulated by a negative 
feedback-loop (Hypothalamic-Pituitary-Thyroid (HPT) axis). Even though thyrocytes exhibit 
thyroid hormone transporters and receptors, the evidence for direct regulatory effects of THs 
on thyroid function itself remain scarce.   
Aim: Our main objective was to determine if and how, T3 directly affects iodide uptake and 
whether this corresponds to NIS levels. Furthermore, we aimed to elucidate some of the 
underlying mechanisms through which T3 modulates thyroid function within thyroid 
follicular cells. 
Methods:  
presence of TSH for 1 to 4 days. The effects of T3 on NIS protein levels and iodide uptake 
were examined by western blotting and radioactive iodide uptake respectively. The effect of 
T3 on 5' adenosine monophosphate activated protein kinase (AMPK) activity modulation in 
thyroid cells was examined by western blotting. Rat NIS promoter constructs were transiently 
transfected into FRTL5 cells to study the possible genomic regulatory action of T3 on NIS 
gene expression.  
Results: Radioactive iodide uptake in FRTL5 cells was significantly reduced at the highest 
respectively) (p<0.05). After 4 days of T3 treatment the effect on iodide uptake became 
duction vs. basal (p<0.05). NIS protein levels in FRTL5 cells 
were significantly decreased in a dose dependent manner after 4 days of T3 (1nM-1 μM). NIS 
promoter activity was significantly reduced in a dose dependent manner. T3 decreased NIS 
p the 
reduction in promoter activity was 
p<0.001. No reduction in promoter activity could be detected in constructs harboring isolated 
regions of the NIS promoter. Furthermore, AMPK phosphorylation (p-AMPK) levels in 
FRTL-5 cells were not affected by T3 treatment.  
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Conclusion: T3 down-regulates NIS protein levels and I-uptake in follicular thyroid cells. 
This may be explained by the persistent reduction in NIS promoter activity after T3 treatment. 
However, the mechanisms leading towards the reduction in promoter activity are unknown but 
seem to involve regions outside the known regulatory regions such as NUE and the proximal 
promoter. This finding may have important clinical consequences for rhTSH aided radioactive 






Thyroid hormone (TH) production is regulated via the negative feedback loop between the 
THs serum levels and the neuroendocrine system (pituitary gland and hypothalamus) . 
Although follicular thyroid cells express TH receptors (TRs), T3 cytoplasmic binding sites (3) 
and thyroid hormone transport (4),evidence for direct influence of THs on thyroid 
growth and function remains limited ( . 
T3 acts either via nuclear receptors or indirectly via the modulation of cytoplasmic 
signalling pathways. On the genomic level, T3 acts as a nuclear regulatory factor of 
transcription after dimerization to its specific receptors on the nuclear membranes (TRs), an 
action that requires hours to days to take effect ( - ). The NIS Upstream Enhancer region 
(NUE) is the main regulatory region in the NIS promoter as it contains all the known 
-
cAMP-dependent manner (10, 11). Previous authors have reported that T3 reduces cAMP 
production in the thyroid (5, ). Mitogen-activated protein kinase superfamily members (ERK 
T3. Via this route T3 can regulate the downstream targets in these pathways. Very recently, 
our group and others have shown that AMPK activation, at least partially through 
transcriptional regulation of NIS protein gene, is able to decrease iodide uptake and NIS 
protein expression both in-vivo and in-vitro ( , 13).  Therefore, AMPK activation by T3 in 
the thyroid provides a possible hypothesis for explaining T3 actions. 
There is some evidence that T3 has effects on NIS protein levels and iodide uptake which 
are rate limiting steps in thyroid hormone synthesis . The effects of T3 on NIS protein and 
iodide uptake were studied only once, to the best of our knowledge, where T3 was found to 
inhibit both (5)
confirming the 
effects of various T3 concentrations representing circulating(1nM), intracellular (10nM) and 
intrathyroidal (1μM) levels at different time points (up to 4 days) and to study the 
mechanisms involved. The clinical relevance of our study is that RAI therapy for DTC 
patients with metastases requires high TSH levels to stimulate iodide uptake. This can be 
realized either by discontinuation of levothyroxine therapy or by the application of 
recombinant human TSH (rhTSH) during levothyroxine therapy. rhTSH preparation is based 
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on the assumption that the continuation of thyroid hormone therapy itself has no direct effects 
on RAI uptake. However, this assumption has not been proven. Therefore, a further insight 
into the role of T3 on iodide uptake may ultimately be beneficial for this group of patients. 
 
MATERIALS AND METHODS 
Cell culture 
The FRTL-5 cell-line was purchased from Health Protection Agency Culture Collections 
(Salisbury, UK) (14). The cells were routinely cultured in Coon's modified Ham's F-
-
n (Sigma) and 
10 ng/mL glycyl-L-histidyl-L-lysine acetate (Sigma)) supplemented with 1 mU/ml bovine 
-
. Prior to treatment 
 
Treatment: 
FRTL-5 cells were treated with T3 at concentrations of 1nM, 10nM and 1μM in presence or 
absence of TSH.  
Iodide uptake in FRTL-5 cells 
Iodide uptake was determined as described previously (15, )
cells were washed and cultured in serum- (14). After washing twice 
with Hanks balanced salt solution (
were washed twice with 1 mL of ice-
-counter. 
Accumulated radioactivity was expressed as percentage of control. 
Western blot 





IL, USA) all subsequent steps were performed in the presence of a commercial protease 
blocking at room temperature, the membrane was incubated (1:1000) with the primary 
antibody GAPDH (sc-
followed by 1 h incubation with horseradish peroxidase conjugated secondary antibody. The 
immune complexes were visualized using the Molecular Imager ChemiDoc XRS System 
, USA). Following equalization of the amounts of protein by comparing 
GAPDH expression, the following primary antibodies and dilutions were used: NIS (1:1000), 
a kind gift of N. Carrasco, and p-
ly, MA, USA). NIS and p-AMPK protein expression was quantified using the 
 
Luciferase promoter reporter assays  
To study transcriptional regulation of NIS expression by T3 gradient concentrations, we have 
obtained three promoter-luciferase constructs of rat NIS (rNIS) in PGL3 (figure 1) (10).  Two 
constructs harbored the known functional NUE region. The NUE region is essential for 
initiating NIS transcription and lies between - -
- (10, 11). The 
first promoter, rNIS promoter-construct 1 (rNIS1) is from -1 bp to -
of the rNIS gene. Thus, rNIS1 harbors NUE, the proximal promoter region and flanking 
st 500bp of the promoter. 
rNIS5 (from -1bp to -
and thus was referred to in rNIS promoter activity studies.  
integral CRE-L sequence . Also, NF-  
at the NUE region to augment activation (11)
-
USA) was co-transfected to correct for transfection efficiency. FRTL-5 cells were transiently 
transfected immediately after seeding in 5H medium with the Luciferase constructs and 
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Results of iodide uptake and luciferase activity are expressed as proportional changes versus 
basal conditions. Each experiment was repeated at least 3 times.  Anova tests were used for all 
SPSS, Inc., 
Chicago, IL). P values of <0.05 were considered significant. 
 
RESULTS 
T3 effect on iodide uptake 
duction vs. basal respectively) 
(p<0.05) whereas lower concentrations did not affect the iodide uptake in FRTL5 cells. After 
Figure1: Illustrative Overview of the constructs used in this study.  Three rat NIS promoter-luciferase 
constructs were used; rNIS1& 9 harbour the NIS upstream enhancer (NUE) region plus flanking regions of the 
proximal and /or distal promoter and rNIS5 is used as a reference of rNIS promoter basal activity. NUE region 
contains the response elements TTF-1, CRE, Pax8 and NF- regulatory region for NIS 
expression.  Two other constructs, each contains 3 repetitive sequences of either CRE-L or NF-









Effect of T3 on NIS protein expression 
To investigate whether the inhibitory effect of T3 on iodide uptake is directly related to 
and 4 days in presence of TSH and analysed NIS protein expression by western blotting. T3 
reduced the NIS protein expression in a time dependent manner (p<0.001). In addition, a clear 
dose dependent reduction in NIS protein levels in the cells exposed to T3 was observed at day 
4 of treatment in comparison to untreated cells (figure3).  
T3 and NIS promoter activity 
A reduction in NIS promoter activity may be a possible explanation for the observed 
reduction in iodide uptake and NIS protein levels after T3 treatment. Therefore, we studied 
Figure2: (A) Radioactive Iodide uptake in presence of TSH in FRTL5 in response to different concentrations of 
T3 after 1, 2 and 4 days (1D, 2D and 4D) of stimulation. In presence of TSH, T3 significantly reduced iodide 
uptake through time (p<0.01). T3 at conc. of 1μM reduced RAI (*p<0.05) both at day 1& 2 in comparison to 
control. At day 4 this effect was detected at 1nM conc. (*= p<0.05) as well as the highest concentration 
(**=p<0.01) with a reduction of 60% of control value.  
 
H on Radioactive Iodide uptake in FRTL5 cells. 
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the effect of T3 on the activity of different regions of the rNIS promoter to elucidate the effect 
of T3 on the known regulatory regions and to examine the possibility of other T3 responsive 





T3 exerted an inhibitory effect on the activity of the whole promoter (rNIS1) in a dose 
dependent manner (p<0.001), while the effect of time of exposure did not reach the level of 
tivity at 
day1 for rNIS1 at 1nM and 1μM concentrations of T3 in comparison to basal condition was 
   ed rNIS1 promoter activity 
(to  and  at 1nM & 1μM respectively). 
 was not influenced by T3.  
Using two luciferase promoter constructs each harboring sequences of either CRE-L or 
NF- -L nor NF-  
promoter activity was affected by T3.  
 
Figure3: In presence of TSH, T3 treatment resulted in reduced NIS protein expression after 4 days in a dose 
dependant manner. T3 reduces the NIS protein expression in a time dependent manner (p<0.001). The effect 







T3 and AMPK phosphorylation 
in iodide uptake and NIS protein levels we have measured AMPK phosphorylation (thr ) in 
FRTL-5 cells after T3 stimulation by western blot ( ) After 4 days of stimulation, T3 in 
presence of TSH had no effect on p-AMPK (figure5).  
 
 
Figure4: T3 treatment of rNIS1 and rNIS9 for 1 and 4 days. Anova test analysis shows that rNIS1 luciferase 
activity is significantly inhibited in a dose dependent manner (p<0.001), an inhibition that was detected from 
day1 (**=p<0.01) in comparison to control and remained inhibited through the 4days time course treatment 
(***=p<0.001 both at 1 nM and 1μM concentrations). rNIS9 luciferase activity did not change neither  in response 
to concentration gradient of T3 nor to the time of exposure. 
Figure5: T3 treatment in presence of TSH for 1 and 4 days did not alter the p-AMPK levels in FRTL5 cells 
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In the current study the effects of T3 on iodide uptake and NIS protein expression were 
studied.  
hrs (3, ). In addition we have studied the time and concentration dependent effects of T3 on 
NIS protein and iodide uptake. At the highest (intrathyroidal) concentration of 1 uM, iodide 
uptake and NIS promoter activation significantly decreased after 1 day although no effect 
could be observed on NIS protein levels. As stated, this T3 concentration reflects the in vivo 
situation within the thyroid, which suggests that intrathyroidal T3 effects on iodide uptake 
may occur within 1 day. After 4 days the effects on iodide uptake and NIS promoter activity 
were amplified and could also be observed at 1nM T3 (circulating levels). These effects were 
accompanied by decreased NIS protein levels.  
The partially delayed effects on NIS protein levels may be explained by the relatively 
long half-life of NIS protein (~ 3- 5 days in absence or presence of TSH respectively) ( ).  
The possibility of a genomic effect of T3 on the NIS promoter was investigated via 
transient transfection of FRTL5 cells with promoter reporter assays. In our experiments, the 
whole promoter region (rNIS1) is regulated in a dose and time dependent manner by T3. 
However, we did not find any T3 effects in promoter constructs which contain isolated 
elements of the NIS promoter region (CRE and NF- y the 
known regulatory regions. These data point towards the involvement of regions outside the 
known regulatory regions. A possibility would be the presence of T3 regulatory responsive 
regions within the NIS promoter but outside the NUE region.  
T3 actions also involve non-genomic actions via different cytoplasmic pathways (1 ). 
pathways is one of these actions. Recently our group has shown that the AMPK signalling 
pathway is also involved in NIS protein and iodide uptake regulation in thyroid follicular cells 
both in-vivo and in-vitro ( , 13).  
Our data show that this non-genomic pathway is not involved in thyroidal T3 actions 





In short, T3 inhibitory action on iodide uptake and NIS protein is dependent on the T3 
concentration and requires days to manifest itself. Our results may explain the observed down 
regulation of NIS and I-uptake by the persistent reduction in NIS promoter activity after T3 
treatment. This reduction, in addition with the relatively long half-life of NIS protein, will 
lead to a reduction in NIS protein over several days and subsequently in reduced I-uptake. 
However, the mechanisms leading towards the reduction in promoter activity are unknown but 
seem to involve NIS promoter regions outside the known regulatory regions such as NUE and 
the proximal promoter. 
Our data will need to be verified in in vivo and human studies before we can conclude 
whether, or to what extent, T3 affects NIS expression and iodide uptake in vivo. If so, the 
impact of rhTSH therapy on RAI may need to be revised as in present practise it is assumed 
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Objective: We conducted a prospective phase II clinical trial to determine the efficacy of 
sorafenib in patients with advanced radio-iodine refractory differentiated thyroid cancer. In 
this article, the long-term results are presented. 
Patients and methods: Thirty-one patients with progressive metastatic or locally advanced 
radioactive iodine refractory differentiated thyroid cancer received sorafenib 400 mg orally 
twice daily. The study end points included response rate, progression-free survival (PFS), 
overall survival (OS), and best response by Response Evaluation Criteria in Solid Tumors 
criteria 1.0, and toxicity 
Results: Median PFS was 18 months (95% confidence interval (95% CI): 7–29 months) and 
median OS was 34.5 months (95% CI: 19–50 months). Eight patients (31%) achieved a partial 
response and 11 patients (42%) showed stable disease after a median follow-up of 25 months 
(range 3.5–39 months). Toxicity mostly included hand foot syndrome, weight loss, diarrhea, 
and rash. 
Conclusion: Sorafenib has clinically relevant antitumor activity in patients with progressive 
metastatic or locally advanced radio-iodine refractory differentiated thyroid cancer. Sorafenib 










Thyroid cancer is the most prevalent endocrine malignancy, accounting for 95% of cancers of 
the endocrine system and 66% of endocrine cancer mortality in 2010 (1). The current 
incidence in Europe is 49/1 000 000 per year, with a nearly three times higher incidence in 
women (2). 
Differentiated thyroid carcinoma (DTC) is by far the most common (95%) subtype and 
includes papillary thyroid carcinoma (PTC, 80%) and follicular thyroid carcinoma (FTC, 10–
15%) as well as subtypes like Hurthle cell carcinomas. The majority of DTCs are slowly 
progressive, and, when identified at an early stage, frequently cured with adequate surgical 
management and radioactive iodine 131-I (RAI) ablation therapy. However, metastatic DTC 
that has become inoperable or refractory to RAI therapy is associated with a less favorable 
prognosis, as 10-year survival varies between 25 and 40% (3, 4). The efficacy of conventional 
chemotherapy in DTC is negligible, and chemotherapy is therefore no longer recommended in 
international guidelines (5, 6). As a result of increased understanding of thyroid 
tumorigenesis, potential targets, and novel therapeutic agents that target biological 
abnormalities have been identified. 
In DTC, the role of activated genetic aberrations in the RET–RAS–RAF–MAPK 
signalling pathway in tumor development and progression has been determined. The B-type 
Raf kinase (BRAF) V600E mutation has been reported in 29–69% of PTC and is associated 
with recurrent and persistent disease with a higher rate of lymph node metastasis and higher 
TNM stage (7, 8). In a review of 11 studies in thyroid cancer, up to 50% of follicular and 12% 
of Hurthle cell malignancies harbored RAS mutations or RAS downstream signalling 
PIK3CA mutations (9). Rearrangements in the RET proto-oncogene occur in up to 25% of 
PTC, resulting in the generation of chimeric oncogenes responsible for the initiation of tumor 
formation (10). Additionally, RAS mutations and RET/PTC translocations also result in 
aberrant signalling through BRAF. Furthermore, the RET–RAS–RAF pathway leads to 
vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) synthesis through 
interconnection with the epithelial growth factor receptor (EGFR)-activated cascade (11). In 
turn, these are the most important regulators in the process of angiogenesis. Increased 
vascularity plays a crucial role in tumor growth and generating metastasis (12). In human 
thyroid cancer, VEGF overexpression is associated with increased tumor stage and 




c-KIT. Its antitumor activity in advanced and progressive DTC was demonstrated in a phase II 
trial, which showed a partial response (PR) rate in 49% of patients (n=39). Median 
progression-free survival (PFS) was 12 months (13, 14). XL184 (cabozantinib) is an oral 
inhibitor of RET, c-MET, and VEGFR1 and 2. c-MET activation triggers tumor growth and 
angiogenesis. Moreover, in patients with PTC and MTC, overexpression and frequent 
mutations of the c-MET receptor have been reported (15). Antitumor activity of cabozantinib 
in patients with DTC was recently reported at the 2012 ASCO Annual Meeting. Cabanillas et 
al. found confirmed PR and stable disease (SD) in 53 and 40% of patients respectively (n=15). 
Disease control rate (PR+SD) was 80% at 16 weeks. At the time of data presentation, median 
PFS and overall survival (OS) had not been reached (16). 
E7080 (lenvatinib) is also an inhibitor of multiple TK, especially VEGFRs, c-KIT, and 
platelet-derived growth factor receptor b stem cell factor receptor. In animal studies, it has 
been shown to have potent antitumor activity against small-cell lung cancer and breast cancer 
most likely through inhibition of VEGFR2 and 3 (17, 18). A phase II trial of lenvatinib in RAI 
refractory DTC (n=58) by Sherman et al. (19) showed a PR rate of 50% and a median PFS of 
13 months. A recent study by Rajoria et al. (20) showed estrogen to be a key regulating factor 
of VEGF expression in thyroid cells, suggesting a role for antiestrogens in the therapeutic 
regimen to treat thyroid cancer. 
As a result of this increased understanding of the biological basis for thyroid cancer 
development, multiple clinical trials with multi-target TKIs have been conducted. Sorafenib 
(BAY 43-9006) is an orally active TKI that targets BRAF, VEGFR1 and 2, and RET, 
implementing antiangiogenic and proapoptotic actions. Results of an update of a phase II 
study on sorafenib, reported at the 2011 ASCO Annual Meeting by Brose et al., showed a PFS 
of 24 months and an OS of 35 months in 47 patients with DTC and poorly differentiated 
thyroid cancer (PD; n=55). A PR was achieved in 38% of patients and 47% had SD (21). 
Another phase II study in mainly patients with advanced DTC (n=30) reported a PR rate of 
23%, an SD rate of 53%, and a median PFS of 20 months (22). Kloos et al. examined the 
effect of sorafenib mainly in patients with metastatic PTC (n=41) and reported a PR and SD 
of 15 and 56% respectively. The median PFS was 15 months (23). Recent results of a study 
with the MEK1/2 inhibitor selumetinib showed reinduction of radio-iodide uptake in 60% of 
patients with RAI refractory thyroid cancers of follicular origin (24). 
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Our phase II study was designed to assess the effects of sorafenib on restoring the 
susceptibility to RAI therapy, tumor progression, and safety in RAI refractory DTC. The first 
report of this study by Hoftijzer et al. (25) showed a promising efficacy and tolerability of 
sorafenib, but no beneficial effects on radioactive-iodide uptake. Here, we report the long-
term outcomes of this sorafenib trial in advanced RAI refractory DTC with results on efficacy, 
safety, and tolerability. 
 
PATIENTS AND METHODS 
Patients 
Details of study design and patient eligibility of this study have been described previously 
(25). Briefly, eligibility criteria were the presence of progressive metastases or unresectable 
local recurrence of DTC for which RAI therapy was no longer effective, as indicated by prior 
negative post-therapeutic whole-body scintigraphy. Progressive disease was defined according 
to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.0 12 months before 
initiation of treatment. Patients had undergone total thyroidectomy and RAI ablative therapy. 
Eastern Cooperative Oncology Group performance status had to be <2 and life expectancy 
had to be more than 3 months. Written informed consent was provided by all patients before 
enrolment onto the trial. The study protocol was approved by the Institutional Review Board 
of the Leiden University Medical Center. This study was registered at Clinical-Trials.gov 
(#NCT00887107).  
Study design 
We performed a nonrandomized, open-arm, phase II trial of sorafenib in 31 patients with 
advanced RAI refractory DTC. For a complete description of study design, we refer to the 
paper of Hoftijzer et al. (25). The primary objective of this study was to determine the 
efficacy of sorafenib treatment with a PR as the primary end point. The secondary objective 
was to study RAI reuptake and the safety of sorafenib as an antitumor drug for advanced RAI 
refractory DTC patients. Sorafenib was administered at a dose of 400 mg orally twice a day 
until disease progression, uncontrollable side-effects, death, or patients’ own request. Safety 
assessments consisted of physical examination, documentation of adverse events (AEs), and 




performed every 4 weeks. The incidence, grade, and relationship of AEs to the drug were 
graded with the use of Common Terminology Criteria for Adverse Events (CTCAE, version 
3.0).  
After completion of 6-month treatment, patients were allowed to continue sorafenib 
treatment when a favorable response (complete remission, partial remission, or SD) had been 
achieved. Sorafenib was thereafter continued until progression according to RECIST 1.0 
criteria with computed tomography (CT) scanning performed every 6 months. 
In this article, we report the long-term outcomes and tolerability of sorafenib in patients 
with  advanced RAI refractory DTC. 
 Statistical methods 
In this study, data are reported as median± S.D., median (range), or proportions. Best 
objective response rate (RR) refers to the proportion of patients who had the best response 
rating for complete response (CR) or PR according to RECIST 1.0. The OS, PFS (defined as 
the time from starting study drug to progression), and overall disease control rate with 
associated 95% confidence intervals (95% CIs) were obtained using the Kaplan–Meier 
method. AEs were scored according to the National Cancer Institute’s CTCAE, version 3.0. 
Other safety parameters, including laboratory data, were summarized descriptively. Variables 
possibly influencing response to sorafenib were analyzed with binomial logistic regression. 




All 31 patients were included in this long-term outcome study on sorafenib. The follow-up of 
the study ended on 1 March 2011 with five patients excluded from the efficacy analysis 
because they did not reach the first radiological evaluation at 6 months. One patient requested 
to stop sorafenib treatment after 4 days, one patient developed small-cell lung cancer, and 
three patients discontinued treatment because of AEs. Median follow-up period was 25 
months (range 3.5–39 months) and median sorafenib treatment period was 9.2 months (range 
0.1–39 months). By the time the follow-up of the study ended (March 2011), four patients 
(15.4%) were still on sorafenib (Fig. 1).  
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 Baseline characteristics of the included patients are listed in Table 1. As can be 
expected, Hurthle cell metaplasia, which is associated with poor RAI responsiveness, was 
overrepresented in the patient group (42%). Two of 13 PTC patients had a poorly 
differentiated carcinoma. A total of 15 mutations were identified on primary tumor material, 
of which BRAF V600E was most frequently observed with 10/13 PTC patients harboring a 
BRAF V600E mutation. 
Efficacy 
Of the 31 patients enrolled in this study, 26 patients were eligible for efficacy analysis. Five 
patients were excluded for the reasons previously mentioned. Data on efficacy are given in 
Table 2 and Fig. 2. 
At a median follow-up of 25 months, the overall disease control rate was 27%. The total 
proportion of PR was 31% (n=8), which were all achieved in the first 6 months of treatment. 
Four patients (15%) had an ongoing PR and three patients (12%) showed ongoing SD. There 
was no CRs. Individual data per patient response is summarized in Table 3. At the time of this 
data analysis, the cumulative number of patients with progressive disease was 15 (58%). 
Disease progression was not influenced by age, gender, or histology, including the presence of 




related to disease progression. The prevalence of other mutations was too low to allow 
statistical analysis.  
 
Table 1 Baseline Characteristics 
  All patients (n=31) 






Age (year) (median, range) 64 (53-82) 
Time from diagnosis (year) (median, range) 3.9 (0.3-18) 
Histology (No.; %) 
Papillary 
   Tall cell 
   Hurthle cell metaplasia 
Follicular variant papillary 
Follicular 
   Hurthle cell metaplasia 









Initial TNM stage (No.; %) 
IB (T2N0M0) 
IIB (T2-3 N0-1 M0) 
IIIA (T1-3 N1-2 M0) 








Tumor extent at study entry (No.; %) 
Thyroid bed only 
Lungs only 
Lungs and bone only 








* Including both thyroid bed (n=5) and neck lymph nodes (n=4) 
 
 
Tabel 2 Efficacy Analysis 
 Number of patients (% of total) 
Total patients 31 
Assessable patients 26 
Median duration of treatment (months; range) 15 (0.1-39) 
Median duration of follow up (months; range) 25 (3.5-39) 
Best response by RECIST 1.0 
   Complete response 
   Partial response 
   Stable disease 






Overall disease control 7 (27) 
Median duration of SD (months; range) 26.5 (3-38) 
Median overall response duration (months; range) 29.6 (3-33) 
Median PFS (95% CI) 
   With BM 




Median OS (95% CI) 
   With BM 




BM: bone metastases; NR: not reached; # not available, † 4 with ongoing PR 
 
Disease progression in soft tissue metastases or bone metastases did not significantly 
differ. However, the favorable responses seen in three patients with bone metastases were 
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based on regression of metastases other than bone, predominantly lung, whereas the bone 
metastases were stable. The overall median OS was 34.5 months (95% CI: 19-50 months). In 
the presence of bone metastases, median OS was significantly worse with 23 months (95% CI: 
20–26 months) compared with the median OS of the whole group. However, at the time of 
this data analysis, median OS was not reached for patients without bone metastases (Fig. 2A). 
Age and gender did not influence OS. Estimation of median PFS was 18 months (95% CI: 7–
29 months). Similarly, the median PFS was influenced by the presence of bone metastases. 
Median PFS was 20 and 12 months in the absence and presence of bone metastases 
respectively (Fig. 2B). A relation between OS and PFS and site of bone metastases could not 
be established as 12 of 13 patients with bone metastases had metastases localized in the axial 





Thyroglobulin (Tg) response reflected the radiological response (Table 4). From baseline, 
patients with a PR had a median decrease of 24 mg/l (range, - 2746 to 2.6 mg/l) in their serum 
Tg levels. Patients with SD showed a median elevation of 19 mg/l (range, - 60 to 3724 mg/l). 
The serum Tg levels in patients that showed PD increased by a median of 49 mg/l (range, - 
5320 to 87 736 mg/l). The 54-year-old woman with pulmonary metastases of a Hurthle cell 
FTC reported at 6 months with high Tg levels (99 900 mg/l) but a decrease in number, size, 
Figure 2 Kaplan–Meier curves of (A) overall survival (OS) and (B) median progression-free survival (PFS) (A) 
Kaplan–Meier estimate of OS. Overall median OS was 34.5 months. In the presence of bone metastases, median OS 
was 23 months. At the time of this data analysis, median OS was not reached for patients without bone metastases. 
(B) Kaplan–Meier estimate of PFS. Estimation of median PFS was 18 months. Median PFS was 20 months in the 





and density of all metastases died 2 months later from disease progression with a Tg level that 
remained high (89 400 mg/l). 
Table3 Data on clinical benefit per patient 
Response Histology Initial tumor stadium Duration of response (months) 
PR Papillary IB 33a 
PR Follicular with Hurthle cellmetaphasia IIB 33
a 
PR Papillary IIB 33
a 
PR Papillary IV 30 
PR Follicular IIB 24 
PR Follicular IIB 24 
PR Papillary IIB 18
a 
PR Papillary IIIA 6 
SD Papillary IIIA 38 
SD Follicular IIB 36 
SD Follicular with Hurthle cell metaphasia IIB 12 
PR: partial response; SD: stable disease; IB (T2N0M0); IIB (T2-3 N0-1 M0); IIIA (T1-3 N1-2 M0); IV (any T any N M1). 
aOngoing response 
 
Table 4 Thyroglobulin response per patient response 
RECIST 1.0 CR PR SD PD  
Baseline serum Tg levels (median, range) Non 50 (4.5 to 3126) 41 (2 to 1817) 382 (26.5 to 8570)  
Last serum Tg levels (median, range) Non 19 (0.9 to 1894) 94 (14 to 4140) 373 (38 to 89 400)  
Delta Tg (vs baseline; median, range) Non -24 (-2746 to 2.6) 19 (-60.8 to 3724) 49 (-5320 to 87 736)  
RECIST, Response Evaluation Ceiteria in Solid Tumors; Tg, thyroglobulin; CR, complete response; PR, partial response; 
PD, progressive disease. 
Treatment tolerability and adverse events 
Eighteen patients (58%) required dose reduction due to toxicity. Four of them (13%) 
discontinued the study later on due to AEs. Of these, three patients suffered from a myocardial 
infarction after 1, 20, and 22 months of sorafenib treatment respectively and one patient quit 
due to complaints of malaise after 39 months. Forty-four percent of dose reductions occurred 
in the first month of treatment. Further details on dose reduction and daily sorafenib dose are 
listed in Table 5. In total, seven patients (23%) terminated study participation as a result of 
drug-related AEs. There were three patients who discontinued sorafenib before dose reduction 
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after 1, 12, and 19 months due to angioedema, congestive heart disease, and malaise and 
weight loss respectively. One patient discontinued treatment after 3 months due to the 
development of small-cell lung cancer. One patient was diagnosed with carcinoma of the 
tongue after 46 months of sorafenib treatment. Thirteen patients (42%) required levothyroxine 
dose adjustments in order to maintain euthyroidism. 
 
Table 5 Daily sorafenib dose and dose reduction 
 3 months 6 months 12 months 
Dose reduction (n, %) 13 (42) 16 (52) 18 (58) 
Daily sorafenib dose (mg)    
Mean (± S.D.) 671 (± 198) 584 (±230) 562 (± 175) 
Median (range) 600 (200- 800) 600 (200- 800) 600 (400- 800) 
 
All observed AEs are listed in Table 6. Treatment related AEs were predominantly of 
grade 1 or 2, with the most common events including hand foot syndrome (HFS), weight loss, 
diarrhea, and rash. Grade 3 AEs consisted of HFS (23%), weight loss (10%), diarrhea (6%), 
rash (16%), mucositis (10%), and congestive heart disease (3%). Grade 4 AEs comprised 
myocardial infarction in three patients (10%), which led to death within 2 months after the 
infarction in one patient. The majority of AEs were seen in the first year of treatment and 
were controllable with dose reduction, medication, or supporting measures (i.e. dietary 
consultation and additional feeding). No correlations were found between toxicity and 
performance state or age. 
 
DISCUSSION 
The developments in the treatment of advanced thyroid cancer are a result of increased 
understanding of thyroid tumorigenesis. A high percentage of differentiated thyroid cancers 
contain aberrations in the RET/PTC–RAS–RAF–MAPK pathway. In addition, the RET–
RAS–RAF pathway leads to VEGF and VEGFR synthesis through the EGFR-activated 
cascade. Hence, compounds targeting the activated RET–RAS–RAF pathway and beyond, 
antiangiogenic compounds or a combination of both, may be effective in RAI non-avid DTC 
(26). Several clinical trials in thyroid cancer have shown considerable percentages of clinical 
responses, suggesting this assumption to be accurate. Of  the  targeted therapies that have 




BRAF and RET, as well as VEGFR. However, sorafenib is a relatively weak BRAF inhibitor. 
The most potent BRAF inhibitor, vemurafenib, might be more effective in PTC harboring a 
BRAF mutation and is currently under study in an international phase II trials 
(www.clinicaltrials.gov, NCT01286753) (27). 
 
Table 6 Adverse events. According to Common Terminology Criteria for Adverse Events (version 3). 
                                                          All Grades No. of patients (% of category) 
                                              No. of patients 
Event                                     (% of total (n=31))     
 
          1                        2                      3                        4 
Hand foot syndrome 22 (71) 8 (36) 7 (32) 7 (32)  
Weight loss 18 (58) 7 (39) 10 (56) 3 (17)  
Diarrhoea 16 (52) 5 (31) 9 (56) 2 (13)  
Rash 17 (55) 11 (65) 1 (6) 5 (29)  
Alopecia 16 (52) 14 (88) 2 (12)   
Mucositis 15 (48) 11 (73) 1 (7) 3 (20)  
Hypocalciemia 15 (48) 14 (93) 1 (7)   
Hypertension 13 (42) 4 (31) 4 (31) 5 (38)  
Hypophosphatemia 11 (35) 11 (100)    
Anemia 11 (35) 11 (100)    
Hypoparathyroidism 10 (32)  10 (100)   
Thrombopenia 9 (29) 9 (100)    
Hypothyroidism 8 (26)  8 (100)   
Leukopenia 7 (23) 7 (100)    
Nausea 3 (10) 3 (100)    
Myocardial infarction 3 (10)    3 (100) 
Congestive heart disease 1 (3)   1 (100)  
Hematuria 1 (3)  1 (100)   
Deep venous thrombose 1 (3)   1 (100)  
Hyponatriemia 1 (3) 1 (100)    
Pneumothorax 1 (3)  1 (100)   








Our study is the first study reporting the long-term effects of sorafenib treatment in 
advanced RAI refractory DTC patients. We also provided results of the influence of bone 
metastases on survival outcome and PFS. Our results were not influenced by subtypes of 
thyroid cancer, as we only included patients with DTC, ensuring a homogeneous study 
population. In our trial, we observed beneficial effects of sorafenib. At 6 and 25 months, 
median PFS was 14.5 and 18 months respectively. At 6 and 25 months, median OS was 25 
months and 34.5 months respectively. The PR rate of 25% we observed in the first 6 months 
of the trial is one of the highest PR rates reported in sorafenib trials in DTC. Kloos et al. (23) 
found a PR rate of 15% in patients with metastatic PTC. Gupta-Abramson et al. (22) reported 
a PR of 23% (DTC, MTC, and anaplastic thyroid carcinoma (ATC)) whereas Ahmed et al. 
(28) observed a PR in 21% of patients with metastatic thyroid cancer (DTC and MTC). Our 
high PR rate could be attributed to the differences in patient categories (histologies, tumor 
stages, sites of metastases, and tumor extent), study design, and analytical methods between 
the different phase II trials. 
The explanation for the significantly less favorable outcome in patients with bone 
metastases remains unclear. The relationship between the genetic profile of bone metastases 
and responsiveness to sorafenib is hard to establish given the lower tissue levels and 
difficulties in obtaining tissue from bone metastases. It can be hypothesized that VEGFR-
targeted therapies are less effective in bone metastases as the role of VEGFR signal 
transduction in tumor expansion may differ between soft tissue and bone metastases. Another 
explanation may be that through systemic release of cytokines or proteins from the bone 
microenvironment, the presence of bone metastases influences the response to sorafenib in 
soft tissue metastases. The dose of sorafenib used in our study was generally well tolerated, 
although dose reductions were required in 58% of patients. Tumor response, however, was not 
affected by dose reductions. Toxicities observed in our study were mostly grades 1 and 2 and 
similar to those reported in the other phase II trials of sorafenib (21, 22, 23, 28, 29). A long-
term safety evaluation of sorafenib in advanced renal cell carcinoma showed similar results, 
supporting our findings (30). Dermatological AEs were the most commonly observed. A 
recent study of sorafenib in patients with hepatocellular carcinoma reported better response in 
patients with early skin reactions (31); however, we were not able to establish that correlation. 




supplementary measures. However, beneficial effects on tumor response should always be 
weighed against the side effects and quality of life of targeted therapies (3, 4, 29). 
There are some issues that have to be addressed too. RECIST criteria should be applied 
for judgment of progression for inclusion in trials and for follow-up scans to determine 
treatment effect. However, RECIST criteria have several limitations for the determination of 
efficacy of targeted drug activity. This is shown by the fact that in our study, some of the 
patients with PD based on new lesions had stable or even reduction in the target lesion’s 
longest diameter. Nevertheless, the RECIST criteria are the best criteria to date and should be 
used in every clinical trial. 
Another issue is that in studies of targeted therapy in advanced thyroid cancer, a 
substantial proportion of patients (33–50%) had SD of varying duration as best response (32). 
Given the indolent natural history of these tumors, SD may be considered to be of limited 
value. Considering this, the determination of the best primary end point remains an issue. 
Objective RRs do not correlate per se with OS. Given the indolent nature of advanced thyroid 
cancer, PFS and OS are not always preferred primary end points. Therefore, only patients with 
documented progressive disease should be included in clinical trials, permitting a smaller 
sample size and a shorter time for follow-up to demonstrate a difference in response to 
therapy between treatment groups. In addition, sorafenib treatment should only be initiated in 
patients with progressive disease or significant tumor burden in the presence of RECIST 
targets. Furthermore, patients with SD at baseline may not benefit from therapy and do not 
need treatment with targeted agents, with all possible side effects. 
In conclusion, sorafenib is generally well tolerated and has demonstrated to be clinically 
active in the long term in advanced RAI refractory DTC. In order to enhance sorafenib 
treatment efficacy, further trials need to focus on sequential or combination therapy, as 
patients eventually become progressive on sorafenib or do not tolerate it. More trials with new 
targeted agentsare underway and the outcomes of these trials will contribute to a better 
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Background: Therapy with tyrosine kinase inhibitors is associated with thyroid dysfunction. 
Decreased serum thyroid hormone levels during tyrosine kinase inhibitors are also observed in 
athyreotic patients with thyroid carcinoma. We therefore hypothesized that tyrosine kinase 
inhibitors may influence thyroid hormone metabolism. 
 Aim: The aim was to study the effects of sorafenib therapy on serum thyroid hormone 
concentrations and iodothyronine deiodination in athyreotic patients. 
Design: This is a retrospective open, single center, single arm 26-weeks phase II study 
Methods:We measured serum thyroxine (T4), free T4, 3,5,3-triiodothyronine (T3), free T3, 
reverse T3 (rT3), and TSH concentrations at baseline and after 26 wk in 21 patients with 
progressive nonmedullary thyroid carcinoma treated with sorafenib. Ratios of T3/T4 and 
T3/rT3, which are independent of substrate availability and reflect iodothyronine 
deiodination, were calculated.  
Results: Serum free T4 and T3 levels, adjusted for levothyroxine dose per kilogram body 
weight, decreased by 11 and 18%, respectively, whereas TSH levels increased. The serum 
T3/T4 and T3/rT3 ratios decreased by 18 and 22%, respectively, which is compatible with 
increased type 3 deiodination.  
Conclusions: Sorafenib enhances T4 and T3 metabolism, which is probably caused by 









Therapy with tyrosine kinase inhibitors in patients with malignancies is associated with 
alterations in thyroid hormone parameters. Sunitinib has been associated with hypothyroidism 
in 14–85% of the patients, ranging from transient increases in TSH to persistent 
hypothyroidism, requiring thyroxine substitution (1– 6). In some patients, sunitinib induced 
hyperthyroidism as well (7–9). Both sunitinib induced hypothyroidism and hyperthyroidism 
may be caused by destructive thyroiditis, but other mechanisms, such as interference of 
sunitinib with thyroid peroxidase (4) or inhibition of thyroidal vascularization leading to 
thyroid atrophy (10, 11), have been proposed. Likewise, sorafenib was associated with TSH 
elevations in 18% of patients with metastatic renal cell carcinoma (12). All of the above 
mentioned studies were performed in patients with intact thyroid glands. However, thyroid 
function abnormalities have also been observed during therapy with imatinib (13, 14), 
motesanib (15), and sorafenib (16) in athyreotic patients with medullary thyroid carcinoma 
and nonmedullary thyroid carcinoma. Imatinib increased TSH levels in all patients with 
medullary thyroid carcinoma (13, 14). Therapy with motesanib caused TSH elevations in 22% 
of 93 patients with nonmedullary thyroid carcinoma. Sorafenib was associated with increased 
TSH levels in 33% of thyroid carcinoma patients (16). Because an increased need of thyroxine 
is observed in athyreotic patients who are treated with tyrosine kinase inhibitors, the 
mechanisms of hypothyroidism may include alterations in thyroid hormone metabolism. 
Stepwise deiodination is the major route of thyroid hormone degradation and is mediated by 
iodothyronine deiodinases (D1, D2, and D3) (17) and by hepatic conjugating enzymes (18). 
No human studies have been published to address the effect of sorafenib on peripheral thyroid 
hormone metabolism. We therefore studied the effects of sorafenib, administered for 26 wk, 
on peripheral thyroid hormone metabolism in athyreotic humans. 
 
PATIENTS AND METHODS 
Design 
The effects of sorafenib on peripheral thyroid hormone metabolism were analysed in an open, 
single-center, single-arm 26-wk prospective phase II study, intended to achieve reinduction of 
Radioiodide uptake in athyreotic patients with progressive metastatic or locally advanced 




Sorafenib was initially administered at a dose of 400 mg orally twice daily. Exclusion criteria 
were pregnancy, contraindications for the application of recombinant human TSH (rhTSH), 
and contraindications for the use of sorafenib. The institutional review board approved the 
study, and all patients provided written informed consent. 
Before initiation of sorafenib therapy and at 26 wk, the patients underwent computed 
tomography scans for analysis of tumor dimensions and rhTSH (Thyrogen; Genzyme, 
Naarden, The Netherlands) assisted 4 mCi diagnostic scintigraphies. During the study, 
patients visited the hospital every month for assessment of thyroid function parameters, 
biochemical safety parameters, and a physical examination. Fasting morning blood samples 
 
All patients were treated with levothyroxine, which was adjusted if needed to maintain a 
target TSH concentration less than 0.1 mU/liter. Only patients who completed 26 wk of 
treatment with sorafenib were included in the present analysis (per protocol analysis). 
 Study aims 
The objective of this study was to evaluate the effects of sorafenib on thyroid hormone serum 
levels and to evaluate the effects of sorafenib on iodothyronine deiodinase activity.  
Study parameters 
The following thyroid function parameters were measured: serum TSH, free thyroxine (fT4), 
total thyroxine (T4), free 3,5,3-triiodothyronine (fT3), total 3,5,3-triiodothyronine (T3), and 
reverse 3,5,3-triiodothyronine (rT3). Because levothyroxine dosages were adjusted during the 
study according to serum TSH levels, serum thyroid hormone levels were corrected for the 
daily levothyroxine dose and body weight. Dose-adjusted fT4 was calculated as follows: (fT4 
(pmol/liter)  
To assess effects of sorafenib on iodothyronine deiodination, ratios of serum levels of 
T3/T4and T3/rT3 were calculated. The T3/rT3 ratio is considered to be a sensitive indicator of 
the peripheral metabolism of thyroid hormone, being positively influenced by D1 and D2 
deiodinase and negatively by D3 deiodinase. Serum thyroxine-binding globulin (TBG) levels 
and fT4/T4 and fT3/T3 ratios were calculated to exclude effects of sorafenib on thyroid 









Fasting blood samples were collected before daily levothyroxine ingestion at both baseline 
and 26 weeks 
chemiluminescence assays (Vitros ECI Immunodiagnostic System; Ortho-Clinical 
Diagnostics via GE Healthcare, Rochester, NY). fT3 was measured with a RIA (Trinity 
Biotech, Bray, Ireland). rT3 was measured with an in-house RIA (20). The detection limit of 
the TSH assay was 0.005 mU/liter. Within-assay coefficients of variation amounted to 4% for 
TSH, 2% for T4, 2% for T3, and 3–4% for rT3.  
Statistics 
Data are reported as mean ± SD, median (range), or proportions. Differences in thyroid 
hormone parameters were analyzed using the two-tailed Student’s t test for paired data, 
comparing measurements between baseline and after 26 weeks sorafenib therapy for normally 
distributed data, or with a Wilcoxon’s test for non-normally distributed data. Differences were 
considered statistically significant at P < 0.05. All calculations were performed using SPSS 
16.0 for windows (SPSS, Chicago, IL).  
 
RESULTS 
Between October 2007 and October 2008, a total of 32 patients were included in the study. 
Twenty-two patients completed the 26 weeks because one patient chose not to start therapy 
and nine patients discontinued treatment during the 26 weeks for disease progression (four 
patients), adverse events (four patients), and the patient’s request (one patient) as reported 
previously (19). Because the thyroid hormone profile of one patient was not recorded, 21 
patients were included in the present analysis: seven females, 14 males, with a median age of 
65 years (range, 53–82 years), all with distant metastases of nonmedullary thyroid carcinoma 
(local, 4%; lungs only, 29%; lungs and bones, 24%; lungs and local, 14%; other, 29%). The 
efficacy of sorafenib with respect to tumor progression and the presence of adverse effects 
have been reported previously (19).  
Effects of sorafenib on study parameters are given in Table 1. We observed a profound 




0.008) (Table 1, Fig. 1). Nevertheless, TSH increased significantly from 0.051 to 0.545 
(1.90 vs. 1.60 nmol/liter) and dose-
observed. Absolute rT3 levels tended to increase after sorafenib therapy, and T3/T4, T3/rT3, 
and T4/rT3 ratios decreased significantly by 18, 22, and 7%, respectively, reflecting an 
increased conversion of T4 into rT3. Potential effects of sorafenib on thyroid hormone 
binding proteins were assessed by measuring TBG levels, which were not influenced by 
sorafenib, and by calculating ratios of free over total T4 and T3 concentrations, which did not 
differ before and after sorafenib.  
 
DISCUSSION 
In this study, we assessed the relationship between treatment with the multiple target kinase 
inhibitor sorafenib and alterations in thyroid hormone parameters. Therapy with tyrosine 
kinase inhibitors is associated with hypothyroidism. Proposed mechanisms include direct 
effects of these drugs on the thyroid, including destructive thyroiditis (4, 10, 11). Because 
Table 1 Thyroid Hormone Parameters 
 N Baseline 26-wks sorafenib P –value  
Weight (kg) 21 77.3 ± 13.5 71.0 ± 14.2 <0.001 
Sorafenib dose (mg/kg.d) 21 10.4 ± 2.4 8.4 ± 2.7 0.003 
Levothyroxine dose (μg/kg.d) 21 2.48  ± 0.67 2.71  ± 0.61 0.008 
T4 (nmol/L) 21 149.4 ±  31.9 152.9 ± 37.7 0.664 
T3 (nmol/L) 20 1.90  ± 0.33 1.60  ± 0.34 0.007 
fT4 (pmol/L) 21 27.3  ± 5.9 26.6  ± 6.9 0.587 
fT4 (pmol/L) × weight (kg)/ 
levothyroxine dose (μg) 
21 11.7 ± 3.6 10.4 ± 3.6 0.034 
fT3 (pmol/L) 13 5.43 ± 0.71 4.80 ± 1.09 0.075 
fT3 (pmol/L) × weight (kg)/ 
levothyroxine dose (μg) 13 1.59 ± 1.38 1.35 ± 1.15 0.005 
rT3 (nmol/L) 20 0.68 (0.50- 1.02) 0.79 ( 0.63- 1.12) 0.091a 
TSH (mU/L) 21 0.01 (0.005- 0.33) 0.100 (0.005- 4.670) 0.023a 
TBG (mg/L) 21 19.8± 4.3 19.5 ± 4.0 0.620 
fT3/T3 ×103 13 2.73 ± 0.33 2.93 ± 0.31 0.279 
fT4/T4 ×103 21 5.55 ± 0.94 5.84 ± 0.95 0.124 
T3/T4 × 100   20 1.28 ± 0.00 1.05 ± 0.00 <0.001 
T3/rT3 20 2.74 ± 0.50 2.16 ± 0.53 <0.001 
T3/rT3 20 220 ± 27 205 ± 32 0.036 
Data expressed as mean ± SD or median (range) 
a Wilcoxon`s Test. 
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thyroid function abnormalities have also been observed in athyreotic patients on thyroxine 
substitution, the mechanisms of hypothyroidism may include alterations in thyroid hormone 
metabolism as well. We hypothesized that sorafenib may influence the activities of 
iodothyronine deiodinases (D1, D2, and D3) (17), which has not been studied in humans so 
far. We found that a higher substitution dose of thyroxine was needed to maintain serum fT4 
levels. These findings are consistent with a previous report in which eight imatinib treated 
patients that had undergone thyroidectomy required substantial increases in levothyroxine 
replacement dose (13). Indeed, the increased need of levothyroxine may be underestimated 
because some patients may have been over treated before initiation of the trial. In addition, we 
found a clear decrease in serum T3/T4, T3/rT3, and T4/rT3 ratios. These ratios reflect 
alterations in the peripheral metabolism of thyroid hormone, being positively influenced by 
deiodinases D1 and D2 and negatively by D3 (17). Moreover, they are independent of 
levothyroxine administration. The decreased T3/T4 and T3/rT3 ratios may be caused by a 
decrease in D1 and/or D2 activity. However, this would be associated with a decreased rather 
than an increased T4 metabolism. Therefore, the decreased T3/T4 and T3/rT3 ratios are best 




FIG. 1:  A, Relation between levothyroxine dose adjusted for 
body weight (Dose Thyroxine) and serum 
fT4 concentrations during 6 months of treatment with 
sorafenib. B, Individual T3/rT3 ratios before and 6 months 




The fact that, 2 months after the start of sorafenib, a significantly higher T4 dose per 
kilogram body weight was necessary to maintain fT4 concentrations strongly suggests that the 
phenomenon is already present early after initiation of sorafenib therapy. It is worthwhile to 
further elucidate the effects of sorafenib on D3 in in vitro studies. It is unlikely that the 
increased D3 activity reflects a state of nonthyroidal illness because serum TSH increased 
during sorafenib, whereas in nonthyroidal illness, decreased rather than increased TSH levels 
would be expected. Although it can be hypothesized that decreased absorption of T4 could 
also have played a role, the interval between sorafenib and thyroxine intake was 
approximately 12 h. In addition, decreased T4 absorption would not affect T3/T4 and T3/rT3 
ratios. No changes in TBG levels and the ratios between free and bound thyroid hormones 
were observed, ruling out effects of sorafenib on thyroid hormone binding proteins, which 
again, even if present, would not have affected the T3/rT3 ratio. It may hypothesized that 
sorafenib may also influence conjugation of thyroid hormone with glucuronates and sulfates 
by hepatic microsomal enzymes. However, altered conjugation would not influence T3/rT3 
ratios. The fact that the increase in overall rT3 levels was non-significant may suggest that 
rT3 degradation may be enhanced as well. It is likely that, because rT3 is the preferred 
substrate for type1 deiodinase (in the absence of hyperthyroidism), increased rT3 may lead to 
enhanced type 1 deiodinase-mediated rT3 degradation. 
In conclusion, this study shows that, in addition to direct effects of tyrosine kinase 
inhibitors on the thyroid gland, enhanced peripheral metabolism of thyroid hormone, likely by 
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Impact of Metformin and 
compound C on NIS expression 
and iodide uptake in vitro and in 
vivo: a role for CRE in AMPK 





















Background: Although adenosine monophosphate activated protein kinase (AMPK) plays a 
crucial role in energy metabolism, a direct effect of AMPK modulation on thyroid function 
has only recently been reported, and much of its function in the thyroid is currently unknown. 
The aim of this study was to investigate the mechanism of AMPK modulation in iodide 
uptake. Furthermore, we wanted to investigate the potential of the AMPK inhibitor compound 
C as an enhancer of iodide uptake by thyrocytes. 
Methods: The in vitro and in vivo effects of AMPK modulation on sodium-iodide symporter 
(NIS) protein levels and iodide uptake were examined in follicular rat thyroid cell-line cells 
and C57Bl6/J mice. Activation of AMPK by metformin resulted in a strong reduction of 
iodide uptake (up to sixfold with 5mM metformin after 96 h) and NIS protein levels in vitro, 
whereas AMPK inhibition by compound C not only stimulated iodide uptake but also 
enhanced NIS protein levels both in vitro (up to sevenfold with 1 μM compound C after 96 h) 
and in vivo (1.5-fold after daily injections with 20mg/kg for 4 days). We investigated the 
regulation of NIS expression by AMPK using a range of promoter constructs consisting of 
either the NIS promoter or isolated CRE (cAMP response element) and NF-
which are present within the NIS promoter. 
Results:  Metformin reduced NIS promoter activity (0.6-fold of control), whereas compound 
C stimulated its activity (3.4-fold) after 4 days. This largely coincides with CRE activation 
(0.6- and 3.0-fold). These experiments show that AMPK exerts its effects on iodide uptake, at 
least partly, through the CRE element in the NIS promoter. Furthermore, we have used 
AMPK-alpha1 knockout mice to determine the long-term effects of AMPK inhibition without 
chemical compounds. These mice have a less active thyroid, as shown by reduced colloid 
volume and reduced responsiveness to thyrotropin.  
Conclusion: NIS expression and iodide uptake in thyrocytes can be modulated by metformin 
and compound C. These compounds exert their effect by modulation of AMPK, which, in 
turn, regulates the activation of the CRE element in the NIS promoter. Overall, this suggests 
that the use of AMPK modulating compounds may be useful for the enhancement of iodide 
uptake by thyrocytes, which could be useful for the treatment of thyroid cancer patients with 









Adenosine monophosphate-activated protein kinase (AMPK) is an energy-sensing 
heterotrimeric complex that plays an important role in the energy balance at both the cellular 
level and the whole body by balancing nutrient supply and demand. It consists of a catalytic 
-subunit and two regulatory subunits,  and , which in turn are expressed as different 
isoforms ( 1, 2, 1, 2, 1, 2 and 3). Theoretically, this enables the formation of 12 
different complexes that may reflect the function of AMPK through different subcellular 
locations and signalling functions enabling the activation of different pathways (1,2). AMPK 
is known to influence the function of a variety of organs, such as the liver and pancreas (3). 
However, reports on the role of AMPK in thyroid function and iodide uptake remain scarce, 
and much of its function in the thyroid is currently unknown. AMPK can be activated by a 
range of stimuli, for example hypoxia, starvation, and glucose deprivation, which leads to the 
activation or inhibition of multiple downstream pathways (4,5). Different compounds are 
known to modulate AMPK activity, such as the AMPK activators metformin and 5-
aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR), and the AMPK inhibitor 
compound C, which is a small-molecule cell-permeable pyrrazolopyrimidine derivative that 
acts as a reversible ATP competitive inhibitor of AMPK (6–8). 
In the normally functioning thyroid, iodide accumulation is an essential step in the 
production of thyroid hormone (TH) and is mediated by the sodium iodide symporter (NIS). 
NIS expression itself is driven by several thyroid specific and non-specific regulators (9-11). 
Furthermore, iodide uptake is also regulated by the presence or absence of NIS on the cell 
surface. The shuttling of NIS between cell-surface and cytoplasm provides an extra layer of 
regulation and is dependent on several factors with an emphasis on thyroid stimulating 
hormone (TSH) stimulation (11-13). The accumulation of iodide by thyrocytes is also 
exploited in the treatment of thyroid carcinomas by the administration of radioactive iodide-
131 (131I; RAI-therapy) and is often the only curative option for recurrent or metastatic disease 
(14-16).  
Although both AMPK and the thyroid play a crucial role in energy metabolism (3,17), a 
direct effect of AMPK modulation on thyroid function has only recently been reported in a 
study by Andrade et al. (18). In this study, iodide uptake and NIS expression were suppressed 




which could be reversed by the AMPK inhibitor Compound C. Furthermore, iodide uptake 
was reduced in rat thyroid glands after 24 h following a single injection with AICAR. 
The aim of our study was to further investigate the role of AMPK in the thyroid using the 
AMPK activator Metformin and the AMPK inhibitor Compound C, and to provide 
mechanistic insights into its role in NIS expression and iodide uptake. Our findings give new 
insight in the subunit composition of AMPK and demonstrate the effects of prolonged 
modulation of AMPK, an aspect that could be of great importance in the treatment of thyroid 
cancer, which depends on NIS expression and RAI uptake (14-16). We show for the first time 
that inhibition of AMPK by Compound C in the thyroid results in increased NIS expression, 
iodide uptake and plasma T4 levels. Thus, inhibition of AMPK or one of its downstream 
pathways may be a promising treatment strategy to enhance iodide uptake by thyrocytes, 
which might enhance RAI treatment of thyroid cancer patients. Furthermore, we provide 
insight in the regulation of NIS expression by AMPK using a range of promoter constructs 
consisting of either the NIS promoter or isolated CRE (cAMP response element) and NF-
elements, which are present within the NIS promoter. These experiments show that AMPK 
exerts its effects on iodide uptake, at least partly, through the CRE element in the NIS 
promoter.  
 
MATERIALS AND METHODS 
Cell culture 
The follicular rat thyroid cell-line (FRTL-5) was purchased from Health Protection Agency 
Culture Collections (Salisbury, UK) (19). FRTL-5 cells were routinely cultured in Coon's 
modified Ham's F-12 medium supplemented with 10% charcoal stripped calf serum and a six-
hormone (6H) preparation consisting of 5 hormones (5H) (10 g/mL human recombinant 
insulin (Sigma), 10 ng/mL somatostat
transferrin (Sigma) and 10 ng/mL glycyl-L-histidyl-L-lysine acetate (Sigma) supplemented 
with 100 mU/L bovine TSH (Sigma) (making 6H medium). Cells were maintained in a 5% 
CO2-95% air atmosphere at 37°C with a change of medium every third day, and passed every 
7 days. Prior to incubation with AMPK modulating chemicals, monolayers were cultured 
without calf serum for 8 h.  
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In vitro treatments 
FRTL-5 cells were treated with Metformin or Compound C at a concentration of respectively 
2 mM and 5 M for in vitro work.  
Iodide uptake in FRTL-5 cells 
Iodide uptake was determined as described previously (20,21). Briefly, 24 h before the assay, 
cells were washed and cultured in serum-free medium containing 6H or 5H for TSH-induced 
iodide uptake in time (19). After washing twice with Hanks balanced salt solution (HBSS), 
cells were incubated for 30 min with 500 L of HBSS containing 0.1 Ci of Na125
unlabeled NaI, with or without 80 M of sodium perchlorate to control for specific uptake. 
The radioactive medium was aspirated; cells were washed twice with 1 mL of ice-cold HBSS 
and accumulated iodide was extracted with 1 mL of 1xSSC+ 0.1% SDS for 30 minutes. All 
fluids were counted in a -
DNA. 
Western blot 
FRTL-5 cells were lysed directly in Laemmli sample buffer (BioRad, Hercules, CA, USA) 
and thyroid tissue extracts were prepared in NP buffer using a mini bead beater (BioSpec, 
Bartlesville, OK, USA) with 1 mm glass beads (Sartorius AG, Goettingen, Germany). 
Thyroid tissue samples obtained from in vivo studies were subsequently diluted 1:1 in 
Laemmli buffer. Cell or thyroid tissue extracts were subjected to SDS-polyacrylamide gel 
electrophoresis and transferred to a nitrocellulose membrane (0.45 m) (Pierce, Rockford, IL, 
USA) all subsequent steps were performed in the presence of a commercial protease inhibitor 
cocktail in the recommended dose (Roche, Basel Switzerland). After 20 min of blocking at 
room temperature, the membrane was incubated (1:1000) with the primary antibody GAPDH 
(sc-25778) (Santa Cruz Biotechnology, Santa Cruz, Ca, USA) at 4°C O/N followed by an 1 h 
incubation with horseradish peroxidase conjugated secondary antibody. The immune 
complexes were visualized using the Molecular Imager ChemiDoc XRS System (Biorad, 
Hercules, CA, USA). Following equalization of the amounts of protein by comparing 
GAPDH expression, the following primary antibodies and dilutions were used: NIS (1:1000), 
a kind gift of  (1:2500) (Kinasource, Dundee, UK), 




Biotechnology, Santa Cruz, Ca, USA). NIS protein expression of the in vivo samples was 
quantified using the Molecular Imager ChemiDoc XRS System (Biorad, Hercules, CA, USA)  
Luciferase promoter reporter assays 
To study transcriptional regulation of NIS expression by AMPK modulation, we have 
obtained a range of promoter-luciferase constructs which either contain all the known 
functional regions of the NIS upstream enhancer region (NUE; including CRE and NF-
plus the proximal promoter of the rat NIS promoter or an isolated CRE or NF-kb element. 
FRTL-5 cells were transiently transfected immediately after seeding in 5H medium with 
either rNIS9-LUC [containing the proximal promoter – 1 to - 564 bp (relative to ATG) and 
the NUE region - 2264 bp to - 2495 bp (relative to ATG) in pGL3 (10)], CRE-LUC 
(kindlyprovided by A. Himmler, Ernst Boehringer Institute, Bender + Co. GmbH, Vienna, 
Austria) or NF- -LUC (Stratagene, La Jolla, Ca, USA). Renilla luciferase (pRL-CMV; 
Promega, Madison, WI, USA) was co-transfected to correct for transfection efficiency. After 
24 h, the medium was replaced by fresh 5H or 6H medium with or without the addition of 
Metformin or Compound C. Promoter activity (luciferase/renilla) is depicted as % of controls.  
Animals 
For all in vivo experiments with AMPK modulating compounds, 8-week old male C57Bl6/J 
mice were used. Mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and 
housed in conventional cages with a 12:12-h light-dark cycle and free access to food and 
water. All animal experiments were approved by the institutional ethics committee on animal 
care and experimentation at Leiden University Medical Center (Leiden, the Netherlands).  
of thyroids from AMPK-alpha 1 nockout mice (22) and their littermates were a kind gift from 
Dr. Benoit Viollet (Département endocrinologie, métabolisme et cancer, Inserm, Institut 
Cochin Paris, France) and Dr. Sandrine Horman (Université catholique de Louvain, Brussels, 
Belgium). 
In vivo treatments 
To evaluate the effect of AMPK modulation on NIS expression in vivo, mice were 
randomized according to their body weight and divided into 3 groups (n=9). Mice received 
daily i.p. injections with either Metformin (100 mg/kg), Compound C (20 mg/kg) or vehicle 
(PBS; control) for 4 days while feeding on a chow diet.  
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In vivo iodide uptake 
After 4 days of treatment with Metformin, Compound C or vehicle, the in vivo iodide uptake 
125I (1.0x106 cpm; Perkin Elmer, 
Waltham, MA, USA) via the tail vein. After 15 min, mice were sacrificed via cervical 
dislocation and perfused with ice-cold PBS through the right ventricle to wash out residual 
125I. The thyroids were subsequently taken out and 125I-activity was counted using a -counter.  
Plasma T4 levels 
Plasma T4 levels were measured using the 1100 T4 ELISA kit (Alpha diagnostic, San 
Antonio, TX, USA) and TSH levels were measured using the E90463Mu TSH ELISA kit 
(USCN Life Science Inc., Houston, TX, USA) according to the manufacturer’s instructions.  
Immunohistochemistry 
Mouse thyroids were embedded in paraffin and cut into 4-
deparaffinized in histoclear for 10 min. Endogenous peroxidase was blocked with hydrogen 
peroxide (0.3% H2O2 in methanol) at room temperature for 20 min. After rehydration, antigen 
was retrieved by boiling for 10 min in 0.1 M citric acid, pH 6.0. After cooling to room 
temperature and washing with PBS, slides were incubated overnight with primary antibody 
(1:1000) in 1% BSA at 4°C. The next day, slides were washed and incubated for 30 min at 
room temperature with HRP-labeled polymer anti-rabbit (DAKO envision system) (Dako, 
Glostrup, Denmark) followed by an incubation with the peroxidase substrate, vector nova red 
(Vector Laboratories, Burlingame, CA, USA) for 5 min. The reaction was stopped in milliQ 
and the sections were counterstained with Mayer’s hematoxylin, washed, dehydrated and 
mounted in histomount. The slides were subsequently visualized under a microscope (Eclipse 
E800, NIKON instruments inc., Melville, NY, U.S.A.) 
Statistical analyses 
Results are expressed as means ± the standard error of means. All data have been analyzed by 
one-way analysis of variance (ANOVA) followed by a Tukey’s post-hoc test with the 
exception of the results shown in Figure 1 (two-way ANOVA) and Figure 8 (Student’s t-test). 







Metformin and Compound C influence NIS expression and iodide uptake in vitro 
First, we investigated the effect of AMPK activation and inhibition on NIS expression and 
iodide uptake in vitro by treating follicular thyroid cells (FRTL-5 cells) with Metformin or 
Compound C, respectively. The AMPK activator Metformin suppressed TSH-induced iodide 
uptake in a time- (significant at 16 h) and dose-dependent manner which coincided with a 
reduction in NIS protein levels (Fig. 1, 2). Treatment of Metformin-stimulated FRTL-5 cells 
with Compound C, an AMPK inhibitor, counteracted the effects of Metformin on iodide 
uptake and NIS expression (Fig. 3). Furthermore, Compound C treatment alone was able to 
increase iodide uptake (significant at 96 h) up to 7-fold after 4 days of treatment (Fig. 1, 3). 
This increase in iodide uptake coincided with an increase in NIS protein. Interestingly, as 
shown in Fig. 3B, in the absence of TSH, remnant NIS protein levels could be repressed even 






Figure.1. Effect of Metformin and Compound C on TSH-induced iodide uptake by FRTL-5 cells. TSH-
induced iodide uptake in FRTL-5 cells ( ) is altered by Metformin ( ) and Compound C ( ) in a time-




















As the expression patterns of the different isoforms of AMPK ( 1, 2, 1, 2, 1,  2 and 3) 
in thyrocytes are unknown, we determined the expression level of each of the subunits by 
western blot in FRTL-
-5 cells with either Metformin or Compound C, 
wh -subunit at Thr-
 
 
Figure. 2. Dose-dependent effect of metformin treatment on TSH-induced iodide uptake and sodium-iodide symporter 
(NIS) protein levels in FRTL-5 cells after 96 h of treatment. Iodide uptake was corrected for DNA content (A), and NIS 
protein levels were equilibrated for GAPDH (Western blot) (B) in stimulated FRTL-5 cells ( + TSH). Values are mean ± 
SD (n = 3). ***p < 0.001 vs. control.  
FIG. 3. Effect of compound C (CC) on TSH-induced iodide uptake and NIS protein levels in FRTL-5 cells. 
Compound C treatment (AMPK inhibitor) increased iodide uptake and counteracted the effects of metformin 
(AMPK activator) on iodide uptake (A). The observed effects on iodide uptake coincide with NIS protein levels, 
as shown by Western blot (B) in stimulated FRTL-5 cells ( + TSH) after 96 h. Acetyl-CoA carboxylase (ACC) that 
is directly phosphorylated by AMPK functions as an AMPK activation control. Values are mean ± SD (n = 3). ***p 




Regulation of NIS transcription by Metformin and Compound C 
The decrease in iodide uptake after Metformin treatment or the increase after Compound C 
treatment could, at least partially, be explained by de- or increased NIS protein levels (Fig. 2, 
3). This prompted us to investigate the transcriptional regulation of NIS by Metformin and 
Compound C. The regulatory elements in the NIS promoter are located in the NIS upstream 
enhancer region (NUE), which includes CRE and NF-
not inhibit the activation of any of the promoter constructs. However, Compound C was able 
to increase CRE promoter activity 4.8 fold and slightly activated both rNIS and NF-kb 
promoter activity by respectively 1.2 and 1.6 fold (Fig 5A). At day 4, activation of the CRE 
element coincided with rNIS-promoteractivity after treatment with either Compound C or 
Metformin (Fig. 5B). Metformin treatment resulted in a decrease in both rNIS and CRE 
reporter activity of respectively 1.8 fold and 1.9 fold. Compound C treatment resulted in an 








FIG. 4. Prevalence of AMPK subunits in FRTL-5 cells.FRTL-5 cells were treated for 4 days with 
metformin or compound C. The amount of protein was visualized by Western blot after normalization 
for actin. ACC-ser79 phosphorylation (p-ACC-Ser79) was used as a measure for AMPK activation with 
rat liver tissue as a positive control. 
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Regulation of thyroid function in vivo 
To investigate whether modulation of AMPK activity could also influence NIS expression and 
iodide uptake in thyroid in vivo, we treated mice daily for 4 days. Mice received daily i.p. 
injections with either Metformin (100 mg/kg), Compound C (20 mg/kg) or vehicle (PBS; 
control) for 4 days. After 4 days of treatment body weight was not affected by either treatment 
although initially the Compound C treated group had a slightly decreased body weight at day 
2 of 8% (p<0.05). Although Metformin treatment reduced immunohistochemical staining of 
NIS protein in the thyroid, the decrease in NIS protein levels was nonsignificant and 125I 
uptake was unaffected (Fig 6A-C). This indicates that the effect of Metformin on NIS protein 
levels was insufficient to reduce iodide uptake.  
 
FIG. 5. Activation of reporter 
constructs after 1 day (A) and 4 
days (B) of metformin or 
compound C treatment.  
The luciferase-reporter 
constructs include the rat NIS 
promoter (fusion of the rNIS 
proximal promoter -1 to - 564 
bp and the NUE region - 2264bp 
to - 2495 bp, which contains a 
CRE element and an NF-
element) an isolated 3 CRE 
element and an isolated 3· NF-
(lacking TSH) was used as a 
negative control for CRE 
as a positive control for NF-
Values are mean ± SD (n = 6).  
*p < 0.05 vs. control; **p < 0.01 













However, after Metformin treatment T4 levels were significantly lower than in 
Compound C treated animals (Fig. 7A) but no effects on TSH levels were observed (Fig. 7B). 
A possible explanation for the apparent discrepancy between NIS function and T4 levels 
could be that Metformin-treated animals were slightly ill (23), or it may be due to a reduction 
in serum T4 binding proteins which are known to be regulated by metabolic parameters (24). 
In line with our in vitro data, treatment of mice with Compound C resulted in marked 
upregulation of NIS protein levels (+39%, p<0.05) and 125I uptake (+55%, p<0.001) in thyroid 
tissue (Fig 6A, B). This was also supported by the finding of increased immunohistochemical 




FIG. 6. NIS protein levels and iodide uptake in mice after 4 days of treatment with metformin or compound C. 
Mice received daily i.p. injections with metformin (100 mg/kg), Compound C (20 mg/kg) or vehicle for 4 days. 
NIS protein levels in thyrocytes were analyzed by Western blot (A) (n = 9/group) and IHC staining (C) (n = 
3/group). NIS Western blot data of individual animals were quantified and corrected for GAPDH (A) (inlay 
pooled fractions) and NIS protein levels were depicted as % of controls ([NIS/GAPDH]/controls · 100%). Iodide 
– SD (n = 8). **p < 0.05 vs. control; ***p < 0.001 
vs. control.  
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The effects of AMPK-alpha 1 on thyroid function were studied in AMPK alpha 1 
knockout mice (Fig. 8). When compared to controls these mice have an increased colloid 
diameter (Fig. 8A,B), raised TSH levels (6-fold) (Fig. 8C) and decreased T4 levels (0.6-fold) 




The aim of this study was to investigate the mechanism of AMPK modulation of iodide 
uptake in thyrocytes. Furthermore, we evaluated the potential of the AMPK inhibitor 
Compound C as an enhancer of iodide uptake by thyrocytes, which could be of potential 
benefit in the RAI treatment of thyroid cancer patients. We show that NIS expression and 
iodide uptake in thyrocytes can be upregulated by Compound C, in vitro and in vivo. 
Furthermore, we show that AMPK exerts its effects on iodide uptake, at least partly, through 
stimulation of the CRE element in the NIS promoter. 
In vitro, Metformin was able to increase AMPK activity, which resulted in a strong 
reduction of iodide uptake and NIS expression, whereas treatment with the AMPK-inhibitory 
Compound C resulted in a strong increase of iodide uptake and NIS expression. Although 
these chemical compounds may induce cellular effects which are not directly linked to AMPK 
repression/or stimulation (25-29) the opposing effects of Metformin and Compound C on 
iodide uptake and NIS expression point towards an AMPK-related mechanism, which is 
further supported by a recent study where AICAR was able to inhibit iodide uptake in PCCL3 
follicular thyroid cells and rat thyroid glands (18). In addition, we demonstrate that AMPK in  
FIG. 7. T4 and TSH serum levels after 4 days of treatment. Mice received daily i.p. injections with metformin 
(100mg/kg), compound C (20 mg/kg), or vehicle for 4 days. T4 (A) and TSH (B) serum levels were determined by 






FRTL- (30). The subunit 




 FIG. 8. Difference in follicle size (A, B) and TSH (C), T3 (D), and T4 (E) serum levels between wild type and 
AMPK-alpha 1 knockoutmice. TSH(C), T3(D), andT4(E) serum levelswere determined by ELISA (n = 
4/group). *p < 0.05 vs.wt; ***p < 0.001 vs.wt. 
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In vivo, Compound C clearly enhanced iodide uptake which suggests that AMPK 
inhibition may provide a useful mechanism for the enhancement of iodide uptake which may 
be of potential benefit in the treatment of papillary and follicular thyroid carcinomas with RAI 
(14-16). A possible use of AMPK inhibiting compounds in the enhancement of RAI therapy 
will require further investigation. It should be noted that AMPK modulation is known to 
modulate several factors involved in growth; for example, the glucose transporter protein 
GLUT 1 e.g. Glut 1 is up-regulated by AICAR at a concentration of 1,5 mM after 24h 
resulting in reduced glucose uptake in the follicular thyroid cell-line PCCL3 this effect could 
be reversed by Compound C (30). Furthermore, it is unclear if inhibition or stimulation of 
AMPK will inhibit or increase growth of tumor cells as both have been documented to 
suppress growth (31,32). 
Considering the fact that at this point it is unclear what the effects of AMPK modulation 
on growth and iodide uptake will be in thyroid tumors, we can only speculate on the clinical 
impact of AMPK modulation on iodide uptake. However, we think that unraveling the 
pathways downstream of AMPK leading towards enhanced iodide uptake may enable the 
differentiation between enhanced iodide uptake and effects on growth. 
As the uptake of iodide is the first essential step in the production of TH, we also 
examined serum T4 levels. There was no difference between control and either treatment but 
T4 levels were significantly higher in the Compound C treated group when compared to the 
Metformin treated group (28% increase). Remarkably, TSH levels remained unaffected.  
We are aware that long term Metformin treatment (12 months) has been associated with a 
reduction in TSH levels (33-35). These studies describe a lowering of serum TSH levels in 
hypothyroid and euthyroid diabetic patients with basal TSH levels in the upper normal range 
without affecting T4 levels. So far no definite explanation has been given for these 
observations but in our view a possible explanation may be that Metformin sensitizes the 
thyroid for TSH stimulation after a few months of treatment. 
Our study describes the shortterm effects of AMPK modulation by Metformin and 
Compound C treatments. 4 days of Metformin treatment resulted in decreased iodide uptake 
and NIS protein levels in follicular thyroid cells, which would suggest a decrease in thyroid 
function. Therefore short- (4 days) and long-term (1 year) stimulation of AMPK by 




the addition of new data from AMPK alpha knockout mice, which have increased serum TSH 
levels without changes in T4 levels (completely opposite to long term AMPK stimulation by 
Metformin) (33-35).  
The in vitro decrease in iodide uptake after Metformin treatment or the increase after 
Compound C treatment can, at least partially, be explained by decreased or increased NIS 
protein levels (Fig. 2 and 3).  We therefore decided to analyze the transcriptional regulation of 
the NIS promoter. The main regulatory region in the NIS promoter is the NIS upstream 
enhancer (NUE) region which contains response elements for TTF-1, CRE, Pax8 and NF-
(9-11, 36). The rNIS promoter containing both the NUE region and the proximal promoter 
were activated after 4 days of Compound C treatment, whereas Metformin inhibited rNIS after 
4 days. In contrast, 1 day of Metformin or Compound C treatment did not result in any 
changes in rNIS activity. This largely corresponds to the observed effects of AMPK 
modulation on iodide uptake and NIS protein levels, confirming NIS regulation at the 
transcriptional level. This is in contrast with a study by Andrade et al. (18) where activation of 
AMPK by AICAR appears to be due to increased degradation/turnover of NIS. Furthermore, 
in the article by Andrade et al., Compound C was reported to stimulate iodide uptake without 
increasing NIS expression. A possible explanation was offered suggesting an effect on iodide 
uptake by a relocation of NIS. These differences may be explained by the use of different cell-
lines, compounds or the time of stimulation. Possibly a fast non-transcriptional effect that is 
present after 24 h and a long-term effect based on increased or decreased transcription of NIS 
coexist, although in our hands, the effects on iodide uptake were not significant after 24 h. 
An important factor in NIS regulation is TSH, which is known as the main regulator of 
NIS at multiple levels. It positively regulates NIS expression at the protein and mRNA level, 
increases NIS protein half-life, and facilitates translocation to the plasma membrane 
(11,12,20,37,38), making a key regulator of iodide uptake. It activates NIS expression by 
activating the CRE-like element in the NIS promoter (11). We have shown that the CRE 
element may also be involved in the observed effect of AMPK modulation on NIS gene 
expression because AMPK modulation had a strong effect on CRE activation. Apparently, the 
downstream effects of TSH activation and AMPK action seem to synergize on the CRE-like 
element of the NIS promoter. The fact that the CRE element plays a role in both TSH- and 
AMPK-mediated signalling may also explain the observation that AMPK inhibition with 
Compound C increases NIS protein levels even in the absence of TSH. Interestingly, TSH 
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may also be a key player in AMPK modulation by activating its downstream targets cAMP 
and protein kinase A (PKA) (39–42), thus adding an additional pathway to TSH stimulated 
iodide uptake. PKA activation is able to prevent phosphorylation of the catalytic subunit 
AMPK-alpha at threonine172 and therefore activation of AMPK in several cell lines including 
follicular thyroid cell lines (18,39–42). Possible mechanisms include the phosphorylation at 
serine485/491 or serine173 on AMPK, which blocks threonine172 phosphorylation (39,40). 
Although activation of the CRE element coincides with rNIS promoter activity 4 days 
following AMPK modulation, CRE activation by compound C at day 1 exceeds rNIS 
activation. This implies that additional factors are involved, which perhaps is not surprising as 
CRE-like site activation in the NUE region of the NIS promoter is closely associated with 
binding of regulatory elements to flanking regions, especially PAX8 (11). Once bound, PAX8 
can synergize with a range of b-Zip transcription factors at the CRE-like element site to 
stimulate NUE activity (36). In contrast to the CRE-like element, activation of the NF-
element (9) seems to be of minor importance in the activation of NIS following AMPK 
modulation. 
To conclude, we show that NIS expression and iodide uptake can be modulated by 
metformin and compound C in thyrocytes. It is likely that these compounds exert their effect 
by modulation of AMPK, which, in turn, regulates the activation of the CRE element in the 
NIS promoter. The observed effects on iodide uptake and NIS expression suggest that the use 
of AMPK-modulating compounds may be useful for the enhancement of iodide uptake by 
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Background: Subclinical hyperthyroidism is associated with cardiovascular morbidity. 
Recent advances in echocardiography imaging have allowed sophisticated evaluation of 
myocardial tissue properties. 
Objective: To investigate the myocardial effects of long-term exogenous subclinical 
hyperthyroidism using two-dimensional speckle tracking echocardiography imaging (2D-
STE).  
Design: Prospective, single-blinded placebo-controlled randomized trial of 6 months duration 
with 2 parallel groups. 
Patients and methods: Totally 25 patients with a history of differentiated thyroid carcinoma 
on long-term TSH-suppressive levothyroxine (L-T4) substitution were randomized to 
persistent TSH-suppressive L-T4 substitution (low-TSH group) or restoration of 
euthyroidism. Additionally 40 euthyroid controls were studied. 
Results: At baseline, the group of patients showed normal left ventricular (LV) systolic 
function but impaired diastolic function as assessed with conventional echocardiographic 
parameters. Importantly, 2D-STE analysis demonstrated the presence of subclinical LV 
systolic and diastolic dysfunction with impaired circumferential and longitudinal strain and 
strain rate at the isovolumic relaxation time. After restoration of euthyroidism, a significant 
improvement in LV systolic and diastolic function as assessed with 2D-STE strain was 
observed. 
Conclusion: Prolonged subclinical hyperthyroidism leads to systolic and diastolic 
dysfunction, which is reversible after restoration of euthyroidism. 2D-STE is a more sensitive 











Subclinical hyperthyroidism is a relatively common thyroid dysfunction with important 
cardiovascular consequences such as left ventricular (LV) diastolic dysfunction, increased LV 
mass, and increased risk of supraventricular arrhythmias (1–7). These cardiovascular effects 
can be accurately evaluated in exogenous subclinical hyperthyroidism, where the duration and 
development of thyroid dysfunction are well controlled, and different strategies to restore 
euthyroidism can be performed in a randomized fashion. We recently performed a 
prospective, randomized; placebo-controlled study in patients treated with total thyroidectomy 
for differentiated thyroid carcinoma, and demonstrated that 10-year thyroid hormone excess 
was related to increased LV mass index and overt diastolic dysfunction (7). More importantly, 
restoration of euthyroidism resulted in normalization of diastolic function. 
Recent advances in echocardiography imaging have allowed sophisticated evaluation of 
myocardial tissue properties that may provide novel insights into the effects of thyroid 
hormone on the myocardium. Particularly, two-dimensional speckle tracking 
echocardiography (2D-STE) imaging is a novel technology that permits the study of 
multidirectional active deformation of the myocardium, providing comprehensive information 
on myocardial function and closely reflecting myocardial contractile properties (8–10). 2D-
STE imaging allows estimation of both strain (radial, longitudinal, and circumferential) and 
strain rate (SR). Strain measures the myocardial fiber deformation (shortening and 
thickening), and SR measures the velocity of deformation. The present study explores further 
the effects of thyroid hormone on the myocardium with the use of 2D-STE and aimed to 
demonstrate whether LV mechanics, as assessed with multidirectional strain, are impaired in 
patients with subclinical hyperthyroidism and whether these abnormalities may be reversed 
after restoration of the euthyroid status. The echocardiographic data collected prospectively in 
the aforementioned randomized placebo-controlled study were reanalyzed in a blinded fashion 








PATIENTS AND METHODS 
The present study was a prospective single-blind randomized study of 6 months duration with 
two parallel groups. As previously described, the patient population consisted of athyreotic 
patients subjected to TSH-suppressive thyroxine (T4) treatment (7). Patients had been 
diagnosed with differentiated thyroid carcinoma and had been initially treated with total 
thyroidectomy and radioiodide ablative therapy. Cure was documented by the absence of 
measurable serum thyroglobulin during TSH stimulation and by a negative total-body 
scintigraphy with 4mCi131I. TSH-suppressive therapy was defined by TSH levels below the 
lower reference value for normal serum levels of TSH (0.4 mU/l) for at least 10 years.  
After inclusion, the patients were randomized in a single-blind fashion to continuation of 
TSH-suppressive therapy (low-TSH group, with TSH target levels <0.4 mU/l) or restoration 
of euthyroidism by reducing the levo-T4 (L-T4) dose (euthyroid group, with TSH target levels 
within the normal reference range 0.40–0.48 mU/l). 
Physical examination, hormonal assessments, and comprehensive echocardiographic 
evaluation were performed at baseline and at 6 months follow-up. Changes in LV 
hemodynamics and performance were evaluated by conventional echocardiography and by 
sophisticated 2D-STE analyses. All echocardiographic analyses were performed by a single 
observer, blinded to treatment modalities. 
The echocardiographic findings were compared with a control group of 40 individuals 
without cardiovascular morbidity: 8 males and 32 females with a mean age 46±8 years. These 
controls were recruited from an echocardiographic database, as previously described (11). 
Those individuals with dilated LV, valvular heart disease, or hypertrophic cardiomyopathy 
were excluded. Accordingly, the control group comprised individuals referred for atypical 
chest pain, palpitations, or syncope without murmur. 
Echocardiography 
Patients were imaged in the left lateral decubitus position using a commercially available 
system equipped with a 3.5 MHz transducer (Vingmed Vivid-7, General Electric Vingmed, 
Horten, Norway). Standard M-mode, two-dimensional, and color Doppler data were acquired 
triggered to the QRS complex and saved in cine loop format for off-line analysis (EchoPac 
108.1.5, General Electric/Vingmed Ultrasound). 
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LV dimensions (end-diastolic diameters (EDD) and end-systolic diameters (ESD), end-
diastolic interventricular septum thickness, and posterior wall thickness (PWT)), fractional 
shortening (FS), and LV ejection fraction (LVEF) were measured from M-mode recordings 
obtained at the parasternal long-axis views, according to the American Society of 
Echocardiography guidelines (12). LV mass was calculated by Devereux’s formula and 
indexed to body surface area (LVMI) (13). 
Diastolic function was evaluated by measuring the following parameters: E-wave, A-
wave, E/A ratio, deceleration time (DT) of the E-wave, and isovolumic relaxation time 
(IVRT) obtained from the pulsed-wave Doppler recordings (14). Finally, left atrial volume 
was measured from the apical two- and four-chamber views as a morphologic marker of 
diastolic function. 
Two-dimensional speckle tracking strain imaging 
2D-STE analysis permits the angle-independent, multidirectional assessment of LV 
myocardial strain and SR. Both strain and SR characterize the LV tissue mechanical 
properties and differentiate the active myocardial contraction from the passive motion. Strain 
is a measure of myocardial deformation and is expressed as percentage (%), whereas SR 
indicates the rate of the myocardial deformation and is expressed as 1/s. 2D-STE analyses 
strain and SR by tracking frame-to-frame natural acoustic markers (so-called speckles), 
equally distributed within the myocardium and visible in the standard grayscale two-
dimensional images. Accordingly, LV deformation can be studied along the cardiac cycle in 
three orthogonal directions as follows: radial, circumferential, and longitudinal (9). Radial and 
circumferential strains are assessed at the LV mid-ventricular short-axis images. Radial strain 
measured the thickening/thinning of the myocardial wall, whereas circumferential strain 
measures the myocardial shortening/lengthening along the curvature of the LV. The mid-
ventricular short axis of the LV is divided into six segments, and the global values of radial 
and circumferential strains are derived from the average of the six segmental peak systolic 
strain values (Fig. 1, panels A and B). Longitudinal strain is measured at the apical two-
chamber, four-chamber, and long-axis views. Longitudinal strain evaluates the 
shortening/lengthening of the myocardial wall, resulting from the movement of the mitral 
annulus plane upward/downward the LV apex. Each LV apical view is divided into six 




segmental peak systolic strain values (Fig. 1, panel C) (10). Finally, global peak longitudinal 
SR at the IVRT (SRIVRT) is measured at the three apical views and averaged for final analysis 
(Fig. 1, panel D), as previously described (15). This parameter is a marker of global 
myocardial relaxation and reflects the LV filling pressures. Therefore, in the present study, 
LV mechanical properties were evaluated through three systolic parameters (global radial, 
circumferential, and longitudinal strains) and one diastolic parameter (SRIVRT), all of them 
derived with 2D-STE imaging.  
Statistical analysis 
Continuous variables are presented as mean ± S.D., and categorical variables are presented in 
number and frequencies. Comparisons between patients and controls were performed with 
Student’s t-test for unpaired data.  
As previously described, the effects of different conditions on echocardiographic 
parameters were evaluated within and between low-TSH group and euthyroid patients using 
Mann–Whitney U test and Wilcoxon sum rank test for unpaired and paired data respectively. 
To evaluate the relationship between free T4 and TSH levels and the various 
echocardiographic parameters, univariate regression analysis was performed. All statistical 
analyses were performed with SPSS software (version 16.0, SPSS Inc., Chicago, IL, USA). A 
P value <0.05 was considered statistically significant. 
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Out of an initial cohort of 33 patients, 25 patients were included in the present study (7). 
Thirteen patients continued TSH-suppressive therapy (low-TSH group, target TSH level<0.4 
mU/l), whereas in the remaining 12 patients, the euthyroid status was restored (euthyroid 
group). At baseline, weight ((73.2±15.9 (low-TSH group) vs 74.0±9.5 kg (euthyroid group), 
P=0.881)), systolic blood pressure (135±23 vs 134±14 mm Hg, P=0.920), diastolic blood 
pressure (81±10 vs 83±5 mm Hg, P=0.728), heart rate (71±7 vs 68±7 bpm, P=0.452), T4 dose 
(166±34 vs 185±40 μg, P=0.200), TSH (0.054 (<0.005–0.339) vs 0.038 (<0.005–0.302) mU/l, 
P=0.617), and free T4 (21.7±5.8 vs 22.6±4.0 pmol/l, P=0.637) were not different between the 
low-TSH group and the euthyroid group. After 6 months, T4 dose (177±33 vs 129±37 μg, 
P%0.001), TSH concentrations (0.015 (<0.005–0.347) vs 2.66 (0.218–6.090) mU/l, P=0.001) 
and free T4 (23.1±1.1 vs 18.5±1.1 pmol/l, P<0.001) differed significantly between the low-
TSH group and the euthyroid group. 
 
Figure 1 Two-dimensional speckle 
tracking strain imaging: 
multidirectional assessment of LV 
strain and strain rate. At the mid-
ventricular short axis view of the LV, 
radial (panel A) and circumferential 
(panel B) strain are calculated, 
obtaining the time-strain curves 
along the cardiac cycle for the 6 LV 
segments. Longitudinal strain of the 
LV is calculated at the apical 4-
chamber, 2-chamber and long-axis 
views (panel C). Global longitudinal 
strain value is obtained from the 
average of 18 segments and results 
are displayed in time-strain curves 
and polar map. Finally, SRIVRT 
(panel D) is measured from the LV 
apical views, as a parameter of LV 
relaxation. The arrow points out the 





Baseline echocardiography and 2D-STE analysis 
At baseline, patients showed significantly higher values of end-diastolic PWT and LV ESD 
than controls (Table 1). However, LV mass index (LVMI) was comparable between the two 
groups. In addition, patients had significantly lower values of LV FS and LVEF compared to 
the group of controls, but within the normal range (Table 1). Regarding the diastolic function, 
the group of patients showed significantly lower values of E- and A-wave with an inverse E/A 
ratio and significantly longer values of E-wave DT and IVRT, indicating impaired LV 
relaxation (Table 1). There were no differences in left atrial volume. Finally, 2D-STE analysis 
demonstrated a significant impairment of LV circumferential and longitudinal strains in the 
group of patients, whereas LV radial strain was preserved compared to the group of controls 
(Table 1). In addition, the SRIVRT was significantly reduced in the group of patients 
compared to the group of controls, indicating higher LV filling pressures. 
 
Table 1 Baseline echocardiographic characteristics 
 Controls (n = 40) Patients (n = 25) p-value 
    
LV mass index (g/m2) 77.2 ± 17.2 86.0 ± 21.0 0.051 
IVST (mm) 8.4 ± 1.0 9.2 ± 1.6 0.056 
PWT (mm) 8.4 ± 0.9 9.2 ± 1.2 0.003 
LV EDD (mm) 49.4 ± 4.7 49.2 ± 4.1 0.989 
LV ESD (mm) 28.8 ± 4.5 31.5 ± 4.5 0.020 
LV FS(%) 41.4 ± 6.1 36.0 ± 7.3 0.004 
LV EF (%) 71.6 ± 7.1 64.7 ± 9.3 0.002 
    
E-wave (cm/s) 72.9 ± 17.6 55.3 ± 9.5 <0.001 
A-wave (cm/s) 56.7 ± 12.6 63.9 ± 10.8 0.029 
E/A ratio 1.3 ± 0.2 0.87 ± 0.13 <0.001 
E-wave DT (ms) 191.1 ± 33.3 234 ± 34 <0.001 
IVRT (ms) 77.7 ± 13.3 121.0 ± 15.0 <0.001 
Left atrial volume (ml) 45.5 ± 13.7 50.5 ± 13.7 0.160 
E’-wave (cm/s) 9.2 ± 1.7 5.7 ± 1.3 <0.001 
A’-wave (cm/s) 6.5 ± 1.4 6.8 ± 1.4 0.494 
E’/A’ ratio 1.4 ± 0.5 0.89 ± 0.35 <0.001 
    
Radial strain (%) 43.9 ± 17.5 42.3 ± 11.8 0.687 
Circumferential strain (%) -19.7 ± 2.8 -16.9 ± 2.3 0.001 
Longitudinal strain (%) -19.9 ± 2.8 -17.7 ± 1.2 <0.001 
SRIVRT (1/s) 0.39 ± 0.09 0.29 ± 0.08 <0.001 
Abbreviations: DT = deceleration time; EDD = end-diastolic diameter; EF = ejection fraction; ESD = end-systolic diameter; 
FS = fractional shortening; IVRT = isovolumic relaxation time; IVST = interventricular septum thickness; LV = left 








Low-TSH group versus euthyroid group: conventional echocardiography  
At 6 months follow-up, the euthyroid group showed significant reductions in LV dimensions 
and improvements in LV FS and LVEF (Table 2). In addition, LV diastolic function improved 
significantly in the euthyroid group as indicated by a reduction in the A-wave velocity and 
normalization of the E/A ratio, a significant reduction in the left atrial volume, and significant 
decreases in E-wave DT and IVRT. In contrast, the low-TSH group exhibited a significant 
increase in LV dimensions (EDDs and ESDs) and a significant reduction in LV FS and LVEF 
(Table 2). No changes in conventional imaging-derived LV diastolic parameters were 
observed in the low-TSH group. 
 
Table 2 Low-TSH group vs. euthyroid group: conventional echocardiography and tissue Doppler imaging 
 
 Low-TSH (n= 13) Euthyroid (n = 12)  
 Baseline 6-months Baseline 6-months p-value  
      
LV mass index (g/m2) 86.0  26.0 89.0  12.0 87.0  16.0 95.0  24.0 0.468 
IVST (mm) 8.9  1.9 9.2  1.1 9.4  1.4 10.0  1.6 0.630 
PWT (mm) 9.0  1.2 8.9  1.2 9.5  1.3 9.6  0.9 0.763 
LV EDD (mm) 49.1  4.0 52.1  3.3 49.3  4.5 48.6  3.3 0.045 
LV ESD (mm) 30.1  4.0 34.1  5.4* 33.1  4.8 29.5  2.5* <0.001 
LV FS (%) 38.4  7.0  34.8  8.0* 33.3  7.2 39.4  3.8* <0.001 
LV EF (%) 67.6  8.6 62.6  11.4* 61.3  9.6 69.8  4.6* <0.001 
E-wave (cm/s) 58.1  7.9 58.9  8.2 51.0  10.0 54.8  13.3 0.353 
A-wave (cm/s) 66.1  11.2 67.7  12.4 61.3  10.6 47.4  11.6* <0.001 
E/A ratio 0.91  0.16 0.88  0.12 0.83  0.10 1.18  0.27* <0.001 
E-wave DT (ms) 230  34 236  26 237  38 196  24* 0.001 
IVRT (ms) 115  15 121  17 127  13 95  15* <0.001 
Left atrial volume (ml) 48.6  14.7 50.7  17.4 52.0  12.4 44.9  12.4* 0.009 
E’-wave (cm/s) 5.9  1.8 5.2  1.8 5.5  0.6 7.2  1.3* <0.001 
A’-wave (cm/s) 6.4  1.4 5.7  1.5 7.1  1.4 6.7  1.6 0.493 
E’/A’ ratio 0.97  0.42 0.97  0.34 0.81  0.26 1.13  0.34* 0.003 
Abbreviations: DT = deceleration time; EDD = end-diastolic diameter; EF = ejection fraction; ESD = end-systolic diameter; 
FS = fractional shortening; IVRT = isovolumic relaxation time; IVST = interventricular septum thickness; LV = left 
ventricular; PWT = posterior wall thickness.  
*p <0.05 vs. Baseline (wihtin the groups); Difference between 6 months and baseline, euthyroid vs. low-TSH group  
 
Low-TSH group versus euthyroid group: 2D-STE analysis 
At baseline, both groups of patients showed comparable values of LV radial, circumferential, 
and longitudinal strains and comparable values of SRIVRT as measured with 2D-STE imaging 




LV circumferential and longitudinal strains and in SRIVRT, whereas no changes in LV radial 
strain were observed (Fig. 2). In contrast, the low-TSH group did not have significant changes 
in multidirectional LV strain or SRIVRT (Fig. 2). There were significant differences in changes 
in circumferential and longitudinal strains and in SRIVRT between the two groups (Table 3). 
 
Table 3 Low-TSH group vs. euthyroid group: 2-dimensional speckle tracking strain imaging 
 Low-TSH (n= 13) Euthyroid (n = 12)  
 Baseline 6-months Baseline 6-months p-  
      
Radial strain (%) 42.9 ± 10.2  39.7 ± 13.7  41.7 ± 13.7  42.0 ± 11.2  0.431 
Circumferential strain (%) -17.0 ± 2.8  -16.5 ± 1.3  -16.9 ± 1.7  -18.8 ± 2.3*  0.018 
Longitudinal strain (%) -17.9 ± 1.3  -17.5 ± 1.8  -17.5 ± 1.1  -19.7 ± 2.1*  0.001 
SRIVRT (1/s) 0.29 ± 0.1  0.28 ± 0.08  0.29 ± 0.06  0.42 ± 0.09*  0.004 
Abbreviations: SRIVRT = strain rate at the isovolumic relaxation time. 








Figure 2 Changes in multidirectional LV strain and SRIVRT in low- TSH and euthyroid groups. The bar 
graphs show multidirectional LV strain and strain rate values at baseline (white bars) and follow-up (solid 
bars) in the low-TSH group and the euthyroid group. In those patients who continued TSH-suppressive 
therapy, there were no changes in multidirectional LV strain and strain rate at the isovolumic relaxation 
time (SRIVRT). In contrast, those patients with restoration of the euthyroid status showed significant 
improvements in circumferential and longitudinal strains and in SRIVRT  
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Relationship between TSH levels and echocardiographic parameters at follow-up 
Univariate regression analysis was used to evaluate the influence of free T4 and TSH levels 
on different echocardiographic parameters (Table 4). Free T4 and TSH levels were not related 
to LV dimensions or systolic function as measured with conventional parameters. In contrast, 
some LV diastolic parameters as measured with transmitral pulsed-wave Doppler 
echocardiography (A-wave, E/A ratio, DT, and IVRT) or tissue Doppler imaging (E’-wave) 
were significantly related to free T4 and TSH levels. Finally, novel indices of LV systolic 
function based on 2D-STE analysis showed a borderline association with TSH levels but not 
with free T4 levels. 
 
Table 4 Univariate regression analysis between free thyroxine (T4) and TSH levels and echocardiographic 
parameters at follow-up. 
 T4 (pmol/l) TSH (mU/l) 
  95% confidence interval 
P value  95% confidence 
interval 
P value 
LV mass index (g/m2) 0.286 - 0.770 to 3.294 0.209 0.176 - 1.746 to 4.113 0.411 
IVST (mm) 0.148 - 0.100 to 0.190 0.521 0.174 - 0.166 to 0.385 0.827 
PWT (mm) 0.067 - 0.095 to 0.126 0.774 0.232 - 0.097 to 0.325 0.275 
LV EDD (mm) 0.126 - 0.295 to 0.508 0.586 0.138 - 0.813 to 0.424 0.521 
LV ESD (mm) 0.120 - 0.405 to 0.676 0.606 0.335 - 1.486 to 0.161 0.109 
LV FS (%) 0.089 - 0.870 to 0.597 0.701 0.324 - 0.278 to 2.188 0.123 
LV EF (%) 0.094 - 1.250 to 0.839 0.685 0.331 - 0.362 to 3.132 0.114 
E-wave (cm/s) 0.037 - 1.243 to 1.067 0.875 0.103 - 2.741 to 1.697 0.630 
A-wave (cm/s) 0.438 - 2.924 to - 0.020 0.047 0.672 - 12.672 to - 4.376 <0.001 
E/A ratio 0.413 - 0.001 to 0.043 0.063 0.587 - 6.911 to -1.677 0.003 
E-wave DT (ms) 0.112 - 2.692 to 4.351 0.628 0.575 0.025 to 0.110 0.003 
IVRT (ms) 0.153 - 2.593 to 1.327 0.507 0.459 - 7.747 to - 0.597 0.024 
Left atrial volume (ml) 0.407 - 2.316 to 0.088 0.067 0.030 - 3.285 to 2.871 0.890 
E’-wave (cm/s) 0.461 0.012 to 0.308 0.036 0.446 0.040 to 0.665 0.029 
A’-wave (cm/s) 0.191 - 0.102 to 0.241 0.407 0.230 - 0.147 to 0.484 0.289 
E’/A’ ratio 0.231 - 0.012 to 0.036 0.313 0.213 - 0.033 to 0.097 0.319 
Radial strain (%) 0.152 - 1.061 to 1.970 0.535 0.386 - 0.202 to 4.937 0.069 
Circumferential strain 
(%) 
0.044 - 0.246 to 0.207 0.857 0.389 - 0.837 to 0.030 0.067 
Longitudinal strain (%) 0.243 - 0.270 to 0.085 0.288 0.377 - 0.760 to 0.031 0.069 
SRIVRT (1/s) 0.035 - 0.011 to 0.012 0.879 0.298 - 0.006 to 0.035 0.157 
DT, deceleration time; EDD, end-diastolic diameter; EF, ejection fraction; ESD, end-systolic diameter; FS, fractional 




The present study provides new insights into the effects of thyroid hormone on myocardial 




subclinical hyperthyroidism and preserved LVEF, 2D-STE analysis demonstrated the 
presence of impaired LV myocardial deformation. After restoration of euthyroid status, a 
significant improvement in circumferential and longitudinal strains and SRIVRT was 
observed. Therefore, in patients with exogenous subclinical hyperthyroidism and preserved 
LVEF, the excess of thyroid hormone exerts a deleterious effect on myocardial function that is 
reversible upon restoration of euthyroid status. It remains to be determined whether these 
changes may be reversed or not once overt heart failure is present. 
The cardiovascular effects of subclinical hyperthyroidism have been well documented, 
and include increased LV mass, diastolic dysfunction, and increased risk of cardiac 
arrhythmias (1–6, 16). However, it is important to note that previous studies included 
retrospective series and yielded observational and controversial results (4, 16–18). In contrast, 
the randomized design of the present study permitted evaluation of the direct cardiovascular 
effects of thyroid hormone. Patients with subclinical hyperthyroidism showed impaired 
diastolic function as assessed with conventional pulsed-wave Doppler echocardiography and 
tissue Doppler imaging (7). After restoration of euthyroid hormone levels, significant 
improvements in diastolic function were observed. The present study represents a step further 
in the characterization of LV diastolic performance by evaluating the relaxation properties of 
the myocardium with 2D-STE. At baseline, the overall population showed a reduced SRIVRT, 
a surrogate of increased LV filling pressures (15). Improvement in LV filling pattern with an 
increase in SRIVRT was only observed in those patients with restored euthyroidism, whereas 
in those patients with low-TSH levels, SRIVRT remained unchanged. The measurement of 
SRIVRT provides additional insight to previous findings based on tissue Doppler imaging, as 
this parameter may be less load-dependent and relies on active deformation of the 
myocardium. In addition, these changes in LV diastolic dysfunction were independent of LV 
mass. The present study population had an increased LV mass as compared with controls. 
However, most patients did not show LV hypertrophy. As previously demonstrated, thyroid 
hormone exerts direct effects on myocardial diastolic relaxation independent of protein 
synthesis and cardiac growth (1, 19). Therefore, it may reflect more the direct biochemical 
effects of thyroid hormone on the myocardium, which lead to activation of local signal 
transduction pathways rather than the effects of LV hypertrophy (1, 20). In earlier studies, 
more profound LV hypertrophy was found that was reversed by b-blockers (5, 21, 22) or dose 
reduction (23). These studies also included patients with multinodular goiter, who may have 
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been exposed to higher levels of free T4 and have subsequently shown more profound 
myocardial hypertrophy. 
It can be hypothesized that the fact that we did not find a significant difference between 
patients and controls in LVMI and IVST could be explained by the fact that TSH levels were 
not suppressed in all patients. We therefore compared IVST and LVMI between patients with 
completely suppressed TSH levels at baseline and patients with TSH R0.1 mU/l, but did not 
find significant differences between these two groups. 
The most insightful finding of the present study is, perhaps, the presence of subclinical 
LV systolic dysfunction as assessed by means of multidirectional strain. In patients with 
subclinical hyperthyroidism, the prevalence of overt LV systolic dysfunction as assessed with 
conventional two-dimensional echocardiography (LVEF <45%) is rather low (2.4%) (24). 
However, it has been shown that despite preserved or even increased LVEF at rest, patients 
with thyroid hormone excess may have impaired LV contractile reserve with no further 
increase in LVEF during exercise (25). Myocardial strain analysis based on 2D-STE may be a 
more sensitive tool than conventional measurements of systolic LV function, as it provides 
information on active deformation of the myocardium. In addition, this imaging tool enables 
the evaluation of subtle changes in myocardial strain after restoration of euthyroidism, as 
demonstrated in the present study. 
These findings may have important clinical implications as long-term subclinical 
hyperthyroidism has been related to increased incidence of cardiovascular events (6). The 
tight control of thyroid hormone level with restoration of euthyroidism may help to improve 
the cardiovascular risk profile of these patients and therefore may reduce the risk of 
cardiovascular events. In this regard, 2D-STE may allow refining the therapy of this group of 
patients. 
Some limitations have to be acknowledged. First, the assessment of LV myocardial 
function with 2D-STE analysis after an acute change of TSH or free T4 was not performed, 
and therefore the effects of these hormones at the tissue level could not be elucidated. In 
addition, the small study population may preclude us from observing stronger relationships 
between the 2D-STEderived parameters of LV function and TSH levels.  
In conclusion, patients with prolonged subclinical hyperthyroidism show subtle LV 
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Background: The cardiovascular effects of transitions from exogenous subclinical 
hyperthyroidism to short-term overt hypothyroidism in patients treated for differentiated 
thyroid carcinoma (DTC) remain unclear. The present study aims to evaluate the changes in 
multidirectional myocardial strain using 2-dimensional (2D) speckle tracking during this 
controlled transition from exogenous subclinical hyperthyroidism to overt hypothyroidism. 
Patients and methods: The study included 14 patients with DTC on TSH suppressive 
thyroxine substitution who were subsequently withdrawn from thyroxine for 4 weeks. Cardiac 
function was assessed by 2D speckle tracking echocardiography before, and 1 and 4 weeks 
after withdrawal and compared to values obtained in a control group of 24 individuals.  
Results: At baseline the LV dimensions were significantly higher in patients as compared to 
controls. Using 2D speckle tracking imaging, the patients had significantly impaired baseline 
myocardial systolic function in the circumferential (-16.0±2.1% vs. -19.2±3.0%, p=0.001) and 
longitudinal (-17.1±2.5% vs. -19.7±3.0%, p=0.001) directions as compared to controls. 
Withdrawal of thyroid hormone did not induce significant changes in LV dimensions or 
systolic function. During the transition from exogenous  subclinical hyperthyroidism to overt 
hypothyroidism, a significant improvement in circumferential and longitudinal systolic 
shortening was observed, and returned to abnormal values when the patients were overt 
hypothyroid (circumferential strain: from -16.0±2.1% to -18.6±1.9% and -14.7±2.8%, 
p<0.005; longitudinal strain: from -17.1±2.5% to -18.8±1.4% and -16.3±1.3%, p<0.005).  
Conclusions: A U-shaped relationship between a range of thyroid hormone levels (from 
hyper- to hypothyroid concentrations) and myocardial strain was observed. The clinical 
consequences of these findings remain to be determined, but may point out an increased 
myocardial vulnerability even in states of moderate subclinical hyperthyroidism and short-












The cardiovascular consequences of hyper- and hypothyroidism have been extensively 
described and include systolic and diastolic left ventricular (LV) dysfunction, increased LV 
mass and cardiac arrhythmias (1-6). Many of these studies have been performed in patients 
with endogenous thyroid disorders and used cross-sectional designs. Ideally, effects of thyroid 
hormone on myocardial function should be studied in subjects being exposed in a controlled 
fashion to a wide spectrum of plasma thyroid hormone levels. Patients with differentiated 
thyroid carcinoma (DTC), who until recently were substituted with TSH suppressing dosages 
of levothyroxine and routinely withdrawn from thyroid hormone substitution for diagnostic 
studies, offer an attractive group to perform this type of studies as they undergo short term 
controlled transitions from subclinical hyperthyroidism to hypothyroidism. Results from 
earlier published studies, including our own, on myocardial effects of short-term thyroid 
hormone withdrawal however have been inconclusive, varying from mainly decreased 
diastolic function to mainly altered systolic function (7-15). These studies have all been 
performed with conventional echocardiographic parameters, which may not be sensitive 
enough to detect subtle abnormalities at the myocardial level.  
Currently, 2-dimensional (2D) speckle tracking echocardiography permits the 
multidirectional evaluation of the mechanical properties of the myocardial tissue (16-18). 
Importantly, active myocardial deformation can be evaluated providing information on 
myocardial contractility. Therefore, this novel technique may permit the detection of subtle 
effects of thyroid hormone at the myocardial level.  Accordingly, we re-analyzed data from 
the aforementioned study (13), to comprehensively evaluate LV performance in relation to a 
wide spectrum of plasma thyroid hormone levels in DTC patients in transition from 
subclinical hyperthyroidism, through euthyroidism to hypothyroidism and to detect changes in 
LV function using 2D speckle tracking echocardiography.  
 
PATIENTS AND METHODS 
Patient population and study design 
The patient population consisted of 14 patients in whom DTC was diagnosed and who were 
subsequently treated with total thyroidectomy and radioiodide ablative therapy. The patient 




therapy, the patients received TSH-suppressive thyroxine replacement therapy, aiming at TSH 
levels <0.1 mU/L (normal reference values 0.4-4.4 mU/L). The patients were scheduled for 
TSH stimulated diagnostic studies (including thyroglobulin measurements and iodide-131 
whole body scanning to evaluate the effect of prior radioiodide therapy). Patients were 
routinely withdrawn from thyroxine therapy during approximately 28 days. On the last day of 
thyroxine therapy (visit 1) and at days 7 (visit 2) and 28 (visit 3) after thyroid hormone 
withdrawal, biochemical and hormonal parameters were evaluated and 2D transthoracic 
echocardiography was performed. The changes in biochemical, hormonal and conventional 
echocardiographic parameters have been previously reported (13). Additionally, LV strain 
was evaluated with 2D speckle tracking imaging in order to characterize the mechanical 
properties of the myocardial tissue. As previously described, none of the patients had previous 
myocardial infarction, rheumatic fever, endocarditis, diabetes mellitus or connective tissue 
disorders (13). In addition, the patients were hemodynamically stable during the study period 
and any treatment that could influence cardiovascular parameters was not used.  
The study was approved by the local ethics committee and written informed consent was 
obtained from all patients. 
Finally, 24 individuals matched by age, gender, body surface area and LV ejection 
fraction (LVEF) were included in the present study and formed the control group. All controls 
were clinically referred to evaluate atypical complaints and rule out structural heart disease. 
Individuals referred for echocardiographic evaluation of known valvular heart disease, 
murmur, congestive heart failure, and cardiac transplantation were excluded. In addition, 
those individuals with any cardiovascular co-morbidity were excluded. Therefore, the controls 
showed normal echocardiographic studies and provided the normal reference values for the 
evaluated echocardiographic parameters (19).  
Echocardiography 
Echocardiography was performed with the patients in the left lateral decubitus position and 
using a commercially available system equipped with a 3.5-MHz transducer (Vingmed Vivid-
7, General Electric Vingmed, Horten, Norway). Standard M-mode, 2-D and color-Doppler 
data were acquired, triggered to the QRS complex, and saved in cine-loop format for off-line 
analysis (EchoPac 108.1.5, General Electric/Vingmed Ultrasound). From the M-mode 
recordings obtained at the parasternal long-axis views, LV dimensions (end-diastolic and end-
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systolic diameters, end-diastolic interventricular septum thickness and posterior wall 
thickness), fractional shortening and LVEF were measured, according to current guidelines 
(19). LV mass was calculated by Devereux’s formula and indexed to body surface area (20).  
2D speckle tracking echocardiography analysis 
2D speckle tracking echocardiography permits the angle-independent, multidirectional 
assessment of LV myocardial strain and strain rate (16). As previously described, the left 
ventricle deforms in three orthogonal directions (radial, circumferential and longitudinal) (16). 
Strain imaging characterizes the LV tissue mechanical properties and differentiates the active 
myocardial contraction from the passive motion. Strain is a measure of myocardial 
deformation and is expressed as percentage (%).  
From the LV mid-ventricular short-axis images, radial and circumferential strains are 
assessed. Radial strain measures the thickening/thinning of the myocardial wall, whereas 
circumferential strain measures the myocardial shortening/lengthening along the curvature of 
the LV. The average of the six segmental peak systolic strain values provides the global 
values of radial and circumferential strain (Fig 1A, B chapter 7, p. 97). 
Longitudinal strain is measured at the apical 2-, 4-chamber and long-axis views. 
Longitudinal strain evaluates the shortening/lengthening of the myocardial wall, resulting 
from the movement of the mitral annulus plane upward/downward the LV apex. The average 
of the 18 segmental peak systolic strain values provides the global longitudinal strain value 
(Fig 1C chapter 7, p. 97) (17). 
Therefore, in the present study, LV mechanical properties were evaluated through three 
systolic parameters (global radial, circumferential and longitudinal strains), all of them 
derived with 2D speckle tracking strain imaging. 
Statistical analysis 
Continuous data are presented as mean ± standard deviation whereas categorical data are 
presented as number and frequencies. Baseline echocardiographic characteristics were 
compared between the patients and the controls using Kruskal-Wallis test. A p-value <0.05 
was considered statistically significant. Changes in clinical and echocardiographic parameters 
within the 3 different time points (baseline [visit 1], 7 days [visit 2] and 28 days [visit 3]) were 




tests, a posthoc correction was applied; consequently, a p-value < 0.017 was considered 
significant (0.05 divided by 3 different stages). All statistical analyses were performed with 




This study included 14 patients with DTC (3 men and 11 women), age 51.6 ± 14.5 years, 
without distant metastases. Median time of TSH suppressive levothyroxine therapy was 1 
year. L-thyroxine dose before the withdrawal was 162.5± 41.6 μg/day. As previously 
described, at visit 1, serum free thyroxine concentrations were above the upper limit of the 
normal range (reference range 10-24 pmol/l), TSH (reference range 0.4-4.8 mU/l) levels were 
below normal range and thyronine (reference range 1.1-3.6 nmol/l) within normal range (13). 
After 7 days of thyroxine withdrawal, free thyroxine levels were already slightly below the 
lower limit of the reference values, and TSH levels had increased significantly, whereas 
thyronine levels were still within normal range. During the transition period from hyper- to 
hypothyroidism the patients showed a significant increase in body mass index and the 
diastolic blood pressure (Table 1). 
The control group included 24 individuals (45.4±8.5 years, 3 men). By design, there were 
no differences between controls and patients for age, gender, and body surface area. In 
addition, there were no significant differences in systolic and diastolic blood pressure and 
heart rate between healthy controls and patients (Table 1). 
LV dimensions and function as assessed with conventional echocardiographic 
parameters  
As previously reported, at baseline the LV dimensions were significantly higher in patients in 
comparison to controls (Table 1). However, none of the patients met the criteria for LV 
hypertrophy (13). As previously reported, the acute withdrawal of thyroid hormone (visit 2) 
did not induce significant changes in LV dimensions or systolic function (Table 1). In 
addition, these conventional echocardiographic parameters remained unchanged after 28 days 
(visit 3) of thyroid hormone withdrawal (Table 1).  
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Changes in LV myocardial tissue mechanical properties as assessed with 2D speckle 
tracking echocardiography 
At baseline, the evaluation of the myocardial tissue properties with 2D speckle tracking 
imaging demonstrated that the group of patients had significantly impaired myocardial 
systolic function in the circumferential and longitudinal directions as compared to the group 
of controls (Table 1). In contrast, radial strain was preserved. 
Remarkably, after short-term withdrawal of thyroid hormone, when the patients had the 
hormone levels within the euthyroid range (visit 2), a significant improvement in 
circumferential and longitudinal systolic shortening was observed (Fig 2). However, after 28 
days of thyroid hormone withdrawal, when the patients were in an overt hypothyroid state 
(visit 3), circumferential and longitudinal strains significantly impaired (Fig 2). Radial strain 
values remained unchanged during the study as it reflects the mid-wall myocardial layer 
which is only affected at late stages of cardiac dysfunction. Therefore, 2D speckle tracking 
permitted the detection of subtle changes in myocardial tissue mechanical properties during 
the acute induction of hypothyroidism. 
 
DISCUSSION 
The current study evaluated subtle changes in LV function using 2D speckle tracking 
echocardiography in relation to a wide spectrum of plasma thyroid hormone levels in DTC 
patients in transition from exogenous subclinical hyperthyroidism via euthyroidism to overt 
hypothyroidism. Exogenous subclinical hyperthyroid status was associated with impaired 
myocardial deformation in the circumferential and longitudinal directions. Restoration of 
euthyroidism induced an improvement in myocardial deformation in these two directions 
whereas overt hypothyroidism was accompanied by impairment in myocardial deformation 
properties. In contrast, radial strain was preserved along the follow-up. As previously 
described (21), the LV myocardial architecture is complex array of longitudinally and 
circumferentially orientated fibers located at the subepi/subendocardium and mid-wall, 
respectively. The subendocardial fibers are more vulnerable to ischemia, hemodynamic 
overload or age-related changes and therefore longitudinal strain is commonly impaired at an 





Table 1. Basic Clinical , Biochemical And Echocardiographic Findings Of  The Patients And Controls 




(7 days after 
withdrawal) 
Visit 3 
(28 days after 
withdrawal) 
Clinical parameters     
Men/Women (number) 3/21 3/11 3/11 3/11 
Age (years) 45.4±8.5 51.6 ± 14.5 51.6 ± 14.5 51.6 ± 14.5 
Body mass index (kg/ m2) 24.9 ± 3.1 26.5 ± 6.1 26.9 ± 5.9a 27.6 ± 6.0a,b 
Systolic blood pressure 
(mmHg) 
124.8 ± 7.7 130.1 ± 23.2 130.2 ± 23.3 131.3 ± 20.1 
Diastolic blood pressure 
(mmHg) 
76.0 ± 6.9 81.7 ± 16.5 77.6 ± 12.9 85.5 ± 10.4b,c 
Heart rate (beats per minute) 70.4 ± 8.4 70.8 ± 8.0 65.2 ± 8.2a 66.6 ± 6.7 
Assays 
fT4 (pmol/ L)  
(ref. 10–24 pmol/ L) 
NA 26.4 ± 3.1 9.6 ± 1.9a 2.2 ± 1.3a,d 
TSH (mU/ L)  
(ref.0·4–4·8 mU/ L) 
NA 0.3 ± 0.58 9.5 ± 15.5a 105.2 ± 57.8ª,b 
T4 (nmol/L) 
(ref. 1.1-3.6 nmol/L) 
NA 1.5 ± 0.44 1.1 ± 0.19a 0.6 ± 0.23a,b 
2D echocardiography     
LV mass index (g/m2) 73.6 ± 9.3 81.6 ± 12.1c 84.1 ± 12.2c 85.2 ± 16.7c 
IVST (mm) 8.3 ± 1.0 9.9 ± 1.3 9.3 ± 1.4 9.5 ± 1.5 
PWT (mm) 8.2 ± 0.7 9.5 ± 1.9 9.4 ± 1.2 9.7 ± 1.5 
LVEDD (mm) 48.5 ± 4.5 46.9 ± 5.3 49.4 ± 5.0 48.9 ± 5.0 
LVESD (mm) 28.1 ± 4.1 28.7 ± 4.6 29.6 ± 3.5 29.1 ± 3.2 
LVFS (%) 38.2 ± 3.4 38.4 ± 7.4 39.8 ± 5.7 40.1 ± 5.8 
LVEF (%) 68.0 ± 4.2 68.0 ± 8.8 70.4 ± 6.1 70.3 ± 6.7 
2D speckle tracking      
Radial strain (%) 43.1 ± 18.5 36.5 ± 16.0 39.8 ± 15.0 36.6 ± 12.4 
Circumferential strain (%) -19.2 ± 3.0 -16.0 ± 2.1c -18.6 ± 1.9a -14.7 ± 2.8b,c 
Longitudinal strain (%) -19.7 ± 3.0 -17.1 ± 2.5c -18.8 ± 1.4a -16.3 ± 1.3b,c 
aP<0.017 compared with visit 1. 
bP<0.017 compared with visit 2. 
c  
2D, two-dimensional; IVST, interventricular septum thickness; LV, left ventricular; LVEDD, left ventricular end-diastolic 
diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVFS, left ventricular 
fractional shortening; PWT, posterior wall thickness; ref, reference ranges used in the Leiden University Medical Center. 
 
Patients with DTC, who until recently were substituted with TSH suppressing dosages of 
levothyroxine and routinely withdrawn from thyroid hormone substitution for diagnostic 
studies, offer an attractive group to perform this type of studies. Particularly, the design of the 
present study permitted to evaluate subtle changes in LV myocardial performance providing a 
reliable and sensitive evaluation of the effects of thyroid hormone at the myocardial level. 
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Earlier studies have been performed using conventional echocardiographic strategies, which 
may not be sensitive enough to detect subtle abnormalities at the myocardial level. 
 
Indeed, in those studies, no clear conclusions on the cardiac consequences of acute 
hypothyroidism in patients with exogenous subclinical hyperthyroidism were reached (7-15). 
None of those studies focused on the direct effect of thyroid hormone on myocardial 
contractility and deformation. 2D speckle tracking strain imaging enables assessment of 
systolic and diastolic myocardial deformation properties in the 3 orthogonal spatial directions. 
Fig 2:  Changes in multidirectional 
LV myocardial functions during 
thyroid hormone withdrawal.  
Baseline values of LV 
multidirectional strain are 
presented for patients at baseline 
(visit 1), 7 (visit 2) and 28 (visit 3) 
days after thyroid hormone 
withdrawal. After 7 days of 
thyroid hormone withdrawal (visit 
2, euthyroid to hypothyroid 
status), a significant improvement 
was observed in circumferential 
and longitudinal strain. However, 
after 28 days of thyroid hormone 
withdrawal (visit 3, overt 
hypothyroidism), circumferential 
and longitudinal strain 
significantly impaired. Radial 
strain remained unchanged during 
the follow-up.  





Unlike tissue Doppler imaging, 2D speckle tracking imaging provides angle-independent 
measurements of myocardial strain. Although conventional echocardiography and tissue 
Doppler imaging did not show any significant changes, 2D speckle tracking strain imaging 
showed remarkable results, with significantly decreased circumferential and longitudinal 
strain as compared with controls during subclinical hyperthyroidism, a significant 
improvement during euthyroidism, and a significant deterioration again during profound 
hypothyroidism. Therefore, a remarkable U-shaped relationship between thyroid hormone 
concentrations and myocardial strain was observed, with hyper- and hypothyroidism equally 
affecting myocardial mechanical properties. As such, this study demonstrates the myocardial 
effects of a wide spectrum of thyroid hormone levels independently of LV mass. Indeed, it has 
been previously demonstrated, that thyroid hormone exerts direct effects on myocardial 
diastolic relaxation independent of protein synthesis and cardiac growth (5, 22). Therefore, the 
changes observed in myocardial strain may reflect the direct biochemical effects of thyroid 
hormone on the myocardium that lead to activation of local signal transduction pathways 
rather than changes in LV hypertrophy (23). In addition, changes in hemodynamic conditions 
that take place during transition from exogenous subclinical hyperthyroidism to euthyroidism 
and overt hypothyroidism may also influence myocardial strain (24). Whether these changes 
in multidirectional myocardial strain may influence the TSH suppressive treatment and, 
subsequently, the long-term outcome remain unknown. Additional studies are needed to 
elucidate the effects on long-term outcome of a tailored TSH suppressing therapy based on 2D 
speckle tracking strain imaging. 
Some study limitations should be acknowledged. Circulating levels of TSH and free 
thyroxine were not systematically determined in all controls. Therefore, the controls were 
considered euthyroid based on clinical history and complete physical examination.   
In conclusion this study demonstrates the subtle effects of profound short term changes of 
thyroid hormone levels on the myocardium, likely reflecting direct biochemical effects of 
thyroid hormone on myocardial metabolism, rather than structural changes. A U-shaped 
relationship between the spectrum of thyroid hormone levels from hyper- to hypothyroid 
concentrations and myocardial strain is observed. The clinical consequences of these findings 
remain to be determined, but may point to an increased myocardial vulnerability even in states 
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This thesis describes clinical and fundamental studies addressing clinical challenges in 
patients with differentiated thyroid carcinoma (DTC). The diagnosis of DTC is hampered by 
the fact that although the incidence is low thyroid nodules are prevalent. In this thesis, the 
diagnostic value of a potential marker for DTC has been studied. Unfortunately, in a high 
proportion of patients with metastases of DTC, the tumor has become resistant to RAI 
therapy. We have performed fundamental studies into the mechanisms of the regulation of the 
sodium iodide symporter (NIS) that may have implications for restoring susceptibility to RAI 
therapy. Furthermore, the long-term efficacy of a new treatment with the multi kinase 
inhibitor (MKI) sorafenib for DTC patients with metastases that are unresponsive to RAI has 
been evaluated. Therapy with MKI has numerous adverse effects, including hypothyroidism. 
We have evaluated a potential mechanism of sorafenib associated hypothyroidism. Finally, 
DTC patients have traditionally been treated with TSH suppressive levothyroxine substitution. 
However, high thyroid hormone concentrations may have adverse effects on various organ 
systems, including the heart. In this thesis, we studied the effects of various thyroid hormone 
concentrations on cardiac function in DTC, using dedicated cardiac ultrasound.  
 
CHAPTER 2 
Ultrasonography guided fine needle aspiration cytology (FNAC) is the cornerstone of the 
evaluation of thyroid nodules for malignancy (1). FNAC results are currently described 
according to the Bethesda classification (2). Indeterminate FNAC results (Bethesda class III 
and IV) constitute 17-30% of cases with an overall risk of malignancy of up to 30% (2). 
Bethesda class III and IV may correspond with follicular variant of papillary thyroid 
carcinoma (FVPTC), follicular thyroid carcinoma (FTC) or follicular adenoma (FA). Most of 
these indeterminate cases are referred for diagnostic hemithyroidectomy, but the majority of 
patients will have benign disease. Therefore improved preoperative diagnostic evaluation for 
patients with indeterminate cytologic findings on FNA is warranted. In Chapter 2, we set out 
to analyse the protein expression of Bone morphogenetic protein7 (BMP7) and 2 downstream 
proteins, Smad4 and pSmad1 in a large array of normal and pathological human thyroid 
tissues. We hypothesized that a differential expression would be present, which could have 
potential value for differential diagnosis of thyroid disorders. BMPs are important regulators 
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of growth and apoptosis in numerous tissues and are associated with cancer progression (3, 4). 
Few mechanistic studies on the BMP7 pathway have been published in thyroid (5-7); 
including one study in carcinoma (8). However, until now, no systematic studies on tissue 
expression of BMP7 and downstream proteins in normal and pathological human thyroid 
tissues have been performed. We used a tissue array containing 750 thyroid samples from 118 
patients (38 had benign thyroid tissues lesions and 80 cases of non-medullary thyroid 
carcinomas (PTC, FTC, FVPTC) and mixed PTC and FTC (PTCmixFTC). Expression of the 
above mentioned proteins was studied by immunohistochemistry and analysed semi 
quantitatively by 3 observers. The differential expression was analysed by a multilevel 
regression model followed by Bonferroni correction for multiple testing. Normal thyroid 
tissue was considered as reference. In thyroid carcinoma cytoplasmic BMP-7, Smad4 and p-
Smad1 expression was increased with low nuclear pSmad1 expression. This pattern was 
present in all malignant subtypes except for PTC where the cytoplasmic Smad4 was over-
expressed. However, nuclear expression of pSmad1 (npSmad1, end downstream protein of the 
BMP7 signalling cascade) in all tumor types was consistently decreased Thus, BMP7 
cytoplasmatic protein expression per se may not be necessarily associated with increased 
activity but may rather reflect diminished activity of the BMP7 cascade. In the analysis of 
follicular lesions, npSmad1 expression was lower in FVPTC compared with FA. 
Unfortunately, we found no differences in expression of BMP7 or downstream proteins 
between FTC and FA with diagnostic potential. However, the decreased npSmad1 expression 
in FVPTC vs. increased expression in FA may be worthwhile to explore in further studies. 
Perspective 
We found differentially expressed proteins of the BMP7 signalling pathway in a large array of 
normal, benign and malignant thyroid tissues. The underlying functional mechanisms remain 
to be established, whereas the diagnostic potential of our observations seems to be limited.   
 
CHAPTER 3 
Successful RAI therapy is dependent on the stimulation of iodide uptake by TSH. In terms of 
preparation for RAI, high TSH levels can be realized either by discontinuation of 
levothyroxine therapy or by the application of recombinant human TSH (rhTSH) during 




continuation of levothyroxine substitution has no effect on iodide uptake. However, this has 
never been verified. In Chapter 3, we performed in vitro studies to analyse whether thyroid 
hormone directly affects RAI uptake by thyroid cells independently of TSH. Fischer rat 
1 to 4 days. To study the possible genomic regulatory action of T3 on NIS gene expression, 
rat NIS promoter constructs were transiently transfected in FRTL5 cells. Steady state 
radioactive iodide uptake by FRTL5 was reduced by 35% at the highest concentration of T3 
24 and 48 hours. After 4 days of 1 nM T3 treatment, iodide uptake was reduced 
by 30% vs. basal. NIS protein levels in FRTL-5 cells were significantly decreased in a dose 
dependent manner after 4 days of T3 (1nM-1 μM). Accordingly, NIS promoter activity was 
significantly reduced in a dose dependent manner. In conclusion, T3 down-regulates NIS 
protein levels and iodide uptake in follicular thyroid cells. The T3 effects on iodide uptake, 
NIS protein levels and NIS promoter activity take several days to become manifest. The 
effects seem to be mediated by decreased NIS promoter activity.  
Perspective 
We found that T3 decreases NIS protein expression independently of TSH. If confirmed in 
humans, this may have major impact on the feasibility of RAI therapy with rhTSH, as the 
assumption of this therapy is that T3 in itself does not influence iodide uptake. Although in 
recent studies, a comparable ablation rate was found in rhTSH vs thyroid hormone 
withdrawal, long term outcome analyses are needed to ultimately determine the equivalence 
of both approaches. In addition, our studies do not support rhTSH in RAI therapy in patients 
with structural disease (11), although equivalence studies are need in this context as well.  
 
CHAPTER 4 
Sorafenib (BAY 43-9006) is an oral MKI targeting wild-type and mutant BRAF V600E, RET, 
VEGFR2, VEGFR3, PDGFR- -KIT and Flt-3 (12, 13). Sorafenib has been approved by the 
FDA and the EMA for the treatment of metastatic RAI resistant DTC patients (14, 15). 
Sorafenib has been studied in a number of phase II clinical trials, one retrospective 
longitudinal study and 1 phase III, randomized, placebo-controlled, multicenter trial study 
(DECISION trial) (12, 13, 16- 21). In Chapter 4, we analysed the long-term outcome of a 
phase II study. Thirty-one patients with progressive metastatic or locally advanced RAI 
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refractory (RAIR) DTC received sorafenib 400 mg orally twice daily. The study end points 
included response rate, progression-free survival (PFS), overall survival (OS), best response 
by RECIST 1.0, and toxicity. Median PFS was 18 months and median OS was 34.5 months. 
Eight patients (31%) achieved a partial response and 11 patients (42%) showed stable disease 
after a median follow-up of 25 months. Toxicity mostly included hand and foot syndrome, 
weight loss, diarrhea, and rash. We conclude that sorafenib has clinically relevant antitumor 
activity in patients with progressive metastatic or locally advanced RAIR DTC.  
Perspective 
After our study was completed, the phase III DECISION with sorafenib was published (see 
introduction) (21). Median progression-free survival was significantly longer in the sorafenib 
group (10.8 months) than in the placebo group. Later, the SELECT study with lenvatinib 
showed an even more impressive outcome with PFS of 18.3 months in lenvatinib vs. 3.6 
months in placebo (22). Both studies have for the first time shown that MKI have a benefit on 
PFS in patients with advanced DTC. Important questions to be answered are the selection of 
subgroups of patients who benefit most from these drugs and the optimal time point of 
initiation of therapy. These questions are prominent, as MKI are associated with considerable 
toxicity and subsequent diminished quality of life. It is now recommended to initiate therapy 
with MKI when RAI resistance is present, when progression has been established according to 
RECIST and when considerable tumor load is present. As the pathogenesis of RAIR DTC is 
multifactorial, and resistance to MKI is common, a rational approach to be investigated will 
be the combination of different treatment strategies. Furthermore, the use of MKI’s (e.g 
selumetinib) in restoring RAI-uptake must be further investigated. 
  
CHAPTER 5 
Therapy with MKI in patients with malignancies is associated with alterations in thyroid 
hormone parameters. Sorafenib (17), imatinib (23, 24), motesanib (25), and sunitinib (26) 
have also been associated with thyroid function abnormalities in athyreotic patients with 
thyroid carcinoma. Sorafenib was associated with increased TSH levels in 33% of thyroid 
carcinoma patients. Because an increased need of levothyroxine is observed in athyreotic 
patients who are treated with MKI, we hypothesized that one of the mechanisms of 




conducted a retrospective study that included 21 DTC patients who were receiving 
levothyroxine as a replacement therapy in a dose adjusted to keep the TSH levels below 
0.1mU/L. They were treated with sorafenib for 26 weeks. At baseline and after 26 weeks of 
therapy, serum thyroid parameters were measured (T4, free T4, T3, free T3, reverse T3 (rT3), 
and TSH concentrations). We observed a significant increase in levothyroxine dose/kg while 
T4 and fT4 remained unchanged. Absolute rT3 levels tended to increase after sorafenib 
therapy, and T3/T4, T3/rT3, and T4/rT3 ratios decreased significantly, reflecting an increased 
conversion of T4 into rT3. No effects of sorafenib on thyroid hormone binding were observed. 
The decreased T3/T4 and T3/rT3ratios are best explained by an increased D3 activity. In this 
study we addressed for the first time that MKI in addition to a direct effect on the thyroid 
gland, also enhances peripheral metabolism of thyroid hormones, likely by enhancing activity 
of D3.  
Perspective 
TSH suppressive levothyroxine substitution is the cornerstone therapy in DTC patients with 
metastases. However, we demonstrate in our study that MKI therapy enhances levothyroxine 
metabolism. Surveillance and adjustment of levothyroxine therapy is therefore of utmost 
relevance in DTC patients on treatment with MKI. In a subsequent study by another group it 
was demonstrated that sunitinib (27), induces hypothyroidism through increase of hepatic D3 
and decrease of D1 activity respectively as well as thyroid capillary regression. Interestingly, 
in a recent study, it was shown that MKI also decreases thyroid hormone influx in the 
pituitary by inhibiting MCT8 activity (28) which may be another explanation for the elevated 
TSH in patients on MKI. 
 
CHAPTER 6 
In Chapter 6, we performed in depth studies on the regulation of functional NIS expression, in 
order to identify new approaches to enhance RAI uptake in DTC. Our studies are based on the 
observation that AMPK plays an important role in NIS expression: AMPK activation in 
thyrocytes decreases iodide uptake, NIS expression and increases glucose uptake (29, 30). We 
examined the effect of AMPK modulators on thyrocyte function in-vitro (FRTL5 cells) and 
in-vivo (C57Bl6/J mice). In addition, we studied the transcriptional regulatory role of the 
AMPK- dependent signalling pathway on NIS protein using rat NIS promoter constructs. 
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Activation of AMPK by metformin resulted in a strong reduction of iodide uptake (up to six 
n levels in vitro, whereas AMPK 
inhibition by compound C not only stimulated iodide uptake but also enhanced NIS protein 
-fold 
 days). Metformin reduced NIS promoter activity 
(0.6-fold of control), whereas compound C stimulated its activity (3.4-fold) after 4 days. This 
largely coincided with cAMP responsive element (CRE) activation (0.6- and 3.0-fold). 
Apparently, the downstream effects of TSH activation and AMPK action seem to synergize 
on the CRE-like element of the NIS promoter. In conclusion, NIS expression and iodide 
uptake in thyrocytes can be modulated by metformin and compound C that exert their effects 
by modulating AMPK, which, in turn, regulates the activation of the CRE element in the NIS 
promoter.  
Perspective 
Enhanced iodide uptake by compound C suggests that AMPK inhibition may provide a useful 
mechanism for the enhancement of iodide uptake in the treatment of DTC. As AMPK has 
multiple effects on numerous signal transduction routes involved in metabolism, proliferation 
and autophagy, additional studies in DTC patients are necessary.  
 
CHAPTER 7 
Patients with DTC will be exposed to either low thyroid hormone levels, during preparation 
for ablation and/or therapy with RAI, or high thyroid hormone levels, when TSH suppressive 
levothyroxine substitution is given. As thyroid hormone plays an important role in cardiac 
function, we analysed the effects of TSH suppressive thyroid hormone substitution and 
withdrawal on cardiac function.  
In Chapter 7, we analysed the effects of prolonged TSH suppressive levothyroxine 
therapy on cardiac dimensions and function using 2-dimensional (2D) speckle tracking 
echocardiography, which permits the study of multidirectional active deformation of the 
myocardium (radial, circumferential and longitudinal strain and strain rate), providing 
comprehensive information on myocardial function (contractility) (31, 32). Twenty-five 




randomized to persistent TSH-suppressive substitution (low-TSH group) or restoration of 
euthyroidism. Additionally 40 euthyroid controls were studied. At baseline, DTC patients 
showed normal left ventricular (LV) systolic function but impaired diastolic function as 
assessed with conventional echocardiographic parameters. Importantly, 2D speckle tracking 
echocardiography demonstrated subclinical LV systolic and diastolic dysfunction with 
impaired circumferential and longitudinal strain and strain rate at the isovolumic relaxation 
time. After restoration of euthyroidism, a significant improvement in LV systolic and diastolic 
function as assessed with 2D- speckle tracking echocardiography was observed. 
Perspective 
Our study contributes to the notion that TSH suppressive levothyroxine substitution has 
disadvantageous effects on the heart, but that functional changes are reversible, even after 
prolonged exposure to TSH suppression. Given the deleterious adverse effects of TSH 
suppression on many organ systems, recently, recommendations regarding TSH suppression 
have become more risk adapted (33). As a consequence, the majority of cured DTC patients 
will receive levothyroxine substitution, aiming at normal TSH levels.  
 
CHAPTER 8 
During levothyroxine withdrawal for RAI therapy, patients are repeatedly exposed to short-
term hypothyroidism. However, the cardiovascular effects of transitions from exogenous 
subclinical hyperthyroidism (TSH suppressive levothyroxine substitution) to short-term overt 
hypothyroidism in patients treated for DTC remain unclear. In Chapter 8, we performed a 
study to evaluate the changes in multidirectional myocardial strain using 2D speckle tracking 
echocardiography during the controlled transition from exogenous subclinical 
hyperthyroidism to overt hypothyroidism. The study included 14 patients with DTC on TSH- 
suppressive levothyroxine substitution who were subsequently withdrawn from levothyroxine 
for 4 weeks. Cardiac function was assessed by 2D speckle tracking echocardiography before 
and at 1 and 4 weeks after withdrawal and compared with values obtained in a control group. 
At baseline, the LV dimensions were significantly higher in patients as compared with 
controls. Using 2D speckle tracking echocardiography, DTC patients had significantly 
impaired baseline myocardial systolic function in the circumferential and longitudinal 
directions as compared with controls. Withdrawal of thyroid hormone did not induce 
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significant changes in LV dimensions or systolic function. We did not observe any change in 
radial strain measurements. Remarkably, during the transition from exogenous subclinical 
hyperthyroidism to overt hypothyroidism, a significant improvement in circumferential and 
longitudinal systolic shortening was observed and returned to abnormal values after 4 weeks 
when the patients were overtly hypothyroid. Apparently, a u-shaped relationship between a 
range of thyroid hormone levels (from hyper- to hypothyroid concentrations) and myocardial 
strain was observed.  
Perspective 
Using advanced cardiac ultrasound techniques, our study uncovered subtle changes in cardiac 
function during the course from TSH suppressive therapy to overt hypothyroidism. We found 
that both TSH suppressive levothyroxine therapy and hypothyroidism affect myocardial 
function. Although the clinical consequences of these observations are not clear, they 
contribute to the findings from numerous studies that DTC patients are at increased risk for 
cardiovascular events, which are related to levothyroxine substitution (34, 35). The risk-based 
tailoring of levothyroxine therapy as mentioned above as well as the introduction of rhTSH to 
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Dit proefschrift beschrijft klinische en fundamentele studies welke gerelateerd zijn aan 
patiënten met gedifferentieerd schildklier carcinoom (DTC).  
Het stellen van de juiste diagnose bij deze groep patiënten wordt bemoeilijkt omdat 
binnen de groep van patiënten met schildkliernodi de incidentie van patiënten met DTC laag 
is. Een verbetering van de diagnostiek is daarom gewenst. In dit proefschrift beschrijven wij 
de potentiele diagnostische waarde van een marker voor DTC.  
Een belangrijk probleem bij de standaard behandeling met radioactief jodium (RAJ) is het 
verlies van het vermogen tot jodiumopname in progressieve tumoren en metastasen. Een 
verder inzicht in de mechanismen die de jodiumopname reguleren geeft wellicht 
aanknopingspunten voor toekomstige behandelingen. Vanuit deze optiek hebben wij op 
moleculair niveau enkele mechanismen onderzocht die de werking van de sodium iodide 
symporter (NIS) beïnvloeden. 
Daarnaast hebben wij de lange termijn effecten onderzocht van de behandeling van DTC 
patiënten met metastasen die het vermogen tot jodiumopname verloren hebben met de 
multikinase remmer (MKI) sorafenib. Een van de bekende bijwerkingen van de MKI 
behandeling is het ontstaan van hypothyreodie. In dit proefschrift beschrijven we een 
mechanisme dat mogelijk ten grondslag ligt aan het ontstaan van de aldus ontstane 
hypothyreodie. 
Binnen de conventionele behandeling van DTC patiënten wordt TSH onderdrukt door 
levothyroxine (schildklierhormoon) substitutie. De gebruikelijke hoge concentraties 
schildklierhormoon kunnen echter resulteren in nadelige effecten op verschillende organen 
met inbegrip van het hart. In dit proefschrift beschrijven wij de effecten van 




Echogeleide fijne naald aspiratie cytologie (fine needle aspiration cytology (FNAC)) neemt 
een centrale plaats in bij het diagnosticeren van maligniteit bij schildkliernodi waarbij de 







patiënten is de uitslag van FNAC bethesda klasse III of IV met een kans van 30% op 
maligniteit. Gezien de onzekere diagnose zullen patiënten binnen deze groepen (die o.a. 
folliculaire variant van papillair schildkliercarcinoom (FVPTC), folliculair 
schildkliercarcinoom (FTC) en folliculair adenoom (FA) bevatten) vaak worden 
doorverwezen voor diagnostische hemithyreoïdectomie ondanks het feit dat de meerderheid 
van de nodi goedaardig zal blijken te zijn. Een verbetering in de diagnostiek bij deze patiënten 
na FNAC is dan ook gewenst. 
In hoofdstuk 2 hebben wij met behulp van een tissue array met een groot aantal 
pathologische en normale humane schildklierweefsels de eiwitexpressie geëvalueerd van 
Bone morphogenetic protein7 (BMP7), Smad4 en pSmad1. Hierbij was onze hypothese dat er 
een verband bestaat tussen de aard van de nodi en de differentiële expressie van deze eiwitten. 
BMP’s reguleren de groei en apoptose in talloze weefsels en worden in verband gebracht met 
progressie van tumoren. Er zijn echter maar enkele mechanistische studies verricht naar de rol 
van BMP’s in de schildklier en tot nu toe zijn er geen systematische studies gedaan naar 
BMP7 expressie in normale en pathologische weefsels. 
Wij hebben gebruik gemaakt van een tissue array met 750 schildklier monsters afkomstig 
van 118 patiënten met goedaardige en kwaadaardige schildkliertumoren. (38 benigne, 80 niet 
medullair schildkliercarcinoom (PTC, FTC, FVPTC) en gemengd PTC/ FTC (PTCmixFTC)). 
Na een immunohistologische bepaling zijn de expressie niveaus geanalyseerd met een 
multilevel regressie model gevolgd door een Bonferroni correctie met normale schildklier 
weefsels als referentie.  
De cytoplasmatische expressie niveaus van BMP7, Smad4 en pSmad1 waren verhoogd in 
alle maligne subtypes met uitzondering van PTC waar alleen de expressie van Smad4  was 
verhoogd. De nucleaire expressie van pSmad1(npSmad1, downstream van BMP7) nam echter 
af in alle maligne weefsels wat erop duidt dat de cytoplasmatische toename van BMP7 
wellicht geassocieerd kan worden met een afgenomen activiteit van de BMP7 pathway. 
De diagnostische mogelijkheden om te differentiëren tussen FTC en FA met behulp van 
BMP7, Smad4 en pSmad1 expressie analyse lijken helaas beperkt aangezien wij geen 
verschillen konden vinden tussen FTC en FA. Alleen in de subgroep FVPTC vs. FA vonden 






Wij hebben differentiële expressie gevonden bij eiwitten van de BMP7 pathway in een tissue 
array met normaal schilklierweefsel, goedaardige en kwaadaardige schildkliertumoren. 
Aangezien differentiatie tussen FTC en FA helaas niet mogelijk was concluderen wij dat 
BMP7, Smad4 en pSmad1 niet geschikt zijn voor de differentiaal diagnose tussen FTC en FA.   
 
HOOFDSTUK 3 
Succesvolle RAJ therapie is afhankelijk van de stimulatie van jodide opname door TSH. 
Voorafgaand aan RAJ kunnen hoge TSH niveaus worden gerealiseerd door stopzetting van de 
levothyroxine therapie of door toediening van recombinant humaan TSH (rhTSH) tijdens de 
levothyroxine therapie. Deze praktijk is gebaseerd op de veronderstelling dat voortzetting van 
levothyroxine substitutie geen nadelig effect heeft op de jodide opname, hoewel dit nooit is 
aangetoond. In hoofdstuk 3 beschrijven wij in vitro experimenten waarin wij de directe 
invloed van schildklierhormoon analyseren op RAJ opname door folliculaire schildkliercellen. 
Fischer rat schildkliercellen (FRTL5) werden gecultiveerd in aanwezigheid van T3 (1 nM, 10 
nM en 1 uM) en TSH gedurende 1 tot 4 dagen. Om de mogelijke genomische regulatie van 
NIS expressie door T3 te bestuderen hebben wij verscheidene NIS promoter constructen 
getransfecteerd in FRTL-5 cellen. 
Steady state RAJ opname door FRTL5 nam af met 35% bij de hoogste T3 concentratie (1 
uM) na 24 en 48 uur. Na 4 dagen was er ook een afname in jodide opname bij 1 nM T3 (30% 
vs. basaal). De hoeveelheid NIS eiwit in FRTL-5 cellen nam eveneens af op een 
dosisafhankelijke wijze na 4 dagen T3 (1nM- 1uM) behandeling. Deze effecten komen 
overeen met effecten op de NIS promoter.  
Perspectief 
Uit onze studies blijkt dat T3 de jodium opname door NIS en de NIS eiwit expressie in FRTL-
5 cellen kan onderdrukken, onafhankelijk van TSH. Indien dit mechanisme ook een rol speelt 
in de humane schildklier kan dit van invloed zijn op het gebruik van RAJ therapie in 
combinatie met levothyroxine. In recente studies kon echter geen relatie worden aangetoond 
tussen de effectiviteit van RAJ en levothyroxine behandeling, hoewel lange termijnstudies 








Sorafenib (BAY 43-9006) is een oraal toegediende  MKI die aangrijpt op BRAF 
V600E, RET, VEGFR2, VEGFR3, PDGFR- -KIT en Flt-3. Sorafenib is goedgekeurd door 
de FDA en de EMA voor de behandeling van DTC patiënten met RAJ ongevoelige 
uitzaaiingen. Sorafenib is onderzocht in een aantal klinische fase II studies, een retrospectieve 
longitudinale studie en een fase III, gerandomiseerde, placebo-gecontroleerde, multicenter 
studie (DECISION trial). In hoofdstuk 4 analyseren wij de lange termijn resultaten van een 
fase II studie. 
Eenendertig DTC patiënten met progressief gemetastaseerd of RAJ refractair 
gedifferentieerd schildkliercarcinoom kregen tweemaal daags 400 mg sorafenib. De studie 
eindpunten waren progressie-vrije overleving (PFS), algemene overleving (OS), beste respons 
volgens RECIST 1.0 en toxiciteit. De mediane PFS was 18 maanden en de mediane OS was 
34,5 maanden. Acht patiënten (31%) hadden een partiële respons en bij 11 patiënten (42%) 
bleef de ziekte stabiel na een mediane follow-up van 25 maanden. Bijwerkingen bestonden uit 
hand en voet syndroom, gewichtsverlies, diarree en huiduitslag. Wij concluderen dat sorafenib 
klinisch relevante anti-tumor activiteit heeft bij DTC patiënten met RAJ resistente 
progressieve metastasen. 
Perspectief 
Nadat onze studie was afgerond is de fase III DECISION met sorafenib gepubliceerd. 
Progressie-vrije overleving was significant langer in the sorafenib group (mediaan 10.8 
maanden) in vergelijking met de placebo groep. De SELECT studie met lenvatinib bleek later 
een nog indrukwekkender resultaat te geven met een PFS van 18.3 maanden vs. 3.6 maanden 
in de placebogroep. Beide studies hebben voor de eerste keer aangetoond dat MKI’s bruikbaar 
kunnen zijn bij de behandeling van patiënten met gevorderde DTC. Belangrijke vragen die 
nog beantwoord moeten worden zijn gerelateerd aan de respons bij deelgroepen van patiënten 
en het optimale tijdstip voor aanvang van de therapie. Deze vragen zijn met name van belang 
omdat MKI’s geassocieerd worden met aanzienlijke toxiciteit en de daaruit voortvloeiende 
verminderde kwaliteit van leven. Aanbevolen wordt om MKI  therapie te starten bij RAJ 
resistentie, wanneer progressie is vastgesteld volgens RECIST en wanneer er een aanzienlijke 
tumor belasting aanwezig is. Aangezien de pathogenese van RAJ resistentie van vele factoren 




welke combinatie van behandelingsstrategieën wenselijk is.  Verder is het zeker de moeite 
waard om de mogelijkheden van MKI therapie te onderzoeken in hoog risico patiënten die 
hun vermogen tot RAJ opname nog niet verloren hebben.  
  
HOOFDSTUK 5 
MKI behandeling van patiënten met maligniteiten wordt geassocieerd met veranderingen in 
schildklier hormoon parameters. Verder zijn sorafenib, imatinib, motesanib, and sunitinib in 
verband gebracht met afwijkingen van de schildklierfunctie in patiënten met 
schildkliercarcinoom die geen schildklier meer hebben.  Na behandeling met sorafenib stegen 
TSH niveaus in 33% van de schildkliercarcinoom patiënten. Aangezien een toegenomen 
behoefte aan levothyroxine wordt waargenomen bij patiënten zonder schildklier die zijn 
behandeld met MKI, postuleerden wij de hypothese dat een van de mechanismen voor het 
ontstaan van hypothyreoidie wellicht te herleiden zou zijn tot veranderingen in het 
schildklierhormoon metabolisme.  
In hoofdstuk 5 beschrijven wij een retrospectieve studie met 21 DTC patiënten die 
levothyroxine therapie ontvingen, bij wie het doel was om de TSH niveaus beneden 0.1mU/L 
te houden. Deze patiënten werden gedurende 26 weken behandeld met sorafenib.  
Bij aanvang en na 26 weken behandeling werden serum schildklier parameters gemeten 
(T4, vrij T4, T3, vrije T3, reverse T3 (rT3), en TSH concentraties) waarbij wij een 
significante toename zagen in de dosis levothyroxine (dosis/kg) terwijl T4 en fT4 stabiel 
bleven. Absolute rT3 niveaus hadden de neiging om na sorafenib therapie toe te nemen terwijl 
T3/T4, T3/rT3, en T4/rT3 verhoudingen aanzienlijk daalden wat wijst op een verhoogde 
omzetting van T4 naar rT3. Sorafenib lijkt geen invloed te hebben op schildklierhormoon 
binding en de afname in T3/T4 enT3/rT3 ratios kunnen het beste verklaard worden door een 
verhoogde activiteit van het enzym deiodinase type 3 (D3). 
Perspectief 
TSH suppressieve levothyroxine substitutie staat centraal bij de therapie van DTC patiënten 
met metastasen. Uit onze studie blijkt dat MKI therapie het levothyroxine metabolisme 
verhoogt. Daarom is het van cruciaal belang dat bij DTC patiënten die worden behandeld met 







sunitinib is onlangs aangetoond dat deze MKI hypothyreoidie induceert door een toename van 
hepatisch D3 en een afname van D1 activiteit. In een recente studie werd onlangs aangetoond 
dat MKI de schilklierhormoon influx in de hypofyse beperkt door remming van MCT8 
activiteit. Dit zou nog een aanvullende verklaring kunnen zijn voor de verhoogde TSH 
waarden in patiënten die worden behandeld met MKI. 
 
HOOFDSTUK 6 
Er zijn aanwijzingen dat jodide opname en functionele NIS expressie worden gereguleerd 
door AMP kinase (AMPK) activatie. Deze recente bevindingen leveren wellicht nieuwe 
aangrijpingspunten voor de verbetering van RAJ behandeling in DTC patiënten. Wij hebben 
de effecten onderzocht van AMPK modulatoren op de functie van thyrocyten, in vitro (FRTL-
5 cellen) en in vivo (C57B16/J muizen). Daarnaast hebben we onderzocht of de effecten op 
jodide opname en functionele NIS expressie door AMPK op transcriptioneel niveau 
gereguleerd worden met behulp van NIS promoter luc-reporter constructen. In vitro leidde 
activatie van AMPK door metformine tot een sterke afname van jodide opname (6-voudige 
afname na 96h, 5mM metformine) en NIS eiwit. AMPK remming door CompoundC 
stimuleerde de jodiumopname in vitro (7-voudige toename na 96h, ) en in 
vivo (1.5x na dagelijkse injecties gedurende 4 dagen met 
activiteit nam af na metformine behandeling (0.6x) terwijl compoundC de NIS promoter 
stimuleerde (3.4x) na 4 dagen. Dit correspondeert grotendeels met cAMP responsive element 
(CRE) activatie (0.6x en 3.0x) wat impliceert dat TSH en AMPK beide aangrijpen op het CRE 
element in de NIS promoter. Concluderend kunnen we stellen dat de NIS expressie en jodide 
opname in thyrocyten gemoduleerd kunnen worden door metformine en compoundC,  waarbij 
regulatie van het CRE element via AMPK in de NIS promoter een rol speelt  
Perspectief 
De toename van jodiumopname na toediening van compoundC duidt erop dat AMPK 
remming interessante aanknopingspunten biedt voor de verbetering van jodide opname bij de 
behandeling van DTC. Additionele studies zullen moeten uitwijzen of AMPK een valide 






Patiënten met DTC worden zowel blootgesteld aan lage (ter voorbereiding op RAJ) als hoge 
schildklierhormoon waarden (TSH onderdrukkende levothyroxine substitutie). Aangezien 
schildklierhormoon een belangrijke rol speelt bij de cardiale functie hebben wij de effecten 
van deze hoge en lage schildklierhormoonwaarden bij DTC patiënten op cardiale dimensies 
en functie onderzocht met behulp van 2-dimensionale (2D) speckle tracking 
echocardiography. Deze methode maakt het mogelijk om het myocard te bestuderen in 
meerdere dimensies (radial, circumferential en longitudinal strain en strain rate), zodat 
uitgebreide informatie wordt verkregen over de myocardiale functie (contractiliteit). 
Vijfentwintig patiënten met een verleden van DTC en langdurige TSH suppressieve 
levothyroxine substitutie werden gerandomiseerd en onderverdeeld in een groep met 
onderdrukte TSH (lage TSH groep) en een waarbij euthyroidie werd hersteld en vergeleken 
met 40 controles met euthyreoidie. 
Bij aanvang vertoonden DTC patiënten een normale linker ventrikel (LV) systolische 
functie maar een verminderde diastolische functie volgens conventionele echocardiografische 
parameters. Met behulp van 2D speckle tracking echocardiography hebben wij subklinische 
LV systolische en diastolische dysfunctie aangetoond waarbij een verminderde 
circumferential en longitudinal strain en strain rate waarneembaar waren tijdens de 
isovolumetrische relaxatie tijd. Na herstel van euthyreoïdie werd een significante verbetering 
in LV systolische en diastolische functie waargenomen. 
Perspectief 
Onze studie onderschrijft dat TSH suppressieve levothyroxine substitutie nadelige effecten 
heeft op het hart. Deze functionele veranderingen zijn echter reversibel, zelfs na langdurige 
blootstelling aan TSH suppressie. Gezien de nadelige effecten van TSH suppressie op vele 
orgaansystemen zijn recent de aanbevelingen betreffende TSH suppressie aangepast. 
Bijgevolg zal de meerderheid van de behandelde DTC patiënten een levothyroxine substitutie 
krijgen die gericht is op normale TSH waarden. 
HOOFDSTUK 8 
Tijdens levothyroxine onttrekking gedurende RAJ therapie worden patiënten herhaaldelijk 







overgangen tussen exogene subklinische hyperthyreoïdie (TSH-suppressieve levothyroxine 
substitutie) naar korte termijn hypothyreoïdie in patiënten behandeld voor DTC waren tot 
dusverre onbekend. In hoofdstuk 8 beschrijven we een studie naar de veranderingen in 
multidirectionele myocardial strain  met behulp van 2D-speckle tracking echocardiografie 
gedurende de transitie van exogene subklinische hyperthyroïdie naar openlijke hypothyroïdie. 
Van 14 DTC patiënten die onder behandeling stonden met TSH-suppressieve levothyroxine 
therapie werd gedurende 4 weken de levothyroxine behandeling stopgezet.  Van deze groep 
werd de hartfunctie beoordeeld met behulp van 2D speckle tracking-echocardiografie vóór en 
1 en 4 weken na onttrekking van levothyroxine waarna deze werden vergeleken met waarden 
uit een controlegroep. 
DTC patiënten bleken een aanzienlijk verminderde circumferential en longitudinal strain 
te hebben ten opzichte van de controle groep. Onttrekking van schildklierhormoon heeft geen 
significante veranderingen in de linker ventrikel dimensies of systolische functie tot gevolg. 
Met behulp van 2D speckle tracking echocardiografie hebben wij geen veranderingen 
waargenomen in radial strain. Opvallend was dat tijdens de transitie van exogene subklinische 
hyperthyreoïdie naar openlijke hypothyreoïdie een aanzienlijke verbetering werd 
waargenomen in omtrek en longitudinale systolische verkorting. Na 4 weken en het bereiken 
van hypothyroïdie verslechterden de parameters weer. Het lijkt erop dat er een u-vormige 
relatie bestaat tussen schildklier hormoon niveaus en myocardial strain.  
Perspectief 
Met behulp van geavanceerde cardiale echografie technieken heeft onze studie subtiele 
veranderingen in de hartfunctie aangetoond tijdens de overgang van TSH suppressieve 
therapie naar openlijke hypothyreoïdie. We vonden dat zowel TSH suppressieve 
levothyroxine therapie als hypothyreoïdie de myocardiale functie kunnen verminderen. 
Hoewel de klinische consequenties van deze vindingen onbekend zijn dragen ze bij aan de 
bevindingen uit tal van studies die laten zien dat DTC patiënten een verhoogd risico hebben 
op cardiovasculaire problemen, die gerelateerd zijn aan levothyroxine substitutie. Het 
nauwkeurig afstemmen van de levothyroxine therapie en de toediening van rhTSH in plaats 
van schildklierhormoon onttrekking om hypothyreoïdie voorkomen zal wellicht bijdragen aan 
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behorend bij proefschrift 
Clinical and Molecular studies in Differentiated thyroid carcinoma management 
Randa Hareedy 
1 Efficacy of therapy with radioactive iodide in thyroid carcinoma patients may be 
diminished when these patients are also being treated with metformin for diabetes 
mellitus   (this thesis). 
2 Co-administration of levothyroxine may hamper the efficacy of radioactive iodide in 
thyroid carcinoma patients (this thesis). 
3 Multikinase inhibitors decrease serum thyroid hormone levels by multiple 
mechanisms, including enhanced thyroid hormone degradation (this thesis).  
4 The profound effects of modulating adenosine monophosphate kinase (AMPK) on the 
functional expression of the sodium iodide symporter expression (NIS) demonstrate 
the important interplay between metabolism and oncology (this thesis). 
5 The worldwide increasing incidence in thyroid carcinoma in South Korea illustrates 
that the introduction of novel diagnostic methods without adequate analysis of benefit 
and harm may lead to overdiagnosis- and treatment of malignancies (Ahn HS, Kim 
HJ, Welch HG. Korea's thyroid-cancer "epidemic"--screening and overdiagnosis. N 
Engl J Med. 2014 6;371(19):1765-7) 
6 Considering thyroid carcinoma a ‘good cancer’ is harmful for patients, not only for 
psychological reasons, but also as it may lead to undertreatment (‘Goede kanker 
bestaat niet’, Anke van Haften, uitgeverij de Graaff, 2015).  
7 The fact that intensive lowering of blood glucose levels in type 2 diabetes mellitus has 
been associated with increased mortality challenges traditional concepts in 
endocrinology. (Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The 
Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From 
Intensive Treatment in the ACCORD Trial. Diabetes Care. 2015 Apr 17. pii: 
dc141844)  
8 Endocrinology should shift its ambitions and goals from optimizing hormone 
substitution therapy to developing curative therapies based on the underlying 
pathophysiology of endocrine disorders (Romijn JA, Smit JW, Lamberts SW. Intrinsic 
imperfections of endocrine replacement therapy. Eur J Endocrinol. 2003;149(2):91-7). 
9 Science, my lad, is made up of mistakes, but they are mistakes which it is useful to 
make, because they lead little by little to the truth. (Jules Verne, 1828 – 1905) 
10 Life is like riding a bicycle. To keep your balance, you must keep moving. (Albert 
Einstein) 
11 The more you know, the more you realise how much you don’t know — the less you 
know, the more you think you know. (David T. Freeman) 
 
